原島 秀吉 (ハラシマ ヒデヨシ)

薬学研究院 医療薬学部門 医療薬学分野特任教授

研究者基本情報

■ 学位
  • 薬学博士, 東京大学
■ URL
researchmap URLホームページURL■ ID 各種
J-Global ID■ 研究キーワード・分野
研究キーワード
  • マイトポーター
  • 核酸ナノ医薬品
  • 個別化医療
  • ナノ医療
  • pH-応答性カチオニック脂質
  • リポソーム
  • 薬物送達システム
  • エンドサイトーシス
  • siRNA
  • 細胞内動態制御
  • MEND
  • オクタアルギニン
  • がん
  • エンドソーム
  • 細胞内動態
  • 遺伝子診断
  • 遺伝子ベクター
  • 遺伝子デリバリー
  • 遺伝子治療
  • 多機能性エンベロープ型ナノ構造体
  • KALA
  • 非ウイルスベクター
  • ミトコンドリア
  • ワクチン
  • ターゲティング
  • 薬物速度論
研究分野
  • ライフサイエンス, 薬系分析、物理化学
  • ライフサイエンス, 医療薬学
  • ライフサイエンス, 生体材料学
  • ライフサイエンス, 生体医工学
  • ライフサイエンス, 薬系化学、創薬科学
  • ライフサイエンス, 薬理学
  • ライフサイエンス, 薬系衛生、生物化学
  • ライフサイエンス, 感染症内科学

経歴

■ 経歴
経歴
  • 2026年04月 - 2027年03月
    北海道大学, 大学院薬学研究院, 未来創剤学研究室, IVReD, 産業創出分野:細胞・オルガネラ製剤学分野(ルカ・サイエンス), 特任教授, 名誉卓越教授, 日本国
  • 2022年04月 - 2026年03月
    北海道大学, 大学院薬学研究院, 未来創剤学研究室, 教授, 卓越教授
  • 2009年04月 - 2023年03月
    北海道大学, 大学院薬学研究院, 未来創剤学研究室, 教授(兼務)
  • 2006年04月 - 2023年03月
    北海道大学, 大学院薬学研究院, 薬剤分子設計学研究室, 教授
  • 1999年07月 - 2006年03月
    北海道大学, 大学院薬学研究院, 教授
  • 1989年07月 - 1999年06月
    徳島大学, 薬学部, 助教授
  • 1987年07月 - 1989年06月
    スタンフォード大学, 医学部麻酔科, JSPS特別研究員
  • 1985年10月 - 1987年07月
    東京大学, 薬学部, 助手
学歴
  • 1983年04月 - 1985年10月, 東京大学, 薬学系大学院, 博士課程退学
  • 1981年04月 - 1983年03月, 東京大学, 薬学系大学院, 修士課程修了
  • 1977年04月 - 1981年03月, 東京大学, 薬学部卒業
委員歴
  • 2018年09月 - 現在
    日本核酸医薬学会, デリバリー担当幹事, 学協会
  • 2016年 - 現在
    製剤種差検討会, リーダー, 学協会
  • 2000年 - 現在
    日本薬剤学会, 評議員, 学協会
  • 1996年 - 現在
    日本薬物動態学会, 評議員, 学協会
  • 2018年05月 - 2022年05月
    公益社団日本薬剤学会, 監事, 学協会
  • 2006年07月 - 2018年06月
    日本DDS学会, 理事, 学協会
  • 2013年04月 - 2018年03月
    日本薬物動態学会, DIS-DDSリーダー, 学協会
  • 2014年05月 - 2016年05月
    公益社団日本薬剤学会, 理事, 学協会
  • 2014年04月 - 2016年03月
    公益社団日本薬学会, 理事, 学協会
  • 2011年 - 2015年
    DDS製剤臨床応用フォーカスグループ, リーダー, 学協会
  • 2012年05月 - 2014年05月
    公益社団日本薬剤学会, 会長, 学協会
  • 2006年05月 - 2012年05月
    公益社団法人日本薬剤学会, 理事, 学協会
  • 2004年 - 2012年
    日本バイオマテリアル学会, 評議員, 学協会

研究活動情報

■ 受賞
  • 2025年04月, 市村清新技術財団, 市村学術賞(功績賞)
    遺伝子・核酸送達法が拓く革新的ナノ医療
    原島秀吉
  • 2024年04月, 秋山記念生命科学振興財団, 秋山財団賞
    細胞内動態制御から革新的医薬品の創出へ
    原島秀吉
  • 2023年03月, 日本薬学会, 学会賞
    細胞内動態制御に基づいた遺伝子・核酸送達システムの創製とナノ医療への展開
    原島秀吉
  • 2021年09月, FIP(国際薬剤師連合), ヘストマドセンメダル
    Multifunctional Envelope-type Nano Device: From controlled intracellular trafficking to clinical application for Nanomedicine
    原島 秀吉
  • 2019年02月, 北海道大学, 総長賞
    原島 秀吉
  • 2016年11月, Song Eum Academy Foundation, 19th SONG EUM Med-Pharm Award
    原島秀吉
  • 2016年05月, 公益社団法人日本薬剤学会, 学会賞
    多機能性エンベロープ型ナノ構造体の創製とナノ医療への展開
    原島秀吉
  • 2016年02月, 北海道大学, 総長賞(優秀賞)
    原島秀吉
  • 2016年02月, 一般財団法人油脂工業会館, 優秀論文表彰(優秀賞)
    秋田英万;原島秀吉
  • 2015年02月, 北海道大学, 総長賞(優秀賞)
    原島秀吉
  • 2013年07月, 国際コントロールドリリース学会, Fellow
    原島秀吉
  • 2011年10月, 米国薬学会, AAPS Journal Manuscript Award
    アイマンエルセイド;二木史朗;原島秀吉
  • 2010年08月, 世界薬学連合, Distinguished Science Award
    原島秀吉
  • 2007年06月, 日本DDS学会, 永井賞
    多機能性エンベロープ型ナノ構造体による人工遺伝子デリバリーシステムの創製
    原島秀吉
  • 2007年03月, 公益社団法人日本薬学会, 学術振興賞
    多機能性エンベロープ型人工遺伝子デリバリーシステムの創製
    原島秀吉
  • 1994年11月, 日本薬物動態学会, 奨励賞
    薬物速度論に基づいたリポソームによる薬物送達システムの構築
    原島秀吉
■ 論文
  • Lipid nanoparticles containing zwitterionic lipids versatilely enhance the efficiency of mRNA delivery
    Yuichi Suzuki; Yuma Yamada; Hideyoshi Harashima; Yusuke Sato
    Journal of Controlled Release, 392, 114709, 114709, Elsevier BV, 2026年04月
    研究論文(学術雑誌)
  • The effect of guide RNA thermal denaturation on the quality of Cas9 ribonucleoprotein-loaded lipid nanoparticle formulations
    Rina Shimizu; Yuji Kashiwakura; Morisada Hayakawa; Shunsuke Kita; Mina Sato; Masatoshi Maeki; Manabu Tokeshi; Katsumi Maenaka; Tsukasa Ohmori; Yuma Yamada; Hideyoshi Harashima; Yusuke Sato
    RSC PHARMACEUTICS, 3, 1, 2026年01月27日
    英語, 研究論文(学術雑誌)
  • Selective vascular disrupting therapy by lipid nanoparticle-mediated Fas ligand silencing and stimulation of STING.
    Rikito Endo; Tomoki Ueda; Takumi Nagaoki; Yusuke Sato; Nako Maishi; Kyoko Hida; Hideyoshi Harashima; Takashi Nakamura
    Biomaterials, 321, 123297, 123297, 2025年10月, [国際誌]
    英語, 研究論文(学術雑誌), Although recent therapeutic developments have greatly improved the outcomes of patients with cancer, it remains on ongoing problem, particularly in relation to acquired drug resistance. Vascular disrupting agents (VDAs) directly damage tumor blood vessels, thus promoting drug efficacy and reducing the development of drug resistance; however, their low molecular weight and resulting lack of selectivity for tumor endothelial cells (TECs) lead to side effects that can hinder their practical use. Here, we report a novel tumor vascular disrupting therapy using nucleic acid-loaded lipid nanoparticles (LNPs). We prepared two LNPs: a small interfering RNA (siRNA) against Fas ligand (FasL)-loaded cyclic RGD modified LNP (cRGD-LNP) to knock down FasL in TECs and a stimulator of interferon genes (STING) agonist-loaded LNP to induce systemic type I interferon (IFN) production. The combination therapy disrupted the tumor vasculature and induced broad tumor cell apoptosis within 48 h, leading to rapid and strong therapeutic effects in various tumor models. T cells were not involved in these antitumor effects. Furthermore, the combination therapy demonstrated a significantly superior therapeutic efficacy compared with conventional anti-angiogenic agents and VDAs. RNA sequencing analysis suggested that reduced collagen levels may have been responsible for TEC apoptosis. These findings demonstrated a potential therapeutic method for targeting the tumor vasculature, which may contribute to the development of a new class of anti-cancer drugs.
  • Examining the Impact of Storage Conditions on the Stability of a Liquid Formulation of mRNA-Loaded Lipid Nanoparticles
    Mina Sato; Eleni Samaridou; Moritz Beck-Broichsitter; Masatoshi Maeki; Shunsuke Kita; Manabu Tokeshi; Katsumi Maenaka; Hideyoshi Harashima; Yusuke Sato
    Pharmaceutics, 17, 9, 1194, 1194, MDPI AG, 2025年09月14日
    研究論文(学術雑誌), Background/Objectives: This study investigated the effect of storage conditions on mRNA-LNPs in situ via identification of the formulation traits necessary for improving storage stability. Methods: We synthesized an ionizable lipid, namely TOT-28, which has a hydrolysis-susceptible ester bond in its hydrophilic head group that allows it to act as an indicator of the hydrophilic environment within the mRNA-LNPs. LNPs were stored either at 4 or 25 °C for up to 8 weeks to investigate the effect of pH and temperature on ester hydrolysis, internal mRNA integrity, physicochemical properties of the LNPs, and mRNA gene expression. Results: The results indicate that, at 25 °C, a lower buffer pH increases ester hydrolysis, whereas an opposite trend slightly occurs in ester hydrolysis with storage at 4 °C. We also found that TOT-28-based LNPs were less hydrated and microviscosity was higher at 4 °C compared with storage temperature at 25 °C. Therefore, TOT-28-based LNPs seem less sensitive to external buffer solutions because of a higher-order structure when stored at lower temperatures. In addition, we found that LNPs with different ionizable lipid structures exhibit distinct responses to pH changes at specific storage temperatures. Conclusions: Our findings provide novel insights into the appropriate conditions for long-term storage of the mRNA-LNPs as a liquid formulation.
  • Microfluidic Production of Exosome-Mimicking Lipid Nanoparticles for Enhanced RNA Delivery: Role of Exosomal Proteins.
    Masatoshi Maeki; Ayuka Niwa; Shota Oyama; Kyoko Aratani; Rina Ito; Yuichi Suzuki; Yusuke Sato; Akihiko Ishida; Hideyoshi Harashima; Manabu Tokeshi
    ACS applied materials & interfaces, 17, 29, 41666, 41679, 2025年07月23日, [国際誌]
    英語, 研究論文(学術雑誌), Exosomes, which are cell-secreted lipid-based nanoparticles, play a crucial role in intercellular communication by encapsulating and delivering various biomolecules such as DNA, mRNA, miRNA, and proteins. They offer potential as drug delivery systems (DDSs) based on their ability to cross biological barriers, use natural communication mechanisms, and minimize immunogenicity. However, the heterogeneity of exosomes presents a bottleneck for functional analysis and the development of exosome-based DDSs. Therefore, engineering techniques are needed to produce exosomes or exosome-mimicking nanoparticles with controlled characteristics, including the presentation of specific exosomal proteins on their surface. Here, a one-step microfluidic method for producing exosome-mimicking lipid-based nanoparticles decorated with specific exosomal proteins was developed, enabling control over the composition and characteristics of the resulting exosomes. Exosome-mimicking nanoparticles decorated with tetraspanin proteins (CD9, CD63, CD81) and integrins (ITG αVβ5, ITG α6β4), which are involved in cell signaling and organ targeting, were thereby generated. Investigating the impact of these exosomal proteins on RNA delivery efficiency revealed that ITG αVβ5-decorated exosome-mimicking nanoparticles significantly enhance RNA delivery both in vitro and in vivo. This study provides an approach for producing precisely decorated exosome-mimicking nanoparticles, which may be applied to elucidate the functions of exosomal proteins and develop targeted DDSs.
  • Lipid nanoparticle delivery of the CRISPR/Cas9 system directly into the mitochondria of cells carrying m.7778G>T mutation in MtDNA (mt-Atp8)
    Kaede Norota; Sen Ishizuka; Misa Hirose; Yusuke Sato; Masatoshi Maeki; Manabu Tokeshi; Saleh M. Ibrahim; Hideyoshi Harashima; Yuma Yamada
    Scientific Reports, 15, 1, Springer Science and Business Media LLC, 2025年06月19日
    研究論文(学術雑誌)
  • Splenic B cell-targeting lipid nanoparticles for safe and effective mRNA vaccine delivery.
    Yuichi Suzuki; Mai Yakuwa; Mina Sato; Eleni Samaridou; Moritz Beck-Broichsitter; Masatoshi Maeki; Manabu Tokeshi; Yuma Yamada; Hideyoshi Harashima; Yusuke Sato
    Journal of controlled release : official journal of the Controlled Release Society, 382, 113687, 113687, 2025年06月10日, [国際誌]
    英語, 研究論文(学術雑誌), mRNA-loaded lipid nanoparticles (LNPs) have emerged as a potent and versatile platform that underpins the success of mRNA vaccines, but guidelines for designing safe and effective formulations with minimal off-target effects remain unclear. In this study, we focused on a rational design for a novel ionizable lipid library that is based on ionizable tri-oleoyl-tris (iTOT) compounds with a high yield via a simple 2-step synthesis. To further enhance the efficacy and safety of this potent library for vaccine applications, we identified the optimal composition for a vaccine by focusing on the molar ratio of specific lipid excipients in the formulation. This composition brought about a shift in delivery to the spleen, and the LNP formulation, which contained 15 mol% DSPC (15%DSPC-LNPs), was thoroughly taken up by both B cells and other splenic immune cells. This formulation requires neither additional lipid components nor targeting ligand modifications, and it is accompanied by antigen-specific cytotoxic T lymphocyte responses. The rigid, hydrophobic, and charge-neutral surface of 15%DSPC-LNPs minimizes apolipoprotein E-dependent hepatic uptake and maximizes complement receptor-mediated B-cell targeting. Furthermore, as an intramuscularly administered vaccine, 15%DSPC-LNPs induce antigen-specific immune responses and, importantly, results in significantly lower levels of hepatotoxicity compared with that of the mRNA vaccine formulations currently being marketed. In summary, this study demonstrated how the passive targeting of mRNA-LNPs to organs and cells could be regulated by designing novel ionizable lipids combined with adjusting the relative proportions of lipid components. The results of this study also emphasize how selective mRNA delivery to the spleen could avoid the liver, which highlights a promising strategy for the development of safe and effective vaccines.
  • PEGコーティングによるミトコンドリアの表面加工技術
    白石 真大; 村松 ゆかり; 中谷 彰洋; 丸尾 優爾; 太田 尚; 菅沼 正司; Tsai Rick C.; 原島 秀吉; 山田 勇磨
    日本DDS学会学術集会プログラム予稿集, 41回, 303, 303, 日本DDS学会, 2025年06月
    日本語
  • Cubic Phase-Inducible Zwitterionic Phospholipids Improve the Functional Delivery of mRNA.
    Kazuki Iwakawa; Rikako Sato; Mariko Konaka; Yuma Yamada; Hideyoshi Harashima; Yusuke Sato
    Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12, 17, e2413016, 2025年05月, [国際誌]
    英語, 研究論文(学術雑誌), Lipid nanoparticles (LNPs) are clinically advanced delivery systems for RNA. The extensively developed structure of ionizable lipids greatly contributes to the functional delivery of mRNA. However, endosomal escape is one of the severe biological barriers that continue to render this process inefficient (e.g., less than 10%). Although LNPs contain phospholipids, their role is poorly understood, and there have been few attempts to perform the chemical engineering required to improve their functionality. Herein, a cubic phase-inducible fusogenic zwitterionic phospholipid derived from 1,2-dioleoyl-3-sn-glycero-phosphoethanolamine (DOPE), DOPE-Cx is described, that is designed to correct this problem. The orientation of a zwitterionic head group of DOPE is engineered by attaching a series of hydrophobic moieties for zwitterionic intermolecular interaction with the head structure of phosphatidylcholine (PC), and this is followed by a lipid-phase transition into non-lamellar phases to facilitate membrane fusion-mediated endosomal escape. A structure-activity relationship study reveals that DOPE-Cx lipids with small hydrophobic chains induce cubic phases instead of a hexagonal phase when mixed with PC, which enhances the functional delivery of mRNA in the liver as opposed to the action of the typically utilized and naturally occurring phospholipids. Engineered functionalized phospholipids will be of great value for the therapeutic applications of mRNAs.
  • Harnessing the composition of lipid nanoparticles to selectively deliver mRNA to splenic immune cells for anticancer vaccination
    Mahmoud A. Younis; Yusuke Sato; Yaser H. A. Elewa; Hideyoshi Harashima
    Drug Delivery and Translational Research, Springer Science and Business Media LLC, 2025年03月07日
    研究論文(学術雑誌)
  • Marginal-zone B cells as promising targets of an mRNA-loaded, lipid-nanoparticle cancer vaccine
    Yuichi Suzuki; Mai Yakuwa; Mina Sato; Eleni Samaridou; Moritz Beck-Broichsitter; Masatoshi Maeki; Manabu Tokeshi; Yuma Yamada; Hideyoshi Harashima; Yusuke Sato
    Next Nanotechnology, 8, 100154, 100154, Elsevier BV, 2025年
    研究論文(学術雑誌)
  • Targeting Tumor Endothelial Cells by EGCG Using Specific Liposome Delivery System Inhibits Vascular Inflammation and Thrombosis.
    Zi Jia; Nako Maishi; Hideki Takekawa; Aya Yanagawa Matsuda; Taisei Nakade; Takashi Nakamura; Hideyoshi Harashima; Yasuhiro Hida; Kyoko Hida
    Cancer medicine, 13, 23, e70462, 2024年12月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Inflammation is one of the hallmarks of cancer and is associated with tumor growth. Tumor endothelial cells (TECs) demonstrate inflamed phenotypes. Endothelial inflammation initiates thrombus formation, which is the second cause of cancer-related deaths. Epigallocatechin-3-O-gallate (EGCG), a natural compound in green tea, has demonstrated an anti-inflammatory effect. However, the tumor progression inhibition effect of EGCG by targeting TEC inflammation remains unclear. This study addresses the anti-tumor effect of EGCG, especially its anti-inflammatory role in TECs. METHODS: In vitro, the effect of EGCG on TECs were studied using real-time quantitative PCR and immunofluoresence to analyza gene and protein expression. In vivo, a cyclic RGD liposome delivery system (MEND) was employed to efficiently deliver EGCG to TECs in tumor-bearing mice. RESULTS: In vitro, EGCG significantly reduces inflammatory cytokine expression, including tumor necrosis factor-α, interleukin-6, IL-8, and IL-1β through NF-κB signaling inhibition. Additionally, von Willebrand factor reduction in TECs, which is involved in platelet adhesion and thrombosis formation, was analyzed. Our results revealed that EGCG-MEND significantly inhibited TEC inflammation and thrombus formation in tumors. Additionally, EGCG-MEND improved tumor immunity by reducing programmed death-ligand 1 expression and promoting high endothelial venule formation by recruiting CD8+ T cells. CONCLUSION: Our results indicate the anti-tumor potential of EGCG-MEND in normalizing the inflammatory immune microenvironment and inhibiting thrombosis by targeting TEC.
  • Different Effects of Berberine Delivery to Mitochondria on Cells Derived from the Neural Crest
    Ikuma Hori; Hideyoshi Harashima; Yuma Yamada
    Biological and Pharmaceutical Bulletin, 47, 10, 1726, 1733, Pharmaceutical Society of Japan, 2024年10月26日
    研究論文(学術雑誌)
  • Engineering branched ionizable lipid for hepatic delivery of clustered regularly interspaced short palindromic repeat-Cas9 ribonucleoproteins.
    Haruno Onuma; Rina Shimizu; Yuichi Suzuki; Mina Sato; Hideyoshi Harashima; Yusuke Sato
    iScience, 27, 10, 110928, 110928, 2024年10月18日, [国際誌]
    英語, 研究論文(学術雑誌), The delivery of the CRISPR/Cas ribonucleoprotein (RNP) has received attention for clinical applications owing to its high efficiency with few off-target effects. Lipid nanoparticles (LNPs) are potential non-viral vectors for the delivery of RNPs. Herein, we report the engineering of a branched scaffold structure of ionizable lipids for the hepatic delivery of RNPs. Both the total carbon number and branching position were critical for the functional delivery of RNPs. The optimal ionizable lipid exhibited a more than 98% reduction in transthyretin protein after a single dose with no obvious signs of toxicity. The mechanistic study has revealed that optimal LNPs have a unique "flower-like structure" that depends on both the lipid structure and the payload and that these LNPs accumulate in hepatocytes in an apolipoprotein E-independent manner. These results represent a major step toward the realization of in vivo genome editing therapy via RNP delivery using chemically synthesizable LNP formulations.
  • Impact of Lipid Tail Length on the Organ Selectivity of mRNA-Lipid Nanoparticles.
    Kazuki Hashiba; Masamitsu Taguchi; Sachiko Sakamoto; Ayaka Otsu; Yoshiki Maeda; Yuichi Suzuki; Hirofumi Ebe; Arimichi Okazaki; Hideyoshi Harashima; Yusuke Sato
    Nano letters, 24, 41, 12758, 67, 2024年10月07日, [国際誌]
    英語, 研究論文(学術雑誌), The delivery of mRNA molecules to organs beyond the liver is valuable for therapeutic applications. Functionalized lipid nanoparticles (LNPs) using exogenous mechanisms can regulate in vivo mRNA expression profiles from hepatocytes to extrahepatic tissues but lead to process complexity and cost escalation. Here, we report that mRNA expression gradually shifts from the liver to the spleen in an ionizable lipid tail length-dependent manner. Remarkably, this simple chemical strategy held true even when different ionizable lipid head structures were employed. As a potential mechanism underlying this discovery, our data suggest that 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) is enriched on the surface of mRNA/LNPs with short-tail lipids. This feature limits their interaction with biological components, avoiding their rapid hepatic clearance. We also show that spleen-targeting LNPs loaded with SARS-CoV-2 receptor-binding domain (RBD) mRNA can efficiently induce immune responses and neutralize activity following intramuscular vaccination priming and boosting.
  • Impact of in vivo fate of STING agonist-loaded lipid nanoparticles on antitumor immunity.
    Rikito Endo; Tomoki Ueda; Takumi Nagaoki; Natsumi Shima; Yusuke Sato; Hideyoshi Harashima; Takashi Nakamura
    Journal of controlled release : official journal of the Controlled Release Society, 372, 609, 618, 2024年08月, [国際誌]
    英語, 研究論文(学術雑誌), Therapeutically manipulating the stimulator of interferon genes (STING) pathway has promising potential for enhancing antitumor immunity. Agonists of this pathway (STING agonists) are being evaluated in clinical trials. Loading the STING agonists into lipid nanoparticles (LNPs) increases their safety and efficacy. We previously developed STING agonists loaded LNPs consisting of the ionizable lipid YSK12-C4 (YSK12-LNPs), which showed significant antitumor effects. However, it is largely unclear how the in vivo fate of STING agonists loaded LNPs affects the antitumor immune responses. In this study, we compared the YSK12-LNPs with LNPs composed of DLin-MC3-DMA (MC3-LNPs) showing different in vivo fates. Biodistribution and flow cytometry analyses of mouse tissues revealed that the MC3-LNPs delivered higher amounts of STING agonists to the liver than the YSK12-LNPs. Additionally, significantly more liver leukocytes internalized the MC3-LNPs than the YSK12-LNPs. In contrast, the YSK12-LNPs delivered higher amounts of STING agonists to the liver leukocytes than the MC3-LNPs, leading to the effective induction of innate immunity and inflammation in the tumors. However, the antitumor effects in the B16-F10 lung metastasis and CT26 tumor models were comparable. Interestingly, flow cytometry analyses suggested that the YSK12-LNPs were more likely to activate natural killer cells and M1 macrophages, while the MC3-LNPs were more likely to activate CD8+ T cells. Our data suggest that different antitumor immune response mechanisms may operate depending on the characteristics and distribution of the LNPs.
  • The impact of, and expectations for, lipid nanoparticle technology: From cellular targeting to organelle targeting.
    Yusuke Sato; Takashi Nakamura; Yuma Yamada; Hideyoshi Harashima
    Journal of controlled release : official journal of the Controlled Release Society, 370, 516, 527, 2024年06月, [国際誌]
    英語, 研究論文(学術雑誌), The success of mRNA vaccines against COVID-19 has enhanced the potential of lipid nanoparticles (LNPs) as a system for the delivery of mRNA. In this review, we describe our progress using a lipid library to engineer ionizable lipids and promote LNP technology from the viewpoints of safety, controlled biodistribution, and mRNA vaccines. These advancements in LNP technology are applied to cancer immunology, and a potential nano-DDS is constructed to evaluate immune status that is associated with a cancer-immunity cycle that includes the sub-cycles in tumor microenvironments. We also discuss the importance of the delivery of antigens and adjuvants in enhancing the cancer-immunity cycle. Recent progress in NK cell targeting in cancer immunotherapy is also introduced. Finally, the impact of next-generation DDS technology is explained using the MITO-Porter membrane fusion-based delivery system for the organelle targeting of the mitochondria. We introduce a successful example of the MITO-Porter used in a cell therapeutic strategy to treat cardiomyopathy.
  • Overcoming thermostability challenges in mRNA-lipid nanoparticle systems with piperidine-based ionizable lipids.
    Kazuki Hashiba; Masamitsu Taguchi; Sachiko Sakamoto; Ayaka Otsu; Yoshiki Maeda; Hirofumi Ebe; Arimichi Okazaki; Hideyoshi Harashima; Yusuke Sato
    Communications biology, 7, 1, 556, 556, 2024年05月10日, [国際誌]
    英語, 研究論文(学術雑誌), Lipid nanoparticles (LNPs) have emerged as promising platforms for efficient in vivo mRNA delivery owing to advancements in ionizable lipids. However, maintaining the thermostability of mRNA/LNP systems remains challenging. While the importance of only a small amount of lipid impurities on mRNA inactivation is clear, a fundamental solution has not yet been proposed. In this study, we investigate an approach to limit the generation of aldehyde impurities that react with mRNA nucleosides through the chemical engineering of lipids. We demonstrated that piperidine-based lipids improve the long-term storage stability of mRNA/LNPs at refrigeration temperature as a liquid formulation. High-performance liquid chromatography analysis and additional lipid synthesis revealed that amine moieties of ionizable lipids play a vital role in limiting reactive aldehyde generation, mRNA-lipid adduct formation, and loss of mRNA function during mRNA/LNP storage. These findings highlight the importance of lipid design and help enhance the shelf-life of mRNA/LNP systems.
  • Duchenne型筋ジストロフィーモデルラット細胞を用いたミトコンドリア呼吸能活性化による治療介入検討
    佐藤 逸美; 日比野 光恵; 佐々木 大輔; 武田 充人; 原島 秀吉; 山田 勇磨
    脳と発達, 56, Suppl., S237, S237, (一社)日本小児神経学会, 2024年05月
    日本語
  • Investigation of the Nanoparticulation Method and Cell-Killing Effect following the Mitochondrial Delivery of Hydrophobic Porphyrin-Based Photosensitizers
    Rina Naganawa; Hanjun Zhao; Yuta Takano; Masatoshi Maeki; Manabu Tokeshi; Hideyoshi Harashima; Yuma Yamada
    International Journal of Molecular Sciences, 2024年04月12日, [査読有り]
    研究論文(学術雑誌)
  • Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bhighCD27low memory-like NK cells.
    Alaa M Khalifa; Takashi Nakamura; Yusuke Sato; Hideyoshi Harashima
    Experimental hematology & oncology, 13, 1, 36, 36, 2024年03月29日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Natural killer (NK) cells are effective in attacking tumor cells that escape T cell attack. Memory NK cells are believed to function as potent effector cells in cancer immunotherapy. However, knowledge of their induction, identification, and potential in vivo is limited. Herein, we report on the induction and identification of memory-like NK cells via the action of a combination of a stimulator of interferon genes (STING) agonist loaded into lipid nanoparticles (STING-LNPs) and cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG-ODNs), and the potential of the inducted memory-like NK cells to prevent melanoma lung metastasis. METHODS: The antitumor effects of either the STING-LNPs, CpG-ODNs, or the combination therapy were evaluated using a B16-F10 lung metastasis model. The effect of the combined treatment was evaluated by measuring cytokine production. The induction of memory-like NK cells was demonstrated via flow cytometry and confirmed through their preventative effect. RESULTS: The combination of STING-LNPs and CpG-ODNs tended to enhance the production of interleukin 12 (IL-12) and IL-18, and exerted a therapeutic effect against B16-F10 lung metastasis. The combination therapy increased the population of CD11bhighCD27low NK cells. Although monotherapies failed to show preventative effects, the combination therapy induced a surprisingly strong preventative effect, which indicates that CD11bhighCD27low cells could be a phenotype of memory-like NK cells. CONCLUSION: As far as could be ascertained, this is the first report of the in vivo induction, identification, and confirmation of a phenotype of the memory-like NK cells through a prophylactic effect via the use of an immunotherapeutic drug. Our findings provide novel insights into the in vivo induction of CD11bhighCD27low memory-like NK cells thus paving the way for the development of efficient immunotherapies.
  • Activation of Mitochondrial Oxygen Consumption Rate by Delivering Coenzyme Q10 to Mitochondria of Rat Skeletal Muscle Cell (L6)
    Itsumi Sato; Mitsue Hibino; Atsuhito Takeda; Hideyoshi Harashima; Yuma Yamada
    Journal of Pharmaceutical Sciences, Elsevier BV, 2024年02月
    研究論文(学術雑誌)
  • Human cardiosphere-derived cells with activated mitochondria for better myocardial regenerative therapy.
    Masahiro Shiraishi; Daisuke Sasaki; Mitsue Hibino; Atsuhito Takeda; Hideyoshi Harashima; Yuma Yamada
    Journal of controlled release : official journal of the Controlled Release Society, 2024年01月29日, [国際誌]
    英語, 研究論文(学術雑誌), Cell transplantation is a promising therapeutic strategy for myocardial regeneration therapy. To improve therapeutic effects, we developed a culture medium additive that enhances the mitochondrial function of cardiomyocytes for transplantation. A mitochondrial targeting drug delivery system (MITO-Porter system) was used to deliver mitochondrial activation molecules to mouse-derived cardiac progenitor cells. In this study, we investigated whether the mitochondrial function of human-derived myocardial precursor cells could be enhanced using MITO-Porter. Human cardiosphere-derived cells (CDCs) were isolated from myocardium which was excised during surgery for congenital heart disease. MITO-Porter was added to the cell culture medium to generate mitochondrial activated CDCs (human MITO cells). The human MITO cells were transplanted into myocardial ischemia-reperfusion rat model rat, and the effect was investigated. The transplanted human MITO cells improved the cardiac function and suppressed myocardial fibrosis compared to conventional cell transplantation methods. These effects were observed not only with myocardial administration but also by intravenous administration of human MITO cells. This study is the first study that assessed whether the mitochondrial delivery of functional compounds improved the outcome of human-derived myocardial cell transplantation therapy.
  • Development of Polymer-Lipid Hybrid Nanoparticles for Large-Sized Plasmid DNA Transfection.
    Masatoshi Maeki; Shuya Uno; Kaisei Sugiura; Yusuke Sato; Yoichiro Fujioka; Akihiko Ishida; Yusuke Ohba; Hideyoshi Harashima; Manabu Tokeshi
    ACS applied materials & interfaces, 16, 2, 2110, 2119, 2024年01月17日, [国際誌]
    英語, 研究論文(学術雑誌), RNA and DNA delivery technologies using lipid nanoparticles (LNPs) have advanced significantly, as demonstrated by their successful application in mRNA vaccines. To date, commercially available RNA therapeutics include Onpattro, a 21 bp siRNA, and mRNA vaccines comprising 4300 nucleotides for COVID-19. However, a significant challenge remains in achieving efficient transfection, as the size of the delivered RNA and DNA increases. In contrast to RNA transfection, plasmid DNA (pDNA) transfection requires multiple steps, including cellular uptake, endosomal escape, nuclear translocation, transcription, and translation. The low transfection efficiency of large pDNA is a critical limitation in the development of artificial cells and their cellular functionalization. Here, we introduce polymer-lipid hybrid nanoparticles designed for efficient, large-sized pDNA transfection. We demonstrated that LNPs loaded with positively charged pDNA-polycation core nanoparticles exhibited a 4-fold increase in transfection efficiency for 15 kbp pDNA compared with conventional LNPs, which encapsulate a negatively charged pDNA-polycation core. Based on assessments of the size and internal structure of the polymer-lipid nanoparticles as well as hemolysis and cellular uptake analysis, we propose a strategy to enhance large-sized pDNA transfection using LNPs. This approach holds promise for accelerating the in vivo delivery of large-sized pDNA and advancing the development of artificial cells.
  • Development of Liposomes That Target Axon Terminals Encapsulating Berberine in Cultured Primary Neurons
    Ikuma Hori; Hideyoshi Harashima; Yuma Yamada
    Pharmaceutics, 16, 1, 49, 49, MDPI AG, 2023年12月28日
    研究論文(学術雑誌), Most of the energy in neurons is produced in mitochondria. Mitochondria generate the ATP that is essential for neuronal growth, function, and regeneration. Mitochondrial axonal transport plays a crucial role in maintaining neuronal homeostasis and biological activity. Decreased mitochondrial axonal transport at axon terminals, where the metabolism of substances is likely to be delayed, may contribute to neurological dysfunction. Therefore, regulation of mitochondrial dynamics at axon terminals has attracted considerable interest as a strategy to modulate neuronal function. Nanoparticles may be useful in controlling local mitochondrial dynamics. Nevertheless, there are few reports on the influence of drug delivery that nanoparticles impart on the mitochondrial dynamics in neurons. This paper reports the results of a study using liposomes (LPs) to examine local drug delivery and pharmacological actions on neurons. We tested berberine (BBR), which is an activator of AMP-activated protein kinase (AMPK), to examine the utility of this drug as a cellular energy sensor. Axon terminals targeting LPs were prepared. The amount of axon terminals targeting LPs was increased compared with treatment using cationic LPs. Moreover, axon terminal-targeting LPs increased anterograde transport by about 40% compared with that of either naked BBR or cationic LPs and suppressed axonal retraction. Our findings suggest that local drug delivery to neurons is important for enhancing pharmacological activity in axon terminals.
  • Cancer Immunotherapy with Lipid Nanoparticles Loaded with a Stimulator of Interferon Genes Agonist against Renal Tumor Lung Metastasis.
    Takashi Nakamura; Shun Sasaki; Yusuke Sato; Hideyoshi Harashima
    Pharmaceutics, 16, 1, 2023年12月26日, [国際誌]
    英語, 研究論文(学術雑誌), Metastatic renal cell carcinoma (RCC) has a poor prognosis, and the major organ of metastasis is the lung. Immunotherapy with immune checkpoint inhibitors (ICIs) is the first-line therapy, but the response rates are low. Thus, the development of a more effective immunotherapy against metastatic RCC would be highly desirable. We previously demonstrated how a stimulator of an interferon gene (STING) agonist-loaded lipid nanoparticles (STING-LNPs) significantly activates natural killer (NK) cells and induces an antitumor effect against cases of melanoma lung metastasis that have shown ICI resistance. In this study, we evaluated the potential of using STING-LNPs in the treatment of lung metastatic RCC (Renca). An intravenous injection of STING-LNPs drastically decreased the amount of Renca tumor colonies. In contrast, monotherapies using ICIs showed no antitumor effect, and even a combination of ICI and STING-LNP therapies failed to enhance the antitumor effects. The main effector cells would be NK cells, and the activation of NK cells by the STING-LNPs may avoid the increased expression of immune checkpoint molecules. These findings provide useful insights into the development of an effective immunotherapy against metastatic RCC.
  • Genetically engineered transfusable platelets using mRNA lipid nanoparticles.
    Jerry Leung; Colton Strong; Katherine E Badior; Madelaine Robertson; Xiaowu Wu; Michael A Meledeo; Emma Kang; Manoj Paul; Yusuke Sato; Hideyoshi Harashima; Andrew P Cap; Dana V Devine; Eric Jan; Pieter R Cullis; Christian J Kastrup
    Science advances, 9, 48, eadi0508, 2023年12月, [国際誌]
    英語, 研究論文(学術雑誌), Platelet transfusions are essential for managing bleeding and hemostatic dysfunction and could be expanded as a cell therapy due to the multifunctional role of platelets in various diseases. Creating these cell therapies will require modifying transfusable donor platelets to express therapeutic proteins. However, there are currently no appropriate methods for genetically modifying platelets collected from blood donors. Here, we describe an approach using platelet-optimized lipid nanoparticles containing mRNA (mRNA-LNP) to enable exogenous protein expression in human and rat platelets. Within the library of mRNA-LNP tested, exogenous protein expression did not require nor correlate with platelet activation. Transfected platelets retained hemostatic function and accumulated in regions of vascular damage after transfusion into rats with hemorrhagic shock. We expect this technology will expand the therapeutic potential of platelets.
  • Erratum: Branching Ionizable Lipids Can Enhance the Stability, Fusogenicity, and Functional Delivery of mRNA.
    Kazuki Hashiba; Yusuke Sato; Masamitsu Taguchi; Sachiko Sakamoto; Ayaka Otsu; Yoshiki Maeda; Takuya Shishido; Masao Murakawa; Arimichi Okazaki; Hideyoshi Harashima
    Small science, 3, 12, 2300285, 2300285, 2023年12月, [国際誌]
    英語, [This corrects the article DOI: 10.1002/smsc.202200071.].
  • π-extended porphyrin-based near-infrared photosensitizers for mitochondria-targeted photodynamic therapy
    Hanjun Zhao; Rina Naganawa; Yuma Yamada; Yasuko Osakada; Mamoru Fujitsuka; Hideyuki Mitomo; Yukiko Miyatake; Hideyoshi Harashima; Vasudevanpillai Biju; Yuta Takano
    Journal of Photochemistry and Photobiology A: Chemistry, 115397, 115397, Elsevier BV, 2023年12月
    研究論文(学術雑誌)
  • Reprogramming activated hepatic stellate cells by siRNA-loaded nanocarriers reverses liver fibrosis in mice
    Mahmoud A. Younis; Yusuke Sato; Yaser H.A. Elewa; Hideyoshi Harashima
    Journal of Controlled Release, 361, 592, 603, 2023年09月
    研究論文(学術雑誌)
  • Harnessing Topology and Stereochemistry of Glycidylamine‐Derived Lipid Nanoparticles for in Vivo mRNA Delivery to Immune Cells in Spleen and Their Application for Cancer Vaccination
    Mahmoud M. Abd Elwakil; Ryota Suzuki; Alaa M. Khalifa; Rania M. Elshami; Takuya Isono; Yaser H.A. Elewa; Yusuke Sato; Takashi Nakamura; Toshifumi Satoh; Hideyoshi Harashima
    Advanced Functional Materials, Wiley, 2023年07月26日
    研究論文(学術雑誌), Abstract

    mRNA lipid nanoparticles (LNPs) have reached an inflection point and are now paving the way for a new wave of precision therapies. The design of nonhepatocyte RNA delivery systems without targeting ligands, however, remains a challenge. It is reported that the development of ligand‐free glycidylamine (GA) derivatives containing LNPs (GA‐LNPs) that preferentially deliver mRNA to immune cells in the spleen. Notably, it is demonstrated that the stereochemistry of GA‐lipids has a significant impact on their self‐assembly and in vitro and in vivo RNA delivery efficiency and tropism. This impact is dependent on the monomeric structure of GA and number of stereogenic centers. Furthermore, the nonlinear topology of GA lipid derivatives induced a sevenfold improvement in mRNA delivery efficiency. The top‐performing estriol‐GA05‐30 LNPs elicited strong antitumor activity in a therapeutic and prophylactic cancer model and are well tolerated in mice. These results highlight the significance of the chemistry of ionizable lipids for extrahepatic RNA delivery and indicated a promising direction for the development of next‐generation mRNA immunotherapies.
  • 骨格筋細胞ミトコンドリアに対する薬物送達および機能活性化についての検討
    佐藤 逸美; 日比野 光恵; 佐々木 大輔; 武田 充人; 原島 秀吉; 山田 勇磨
    日本DDS学会学術集会プログラム予稿集, 39回, 144, 144, 日本DDS学会, 2023年07月
    日本語
  • ミトコンドリア活性化幹細胞(MITO cell)を用いた心筋虚血再灌流モデルマウスにおける細胞移植治療の検証
    佐々木 大輔; 武田 充人; 原島 秀吉; 山田 勇磨
    日本DDS学会学術集会プログラム予稿集, 39回, 176, 176, 日本DDS学会, 2023年07月
    日本語
  • オミックス解析がもたらす小児心血管疾患研究の新たな展開 メタボローム解析を用いたミトコンドリア活性化ヒト心筋前駆細胞移植法の効果検証
    白石 真大; 佐々木 大輔; 武田 充人; 原島 秀吉; 山田 勇磨
    日本小児循環器学会総会・学術集会抄録集, 59回, [III, 04], (NPO)日本小児循環器学会, 2023年07月
    日本語
  • Development of light-induced disruptive liposomes (LiDL) as a photoswitchable carrier for intracellular substance delivery.
    Taichi Tsuneishi; Keiichi Kojima; Fumika Kubota; Hideyoshi Harashima; Yuma Yamada; Yuki Sudo
    Chemical communications (Cambridge, England), 59, 49, 7591, 7594, 2023年06月15日, [国際誌]
    英語, 研究論文(学術雑誌), Light-driven inward proton pump rhodopsin RmXeR was embedded in pH-sensitive liposomes. Substance release from the proteoliposomes was observed following light illumination both in vitro and in cells, indicating the successful production of light-induced disruptive liposomes (LiDL). Thus, LiDL is a photoswitchable carrier utilized for intracellular substance delivery.
  • Differences in the Intracellular Localization of Methylated β-Cyclodextrins-Threaded Polyrotaxanes Lead to Different Cellular States
    Yuma Yamada; Shinnosuke Daikuhara; Atsushi Tamura; Kei Nishida; Nobuhiko Yui; Hideyoshi Harashima
    Biomolecules, 13, 6, 903, 903, MDPI AG, 2023年05月29日
    研究論文(学術雑誌), Activation of autophagy represents a potential therapeutic strategy for the treatment of diseases that are caused by the accumulation of defective proteins and the formation of abnormal organelles. Methylated β-cyclodextrins-threaded polyrotaxane (Me-PRX), a supramolecular structured polymer, induces autophagy by interacting with the endoplasmic reticulum. We previously reported on the successful activation of mitochondria-targeted autophagy by delivering Me-RRX to mitochondria using a MITO-Porter, a mitochondria-targeted nanocarrier. The same level of autophagy induction was achieved at one-twentieth the dosage for the MITO-Porter (Me-PRX) compared to the naked Me-PRX. We report herein on the quantitative evaluation of the intracellular organelle localization of both naked Me-PRX and the MITO-Porter (Me-PRX). Mitochondria, endoplasmic reticulum and lysosomes were selected as target organelles because they would be involved in autophagy induction. In addition, organelle injury and cell viability assays were performed. The results showed that the naked Me-PRX and the MITO-Porter (Me-PRX) were localized in different intracellular organelles, and organelle injury was different, depending on the route of administration, indicating that different organelles contribute to autophagy induction. These findings indicate that the organelle to which the autophagy-inducing molecules are delivered plays an important role in the level of induction of autophagy.
  • A system that delivers an antioxidant to mitochondria for the treatment of drug-induced liver injury.
    Mitsue Hibino; Masatoshi Maeki; Manabu Tokeshi; Yoichi Ishitsuka; Hideyoshi Harashima; Yuma Yamada
    Scientific reports, 13, 1, 6961, 6961, 2023年05月10日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Mitochondria, a major source of reactive oxygen species (ROS), are intimately involved in the response to oxidative stress in the body. The production of excessive ROS affects the balance between oxidative responses and antioxidant defense mechanisms thus perturbing mitochondrial function eventually leading to tissue injury. Therefore, antioxidant therapies that target mitochondria can be used to treat such diseases and improve general health. This study reports on an attempt to establish a system for delivering an antioxidant molecule coenzyme Q10 (CoQ10) to mitochondria and the validation of its therapeutic efficacy in a model of acetaminophen (APAP) liver injury caused by oxidative stress in mitochondria. A CoQ10-MITO-Porter, a mitochondrial targeting lipid nanoparticle (LNP) containing encapsulated CoQ10, was prepared using a microfluidic device. It was essential to include polyethylene glycol (PEG) in the lipid composition of this LNP to ensure stability of the CoQ10, since it is relatively insoluble in water. Based on transmission electron microscope (TEM) observations and small angle X-ray scattering (SAXS) measurements, the CoQ10-MITO-Porter was estimated to be a 50 nm spherical particle without a regular layer structure. The use of the CoQ10-MITO-Porter improved liver function and reduced tissue injury, suggesting that it exerted a therapeutic effect on APAP liver injury.
  • Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles.
    Takashi Nakamura; Taisei Nakade; Yusuke Sato; Hideyoshi Harashima
    International journal of pharmaceutics, 636, 122810, 122810, 2023年04月05日, [国際誌]
    英語, 研究論文(学術雑誌), In cancer immunotherapy, therapeutic methods targeting NK are highly expected. NK cell-based therapy using NK-92, a human NK cell line, has been clinically evaluated. Delivering mRNA into NK-92 cells is a potent strategy for enhancing its functions. However, the use of lipid nanoparticles (LNP) for this purpose has not yet been evaluated. We previously developed a LNP that was composed of CL1H6 (CL1H6-LNP) for the efficient delivery of siRNA to NK-92 cells, and the use of this material for delivering mRNA to NK-92 cells is reported in this study. Compared with a DLin-MC3-DMA based LNP, used as a benchmark, the CL1H6-LNP caused a high mRNA expression intensity and a cell transfection efficiency of 100%. The efficient mRNA delivery by this CL1H6-LNP is attributed to the high affinity for NK-92 cells and the intense, rapid fusion with the endosomal membrane. It therefore appears that the CL1H6-LNP could be a useful non-viral vector for modifying the NK-92 functions by mRNA. Our findings also provide some insights into the design and development of LNPs for delivering mRNA to NK-92 and NK cells.
  • Microenvironmental Changes in Mediastinal Fat-associated Lymphoid Clusters and Lungs in Early and Late Stages of Metastatic Lung Cancer Induction
    Yaser Hosny Ali Elewa; Mahmoud M Abd Elwakil; Hideyoshi Harashima; Sherif Kh A Mohamed; Mahmoud Hosny Zahran
    Microscopy and Microanalysis, 29, 3, 1228, 1243, Oxford University Press (OUP), 2023年04月01日
    研究論文(学術雑誌), Abstract

    The prognosis of metastatic lung melanoma (MLM) has been reported to be poor. An increasing number of studies have reported the function of several immune cells in cancer regression. Although the function of mediastinal fat-associated lymphoid clusters (MFALCs) in the progression of inflammatory lung lesions has been previously reported, the association between MLM progression and MFALCs development has remained unexplored. Herein, we compared the microenvironmental changes in the lungs and MFALCs among phosphate-buffered saline (PBS) and cancer groups at early (1 week) and late (2 weeks) stages following the intravenous injection of B16-F10 melanoma cells into C57BL/6 mice. Except for lung CD4+ helper T-cells and Iba1+ macrophage populations of early stage, we observed a significant increase in the proliferating and immune cell (CD20+ B-lymphocytes, CD3+ T-lymphocytes, CD8+ cytotoxic T-cells, CD16+ natural killer (NK) cells populations, area of high endothelial venules, and lung lymphatic vessels in cancer groups at both the stages as compared with the PBS groups. Furthermore, a significant positive correlation was observed between immune cell populations in MFALCs and the lungs (B- and T-lymphocytes, and NK cells in both stages). Collectively, our findings suggest a promising cancer therapeutic strategy via targeting immune cells in MFALCs.
  • Mass production system for RNA-loaded lipid nanoparticles using piling up microfluidic devices
    Masatoshi Maeki; Yuto Okada; Shuya Uno; Kaisei Sugiura; Yuichi Suzuki; Kento Okuda; Yusuke Sato; Masao Ando; Hiroyuki Yamazaki; Masaki Takeuchi; Akihiko Ishida; Hirofumi Tani; Hideyoshi Harashima; Manabu Tokeshi
    Applied Materials Today, 2023年04月, [査読有り]
    研究論文(学術雑誌)
  • Development of a Mitochondrial Targeting Lipid Nanoparticle Encapsulating Berberine
    Ikuma Hori; Hideyoshi Harashima; Yuma Yamada
    International Journal of Molecular Sciences, 24, 2, 903, 903, MDPI AG, 2023年01月04日
    研究論文(学術雑誌), Delivering drugs to mitochondria, the main source of energy in neurons, can be a useful therapeutic strategy for the treatment of neurodegenerative diseases. Berberine (BBR), an isoquinoline alkaloid, acts on mitochondria and is involved in mechanisms associated with the normalization and regulation of intracellular metabolism. Therefore, BBR has attracted considerable interest as a possible therapeutic drug for neurodegenerative diseases. While BBR has been reported to act on mitochondria, there are few reports on the efficient delivery of BBR into mitochondria. This paper reports on the mitochondrial delivery of BBR using a lipid nanoparticle (LNP), a “MITO-Porter” that targets mitochondria, and its pharmacological action in Neuro2a cells, a model neuroblastoma. A MITO-Porter containing encapsulated BBR (MITO-Porter (BBR)) was prepared. Treatment with MITO-Porter (BBR) increased the amount of BBR that accumulated in mitochondria compared with a treatment with naked BBR. Treatment with MITO-Porter (BBR) resulted in increased ATP production in Neuro2a cells, which are important for maintaining life phenomena, compared with treatment with naked BBR. Treatment with MITO-Porter (BBR) also increased the level of expression of mitochondrial ubiquitin ligase (MITOL), which is involved in mitochondrial quality control. Our findings indicate that increasing the accumulation of BBR into mitochondria is important for inducing enhanced pharmacological actions. The use of this system has the potential for being important in terms of the regulation of the metabolic mechanism of mitochondria in nerve cells.
  • Self-homing nanocarriers for mRNA delivery to the activated hepatic stellate cells in liver fibrosis
    Mahmoud A. Younis; Yusuke Sato; Yaser H.A. Elewa; Yasuhiro Kon; Hideyoshi Harashima
    Journal of Controlled Release, 353, 685, 698, Elsevier BV, 2023年01月
    研究論文(学術雑誌)
  • Non-Viral Gene Therapy in Trabecular Meshwork Cells to Prevent Fibrosis in Minimally Invasive Glaucoma Surgery
    Jinyuan Luo; Greymi Tan; Kai Xin Thong; Konstantinos N. Kafetzis; Neeru Vallabh; Carl M. Sheridan; Yusuke Sato; Hideyoshi Harashima; Aristides D. Tagalakis; Cynthia Yu-Wai-Man
    Pharmaceutics, 2022年11月
    研究論文(学術雑誌)
  • Fine-tuning the encapsulation of a photosensitizer in nanoparticles reveals the relationship between internal structure and phototherapeutic effects.
    Fumika Kubota; Satrialdi; Yuta Takano; Masatoshi Maeki; Manabu Tokeshi; Hideyoshi Harashima; Yuma Yamada
    Journal of biophotonics, 16, 3, e202200119, 2022年09月01日, [国際誌]
    英語, 研究論文(学術雑誌), Photodynamic therapy (PDT) is a cancer therapy that uses a photosensitizer (PS) in the presence of oxygen molecules. Since singlet oxygen is highly reactive, it is important to deliver it to the target site. Thus, an efficient drug delivery system (DDS) is essential for enhancing the efficacy of such a treatment and protecting against the side effects of PDT. Here, we report on attempts to increase the therapeutic effect of PDT by using a DDS, a lipid nanoparticle (LNP). We prepared a porphyrin analog, rTPA (PS) that was encapsulated in LNPs using a microfluidic device. The findings indicated that the internal structure of the prepared particles changed depending on the amount of rTPA in LNPs. The photoactivity and cell-killing effect of PS in LNPs also changed when the amount of the cargo increased. These results suggest that the internal structure of LNPs is important factors that affect drug efficacy. This article is protected by copyright. All rights reserved.
  • Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody.
    Alaa M Khalifa; Takashi Nakamura; Yusuke Sato; Takanori Sato; Mamoru Hyodo; Yoshihiro Hayakawa; Hideyoshi Harashima
    International journal of pharmaceutics, 624, 122034, 122034, 2022年08月25日, [国際誌]
    英語, 研究論文(学術雑誌), Programmed cell death 1 (PD-1) blockade combination to other drugs have attracted the interest of scientists for treating tumors resistant to PD-1 blockade. In this study, the impact of the interval, order of administration, and number of cycles of immunotherapeutic combination of stimulator of interferon genes (STING) pathway agonist loaded lipid nanoparticle (STING-LNP) and PD-1 antibody for inducing the optimal combined antitumor activity against a melanoma lung metastasis is reported. One cycle had no effect, but two and three cycles resulted in a combinedantitumor effect. The interval between the administration was found to influence the induction of the combined effect. The second and third doses increased the gene expression of the NK cell activation marker, interferon γ (IFN-γ), PD-1 and a ligand of PD-1 (PD-L1), whereas the first dose failed. NK cells in the lung showed an increase in the expression of the activation markers and PD-1 after the second dose. The combined antitumor effect of this combination therapy against melanoma lung metastasis model could be dependent on the interval as well as the number of doses of STING-LNP.These findings suggest the importance of the protocol setting when combining a nano system loaded with an immune adjuvant and PD-1 antibody.
  • Inhibitory role of Annexin A1 in pathological bone resorption and therapeutic implications in periprosthetic osteolysis.
    Hend Alhasan; Mohamad Alaa Terkawi; Gen Matsumae; Taku Ebata; Yuan Tian; Tomohiro Shimizu; Yoshio Nishida; Shunichi Yokota; Fayna Garcia-Martin; Mahmoud M Abd Elwakil; Daisuke Takahashi; Mahmoud A Younis; Hideyoshi Harashima; Ken Kadoya; Norimasa Iwasaki
    Nature communications, 13, 1, 3919, 3919, 2022年07月07日, [国際誌]
    英語, 研究論文(学術雑誌), There is currently no therapy available for periprosthetic osteolysis, the most common cause of arthroplasty failure. Here, the role of AnxA1 in periprosthetic osteolysis and potential therapeutics were investigated. Reducing the expression of AnxA1 in calvarial tissue was found to be associated with increased osteolytic lesions and the osteolytic lesions induced by debris implantation were more severe in AnxA1-defecient mice than in wild-type mice. AnxA1 inhibits the differentiation of osteoclasts through suppressing NFκB signaling and promoting the PPAR-γ pathway. Administration of N-terminal-AnxA1 (Ac2-26 peptide) onto calvariae significantly reduced osteolytic lesions triggered by wear debris. These therapeutic effects were abrogated in mice that had received the PPAR-γ antagonist, suggesting that the AnxA1/PPAR-γ axis has an inhibitory role in osteolysis. The administration of Ac2-26 suppressed osteolysis induced by TNF-α and RANKL injections in mice. These findings indicate that AnxA1 is a potential therapeutic agent for the treatment of periprosthetic osteolysis.
  • Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines.
    Takashi Nakamura; Yusuke Sato; Yuma Yamada; Mahmoud M Abd Elwakil; Seigo Kimura; Mahmoud A Younis; Hideyoshi Harashima
    Advanced drug delivery reviews, 188, 114417, 114417, 2022年07月03日, [国際誌]
    英語, 研究論文(学術雑誌), A new era of nanomedicines that involve nucleic acids/gene therapy has been opened after two decades in 21st century and new types of more efficient drug delivery systems (DDS) are highly expected and will include extrahepatic delivery. In this review, we summarize the possibility and expectations for the extrahepatic delivery of small interfering RNA/messenger RNA/plasmid DNA/genome editing to the spleen, lung, tumor, lymph nodes as well as the liver based on our studies as well as reported information. Passive targeting and active targeting are discussed in in vivo delivery and the importance of controlled intracellular trafficking for successful therapeutic results are also discussed. In addition, mitochondrial delivery as a novel strategy for nucleic acids/gene therapy is introduced to expand the therapeutic dimension of nucleic acids/gene therapy in the liver as well as the heart, kidney and brain.
  • mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy
    Kosuke Sasaki; Yusuke Sato; Kento Okuda; Kazuki Iwakawa; Hideyoshi Harashima
    Pharmaceutics, 2022年07月
    研究論文(学術雑誌)
  • ミトコンドリア活性化心筋幹細胞移植療法の臨床応用に向けた取り組み
    白石 真大; 山田 勇磨; 佐々木 大輔; 武田 充人; 原島 秀吉
    日本小児循環器学会総会・学術集会抄録集, 58回, [III, 03], (NPO)日本小児循環器学会, 2022年07月
    日本語
  • On the size-regulation of RNA-loaded lipid nanoparticles synthesized by microfluidic device.
    Kento Okuda; Yusuke Sato; Kazuki Iwakawa; Kosuke Sasaki; Nana Okabe; Masatoshi Maeki; Manabu Tokeshi; Hideyoshi Harashima
    Journal of controlled release : official journal of the Controlled Release Society, 348, 648, 659, 2022年06月18日, [国際誌]
    英語, 研究論文(学術雑誌), The use of lipid nanoparticles (LNPs) for nucleic acid delivery is now becoming a promising strategy with a number of clinical trials as vaccines or as novel therapies against a variety of genetic and infectious diseases. The use of microfluidics for the synthesis of the LNPs has attracted interest because of its considerable advantages over other conventional synthetic methods including scalability, reproducibility, and speed. However, despite the potential usefulness of large particles for nucleic acid delivery to dendritic cells (DCs) as a vaccine, the particle size of the LNPs prepared using microfluidics is typically limited to approximately from 30 to 100 nm. In this study, focusing on Derjaguin-Landau-Verwey-Overbeek (DLVO) theory, the effect of some synthetic parameters, including total flow rate, flow rate ratio, buffer pH, lipid concentration, molar ratio of PEG-lipid as well as salt concentration, on particle size was systematically examined by means of the design of experiment approaches. The findings indicated that the simple addition of salt (e.g. NaCl) to a buffer containing nucleic acids contributed greatly to the synthesis of large LNPs over 200 nm and this effect was concentration-dependent with respect to the salt. The effect of salt on particle size was consistent with a Hofmeister series. The systemic injection of larger mRNA-loaded LNPs resulted in a higher transgene expression in mouse splenic DCs, a higher activation of various splenic immune cells, and had a superior effect as a therapeutic cancer vaccine in a syngeneic mouse model compared to the smaller-sized counterpart with constant lipid composition prepared with lower NaCl concentration. Collectively, size-regulation by the simple addition of salt is a promising strategy for developing potent LNPs.
  • Retrograde Axonal Transport of Liposomes from Peripheral Tissue to Spinal Cord and DRGs by Optimized Phospholipid and CTB Modification.
    Takafumi Fukui; Hironao Tateno; Takashi Nakamura; Yuma Yamada; Yusuke Sato; Norimasa Iwasaki; Hideyoshi Harashima; Ken Kadoya
    International journal of molecular sciences, 23, 12, 2022年06月15日, [国際誌]
    英語, 研究論文(学術雑誌), Despite recent advancements in therapeutic options for disorders of the central nervous system (CNS), the lack of an efficient drug-delivery system (DDS) hampers their clinical application. We hypothesized that liposomes could be optimized for retrograde transport in axons as a DDS from peripheral tissues to the spinal cord and dorsal root ganglia (DRGs). Three types of liposomes consisting of DSPC, DSPC/POPC, or POPC in combination with cholesterol (Chol) and polyethylene glycol (PEG) lipid were administered to sciatic nerves or the tibialis anterior muscle of mature rats. Liposomes in cell bodies were detected with infrared fluorescence of DiD conjugated to liposomes. Three days later, all nerve-administered liposomes were retrogradely transported to the spinal cord and DRGs, whereas only muscle-administered liposomes consisting of DSPC reached the spinal cord and DRGs. Modification with Cholera toxin B subunit improved the transport efficiency of liposomes to the spinal cord and DRGs from 4.5% to 17.3% and from 3.9% to 14.3% via nerve administration, and from 2.6% to 4.8% and from 2.3% to 4.1% via muscle administration, respectively. Modification with octa-arginine (R8) improved the transport efficiency via nerve administration but abolished the transport capability via muscle administration. These findings provide the initial data for the development of a novel DDS targeting the spinal cord and DRGs via peripheral administration.
  • Innovative cancer nanomedicine based on immunology, gene editing, intracellular trafficking control.
    Yuma Yamada; Yusuke Sato; Takashi Nakamura; Hideyoshi Harashima
    Journal of controlled release : official journal of the Controlled Release Society, 348, 357, 369, 2022年06月09日, [国際誌]
    英語, 研究論文(学術雑誌), The recent rapid progress in the area of drug delivery systems (DDS) has opened a new era in medicine with a strong linkage to understanding the molecular mechanisms associated with cancer survival. In this review, we summarize new cancer strategies that have recently been developed based on our DDS technology. Cancer immunotherapy will be improved based on the concept of the cancer immunity cycle, which focuses on dynamic interactions between various types of cancer and immune cells in our body. The new technology of genome editing will also be discussed with reference to how these new DDS technologies can be used to introduce therapeutic cargoes into our body. Lastly, a new organelle, mitochondria will be the focus of creating a new cancer treatment strategy by a MITO-Porter which can deliver macromolecules directly to mitochondria of cancer cells via a membrane fusion approach and the impact of controlled intracellular trafficking will be discussed.
  • Validation of a therapeutic strategy involving the mitochondrial delivery of thiamine pyrophosphate using brain damage induced mouse model
    Yuma Yamada; Takuya Ishimaru; Hideyoshi Harashima
    Clinical and Translational Discovery, 2, 2, Wiley, 2022年06月
    研究論文(学術雑誌)
  • Recent advances in delivering RNA-based therapeutics to mitochondria.
    Yuma Yamada; Sen Ishizuka; Manae Arai; Minako Maruyama; Hideyoshi Harashima
    Expert opinion on biological therapy, 1, 11, 2022年05月11日, [国際誌]
    英語, 研究論文(学術雑誌), INTRODUCTION: After the emergence of lipid nanoparticles (LNP) containing therapeutic mRNA as vaccines for use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the clinical usefulness of nucleic acid-encapsulated LNPs is now a fact. In addition to the nucleus and cytoplasm, mitochondria, which have their own genome, are a site where nucleic acids function in the cell. Gene therapies targeting mitochondria are expected to pave the way for the next generation of therapies. AREAS COVERED: Methods for delivering nucleic acids to mitochondria are needed in order to realize such innovative therapies. However, only a few reports on delivery systems targeting mitochondria have appeared. In this review, we summarize the current state of research on RNA-based therapeutics targeted to mitochondria, with emphasis on mitochondrial RNA delivery therapies and on therapies that involve the use of mitochondrial genome editing devices. EXPERT OPINION: We hope that this review article will focus our attention to this area of research, stimulate more interest in this field of research, and lead to the development of mitochondria-targeted nucleic acid medicine. It has the potential to become a major weapon against urgent and unknown diseases, including SARS-CoV-2 infections.
  • Combined nano cancer immunotherapy based on immune status in a tumor microenvironment.
    Takashi Nakamura; Kyoko Kawakami; Momoka Nomura; Yusuke Sato; Mamoru Hyodo; Hiroto Hatakeyama; Yoshihiro Hayakawa; Hideyoshi Harashima
    Journal of controlled release : official journal of the Controlled Release Society, 345, 200, 213, 2022年05月, [国際誌]
    英語, 研究論文(学術雑誌), Since the effect of cancer immunotherapy is largely dependent on the status of the immune system in the tumor microenvironment (TME), choice of therapy and the development of new therapies based on the immune status in the TME would be predicted to be effective. Unfortunately, the development of delivery systems for such therapy has been slow. Here, we defined a parameter of immune status in TME showing antitumor effects and demonstrated the cancer immunotherapy with an adjuvant loaded lipid nanoparticle (LNP), which was taken advantage the parameter. An analysis was carried out to determine the relationship between antitumor effects and gene expression (22 target genes) in tumors (MC38 and E.G7-OVA) that respond to the programmed cell death 1 (PD-1) antibody and non-responding tumors (B16-F10 and 4T1). The immune status showing an effective antitumor effect, which consisted of 10 genes, was then extracted. Treatment with the adjuvant loaded LNP caused a significant antitumor effect against an E.G7-OVA tumor, and the gene expression in the E.G7-OVA tumor was completely within the range of gene expression for showing an effective antitumor effect, as defined by the identified immune status panel (IS-panel-10). Although the treatment with the adjuvant loaded LNP failed to induce a sufficient antitumor effect against the 4T1 tumor, we succeeded in enhancing the antitumor effect by using a combination therapy that was adopted based on the analysis by the IS-panel-10 in the TME. The 10 genes were found to affect the prognosis in a variety of human cancers. Collectively, the findings reported herein demonstrate the potential of immune status analysis in the TME for developing cancer immunotherapies using a delivery system.
  • Non-invasive gene delivery across the blood-brain barrier: present and future perspectives.
    Seigo Kimura; Hideyoshi Harashima
    Neural regeneration research, 17, 4, 785, 787, 2022年04月, [査読有り], [招待有り], [最終著者], [国際誌]
    英語, 研究論文(学術雑誌)
  • Transplantation of MITO cells, mitochondria activated cardiac progenitor cells, to the ischemic myocardium of mouse enhances the therapeutic effect.
    Daisuke Sasaki; Jiro Abe; Atsuhito Takeda; Hideyoshi Harashima; Yuma Yamada
    Scientific reports, 12, 1, 4344, 4344, 2022年03月22日, [国際誌]
    英語, 研究論文(学術雑誌), Given the potential for myocardial stem cell transplantation as a promising treatment for heart failure, numerous clinical trials have been conducted and its usefulness has been clearly confirmed. However, the low rate of engraftment of transplanted cells has become a clinical problem, and this needs to be improved in the case of transplanting cells to the heart. To address this issue, we report on attempts to prepare mitochondria-activated stem cells (MITO cells) for use in transplantation. MITO cells, which is cardiac progenitor cells (CPCs) activated by the mitochondrial delivery of resveratrol with an anti-oxidant and mitochondrial activation effects were successfully prepared using a mitochondrial targeting nanocarrier (MITO-Porter). The purpose of this study was to validate the therapeutic effect of cell transplantation by the MITO cells using a mouse model of myocardial ischemia-reperfusion. Mouse CPCs were used as transplanted cells. The transplantation of CPCs and MITO cells were conducted after myocardial ischemia-reperfusion, and the therapeutic effect was determined. The MITO cells transplanted group showed increase in postoperative weight gain, improve cardiac function and inhibition of fibrosis compared to the non-transplanted group and the CPC group. The transplantation of MITO cells to the ischemic myocardium showed a stronger transplantation effect compared to conventional CPC transplantation.
  • Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system.
    Nako Maishi; Yu Sakurai; Hiroto Hatakeyama; Yui Umeyama; Takashi Nakamura; Rikito Endo; Mohammad Towfik Alam; Cong Li; Dorcas Akuba-Muhyia Annan; Hiroshi Kikuchi; Hirofumi Morimoto; Masahiro Morimoto; Kosuke Akiyama; Noritaka Ohga; Yasuhiro Hida; Hideyoshi Harashima; Kyoko Hida
    Cancer science, 113, 5, 1855, 1867, 2022年03月09日, [国際誌]
    英語, 研究論文(学術雑誌), Tumor blood vessels play important roles in tumor progression and metastasis. Targeting tumor endothelial cells (TECs) is one of the strategies for cancer therapy. We previously reported that biglycan, a small leucine-rich proteoglycan, is highly expressed in TECs. TECs utilize biglycan in an autocrine manner for migration and angiogenesis. Furthermore, TEC-derived biglycan stimulates tumor cell migration in a paracrine manner leading to tumor cell intravasation and metastasis. In this study, we explored the therapeutic effect of biglycan inhibition in the TECs of renal cell carcinoma using an in vivo siRNA delivery system known as a multifunctional envelope-type nanodevice (MEND), which contains a unique pH-sensitive cationic lipid. To specifically deliver MEND into TECs, we incorporated cyclo(Arg-Gly-Asp-D-Phe-Lys) (cRGD) into MEND because αV β3 integrin, a receptor for cRGD, is selective and highly expressed in TECs. We developed RGD-MEND-encapsulating siRNA against biglycan. First, we confirmed that MEND was delivered into OS-RC-2 tumor-derived TECs and induced in vitro RNAi-mediated gene silencing. MEND was then injected intravenously into OS-RC-2 tumor-bearing mice. Flow cytometry analysis demonstrated that MEND was specifically delivered into TECs. Quantitative RT-PCR indicated that biglycan was knocked down by biglycan siRNA-containing MEND. Finally, we analyzed the therapeutic effect of biglycan silencing by MEND in TECs. Tumor growth was inhibited by biglycan siRNA-containing MEND. Tumor microenvironmental factors such as fibrosis were also normalized using biglycan inhibition in TECs. Biglycan in TECs can be a novel target for cancer treatment.
  • ミトコンドリア標的型DDSによるミトコンドリア病治療戦略の検証
    荒井 愛永; 山田 勇磨; 佐々木 大輔; 真栄城 正寿; 渡慶次 学; 原島 秀吉
    日本薬学会年会要旨集, 142年会, 27I, am02S, (公社)日本薬学会, 2022年03月
    日本語
  • Strategies for fighting pandemic virus infections: Integration of virology and drug delivery.
    Takashi Nakamura; Norikazu Isoda; Yoshihiro Sakoda; Hideyoshi Harashima
    Journal of controlled release : official journal of the Controlled Release Society, 343, 361, 378, 2022年02月03日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Respiratory viruses have sometimes resulted in worldwide pandemics, with the influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) being major participants. Long-term efforts have made it possible to control the influenza virus, but seasonal influenza continues to take many lives each year, and a pandemic influenza virus sometimes emerges. Although vaccines for coronavirus disease 2019 (COVID-19) have been developed, we are not yet able to coexist with the SARS-CoV-2. To overcome such viruses, it is necessary to obtain knowledge about international surveillance systems, virology, ecology and to determine that immune responses are effective. The information must then be transferred to drugs. Delivery systems would be expected to contribute to the rational development of drugs. In this review, virologist and drug delivery system (DDS) researchers discuss drug delivery strategies, especially the use of lipid-based nanocarriers, for fighting to respiratory virus infections.
  • Resveratrol-Encapsulated Mitochondria-Targeting Liposome Enhances Mitochondrial Respiratory Capacity in Myocardial Cells.
    Takao Tsujioka; Daisuke Sasaki; Atsuhito Takeda; Hideyoshi Harashima; Yuma Yamada
    International journal of molecular sciences, 23, 1, 2021年12月22日, [国際誌]
    英語, 研究論文(学術雑誌), The development of drug delivery systems for use in the treatment of cardiovascular diseases is an area of great interest. We report herein on an evaluation of the therapeutic potential of a myocardial mitochondria-targeting liposome, a multifunctional envelope-type nano device for targeting pancreatic β cells (β-MEND) that was previously developed in our laboratory. Resveratrol (RES), a natural polyphenol compound that has a cardioprotective effect, was encapsulated in the β-MEND (β-MEND (RES)), and its efficacy was evaluated using rat myocardioblasts (H9c2 cells). The β-MEND (RES) was readily taken up by H9c2 cells, as verified by fluorescence-activated cell sorter data, and was observed to be colocalized with intracellular mitochondria by confocal laser scanning microscopy. Myocardial mitochondrial function was evaluated by a Seahorse XF Analyzer and the results showed that the β-MEND (RES) significantly activated cellular maximal respiratory capacity. In addition, the β-MEND (RES) showed no cellular toxicity for H9c2 cells as evidenced by Premix WST-1 assays. This is the first report of the use of a myocardial mitochondria-targeting liposome encapsulating RES for activating mitochondrial function, which was clearly confirmed based on analyses using a Seahorse XF Analyzer.
  • An effective in vivo mitochondria-targeting nanocarrier combined with a pi-extended porphyrin-type photosensitizer
    Satrialdi; Yuta Takano; Eri Hirata; Natsumi Ushijima; Hideyoshi Harashima; Yuma Yamada
    NANOSCALE ADVANCES, 3, 20, 5919, 5927, 2021年10月
    英語, 研究論文(学術雑誌)
  • The hydrophobic tail of a pH-sensitive cationic lipid influences siRNA transfection activity and toxicity in human NK cell lines.
    Takashi Nakamura; Taisei Nakade; Koharu Yamada; Yusuke Sato; Hideyoshi Harashima
    International journal of pharmaceutics, 609, 121140, 121140, 2021年09月27日, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), The use of natural killer (NK) cells in cell therapy is an attractive next generation strategy for cancer immunotherapy. NK-92 cells (a human NK cell line) have been tested in clinical trial stages, making them an off-the-shelf medicine. Controlling gene expression in NK-92 cells by an artificial delivery system is an available for enhancing NK-92 cell therapy. We report here on the development of a siRNA-loaded lipid nanoparticle (LNP) composed of CL1H6 (CL1H6-LNP), an optimized, pH-sensitive cationic lipid, with efficient gene silencing and low cytotoxicity in NK-92 cells. The hydrophilic head group of the lipid molecule used in preparing these particles largely influences the pKa of the final LNP, and lipids with an amino moiety substituted with a methyl group showed a high gene silencing activity. Compared with myristate and palmitate, the hydrophobic tail of oleate had a high gene silencing activity and cell viability. Analyses of intracellular trafficking indicated that the CL1H6-LNP appeared to escape from the endosomes via membrane fusion, without disrupting the membrane. The mechanism of endosomal escape should contribute to our understanding of efficient gene silencing with a low degree of cytotoxicity. These results therefore suggest that a CL1H6-LNP has promise for delivering siRNA to NK-92 cells.
  • Maximizing the Oral Bioavailability of Poorly Water-Soluble Drugs Using Novel Oil-Like Materials in Lipid-Based Formulations.
    Saed Abbasi; Haruki Higashino; Yusuke Sato; Keiko Minami; Makoto Kataoka; Shinji Yamashita; Hideyoshi Harashima
    Molecular pharmaceutics, 18, 9, 3281, 3289, 2021年09月06日, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Lipid-based formulations, such as self-microemulsifying drug-delivery systems (SMEDDSs), are promising tools for the oral delivery of poorly water-soluble drugs. However, failure to maintain adequate aqueous solubility after coming into contact with gastrointestinal fluids is a major drawback. In this study, we examined the use of a novel cinnamic acid-derived oil-like material (CAOM) that binds drugs with a high affinity through π-π stacking and hydrophobic interactions, as an oil core in a SMEDDS for the oral delivery of fenofibrate in rats. The use of the CAOM in the SMEDDS resulted in an unprecedented enhancement in fenofibrate bioavailability, which exceeded the bioavailability values obtained using SMEDDSs based on corn oil, a conventional triglyceride oil, or Labrasol, an enhancer of intestinal permeation. Further characterization revealed that the CAOM SMEDDS does not alter the intestinal permeability and has no inhibitory activity on P-glycoprotein-mediated drug efflux. The results reported herein demonstrate the strong potential of CAOM formulations as new solubilizers for the efficient and safe oral delivery of drugs that have limited water solubility.
  • Validation of the mitochondrial delivery of vitamin B1 to enhance ATP production using SH-SY5Y cells, a model neuroblast.
    Yuma Yamada; Takuya Ishimaru; Kohei Ikeda; Hideyoshi Harashima
    Journal of pharmaceutical sciences, 111, 2, 432, 439, 2021年08月31日, [査読有り], [最終著者], [国際誌]
    英語, 研究論文(学術雑誌), Large amounts of ATP are produced in mitochondria especially in the brain and heart, where energy consumption is high compared with other organs. Thus, a decrease in ATP production in such organs could be a cause of many diseases such as neurodegenerative diseases and heart disease. Based on thus assumption, increasing intracellular ATP production in such organs could be a therapeutic strategy. In this study, we report on the delivery of vitamin B1, a coenzyme that activates the tricarboxylic acid (TCA) cycle, to the inside of mitochondria. Since the TCA cycle is responsible for ATP production, we hypothesized delivering vitamin B1 to mitochondria would enhance ATP production. To accomplish this, we used a mitochondrial targeted liposome a "MITO-Porter" as the carrier. Using SH-SY5Y cells, a model neuroblast, cellular uptake and intracellular localization were analyzed using flow cytometry and confocal laser scanning microscopy. The optimized MITO-Porter containing encapsulated vitamin B1 (MITO-Porter (VB1)) was efficiently accumulated in mitochondria of SH-SY5Y cells. Further studies confirmed that the level of ATP production after the MITO-Porter (VB1) treatment was significantly increased as compared to a control group that was treated with naked vitamin B1. This study provides the potential for an innovative therapeutic strategy in which the TCA cycle is activated, thus enhancing ATP production. Relative ATP ratio (%) = IS/IU × 100, where IS and IU represent the intracellular ATP amounts for the treated and untreated cells with samples, respectively.
  • イメージングと操作で見るミトコンドリア機能 ミトコンドリア機能を操作するDrug Delivery System
    山田 勇磨; 原島 秀吉
    バイオイメージング, 30, 2, 38, 38, 日本バイオイメージング学会, 2021年08月
    日本語
  • 心筋症の基礎と臨床の架け橋を探る ヒト心筋前駆細胞を用いたミトコンドリア活性化心筋前駆細胞の製造および、心筋虚血再灌流モデルに対する細胞移植の治療効果の検討
    佐々木 大輔; 山田 勇磨; 後藤 悠太; 白石 真大; 武田 充人; 原島 秀吉
    日本小児循環器学会総会・学術集会抄録集, 57回, [I, 5], (NPO)日本小児循環器学会, 2021年07月
    日本語
  • 心筋ミトコンドリアを標的としたリポソーム製剤の開発研究
    辻岡 孝郎; 山田 勇磨; 佐々木 大輔; 武田 充人; 原島 秀吉
    日本小児循環器学会総会・学術集会抄録集, 57回, [OR31, 1], (NPO)日本小児循環器学会, 2021年07月
    日本語
  • STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.
    Takashi Nakamura; Takanori Sato; Rikito Endo; Shun Sasaki; Naomichi Takahashi; Yusuke Sato; Mamoru Hyodo; Yoshihiro Hayakawa; Hideyoshi Harashima
    Journal for immunotherapy of cancer, 9, 7, 2021年07月, [査読有り], [最終著者], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Resistance to an immune checkpoint inhibitor (ICI) is a major obstacle in cancer immunotherapy. The causes of ICI resistance include major histocompatibility complex (MHC)/histocompatibility locus antigen (HLA) class I loss, neoantigen loss, and incomplete antigen presentation. Elimination by natural killer (NK) cells would be expected to be an effective strategy for the treatment of these ICI-resistant tumors. We previously demonstrated that a lipid nanoparticle containing a stimulator of an interferon gene (STING) agonist (STING-LNP) efficiently induced antitumor activity via the activation of NK cells. Thus, we evaluated the potential of reducing ICI resistance by STING-LNPs. METHODS: Lung metastasis of a B16-F10 mouse melanoma was used as an anti-programmed cell death 1 (anti-PD-1)-resistant mouse model. The mice were intravenously injected with the STING-LNP and the mechanism responsible for the improvement of anti-PD-1 resistance by the STING-LNPs was analyzed by RT-qPCR and flow cytometry. The dynamics of STING-LNP were also investigated. RESULTS: Although anti-PD-1 monotherapy failed to induce an antitumor effect, the combination of the STING-LNP and anti-PD-1 exerted a synergistic antitumor effect. Our results indicate that the STING-LNP treatment significantly increased the expression of CD3, CD4, NK1.1, PD-1 and interferon (IFN)-γ in lung metastases. This change appears to be initiated by the type I IFN produced by liver macrophages that contain the internalized STING-LNPs, leading to the systemic activation of NK cells that express PD-1. The activated NK cells appeared to produce IFN-γ, resulting in an increase in the expression of the PD ligand 1 (PD-L1) in cancer cells, thus leading to a synergistic antitumor effect when anti-PD-1 is administered. CONCLUSIONS: We provide a demonstration to show that a STING-LNP treatment can overcome PD-1 resistance in a B16-F10 lung metastasis model. The mechanism responsible for this indicates that NK cells are activated by stimulating the STING pathway which, in turn, induced the expression of PD-L1 on cancer cells. Based on the findings reported herein, the STING-LNP represents a promising candidate for use in combination therapy with anti-PD-1-resistant tumors.
  • ミトコンドリア人工共生による細胞機能制御の試み
    山田 勇磨; 日比野 光恵; 伊藤 百; 荒井 愛永; 佐々木 大輔; 真栄城 正寿; 渡慶次 学; 太田 善浩; 原島 秀吉
    日本DDS学会学術集会プログラム予稿集, 37回, 111, 111, 日本DDS学会, 2021年06月
    日本語
  • 心筋虚血再灌流モデルラットに対するヒトミトコンドリア強化心筋幹細胞移植療法の治療効果の検討
    佐々木 大輔; 山田 勇磨; 後藤 悠太; 白石 真大; 武田 充人; 原島 秀吉
    日本DDS学会学術集会プログラム予稿集, 37回, 99, 99, 日本DDS学会, 2021年06月
    日本語
  • 心筋虚血再灌流モデルラットに対するヒトミトコンドリア強化心筋幹細胞移植療法の治療効果の検討
    佐々木 大輔; 山田 勇磨; 後藤 悠太; 白石 真大; 武田 充人; 原島 秀吉
    日本DDS学会学術集会プログラム予稿集, 37回, 99, 99, 日本DDS学会, 2021年06月
    日本語
  • ミトコンドリア人工共生による細胞機能制御の試み
    山田 勇磨; 日比野 光恵; 伊藤 百; 荒井 愛永; 佐々木 大輔; 真栄城 正寿; 渡慶次 学; 太田 善浩; 原島 秀吉
    日本DDS学会学術集会プログラム予稿集, 37回, 111, 111, 日本DDS学会, 2021年06月
    日本語
  • Interferon signaling suppresses the unfolded protein response and induces cell death in hepatocytes accumulating hepatitis B surface antigen.
    Ian Baudi; Masanori Isogawa; Federica Moalli; Masaya Onishi; Keigo Kawashima; Yuji Ishida; Chise Tateno; Yusuke Sato; Hideyoshi Harashima; Hiroyasu Ito; Tetsuya Ishikawa; Takaji Wakita; Matteo Iannacone; Yasuhito Tanaka
    PLoS pathogens, 17, 5, e1009228, 2021年05月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Virus infection, such as hepatitis B virus (HBV), occasionally causes endoplasmic reticulum (ER) stress. The unfolded protein response (UPR) is counteractive machinery to ER stress, and the failure of UPR to cope with ER stress results in cell death. Mechanisms that regulate the balance between ER stress and UPR are poorly understood. Type 1 and type 2 interferons have been implicated in hepatic flares during chronic HBV infection. Here, we examined the interplay between ER stress, UPR, and IFNs using transgenic mice that express hepatitis B surface antigen (HBsAg) (HBs-Tg mice) and humanized-liver chimeric mice infected with HBV. IFNα causes severe and moderate liver injury in HBs-Tg mice and HBV infected chimeric mice, respectively. The degree of liver injury is directly correlated with HBsAg levels in the liver, and reduction of HBsAg in the transgenic mice alleviates IFNα mediated liver injury. Analyses of total gene expression and UPR biomarkers' protein expression in the liver revealed that UPR is induced in HBs-Tg mice and HBV infected chimeric mice, indicating that HBsAg accumulation causes ER stress. Notably, IFNα administration transiently suppressed UPR biomarkers before liver injury without affecting intrahepatic HBsAg levels. Furthermore, UPR upregulation by glucose-regulated protein 78 (GRP78) suppression or low dose tunicamycin alleviated IFNα mediated liver injury. These results suggest that IFNα induces ER stress-associated cell death by reducing UPR. IFNγ uses the same mechanism to exert cytotoxicity to HBsAg accumulating hepatocytes. Collectively, our data reveal a previously unknown mechanism of IFN-mediated cell death. This study also identifies UPR as a potential target for regulating ER stress-associated cell death.
  • Novel PEGylated Lipid Nanoparticles Have a High Encapsulation Efficiency and Effectively Deliver MRTF-B siRNA in Conjunctival Fibroblasts.
    Amisha Sanghani; Konstantinos N Kafetzis; Yusuke Sato; Salsabil Elboraie; Julia Fajardo-Sanchez; Hideyoshi Harashima; Aristides D Tagalakis; Cynthia Yu-Wai-Man
    Pharmaceutics, 13, 3, 2021年03月13日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), The master regulator of the fibrosis cascade is the myocardin-related transcription factor/serum response factor (MRTF/SRF) pathway, making it a key target for anti-fibrotic therapeutics. In the past, inhibitors and small interfering RNAs (siRNAs) targeting the MRTF-B gene have been deployed to counter fibrosis in the eye, with the latter showing promising results. However, the biggest challenge in implementing siRNA therapeutics is the method of delivery. In this study, we utilised the novel, pH-sensitive, cationic lipid CL4H6, which has previously demonstrated potent targeting of hepatocytes and endosomal escape, to safely and efficiently deliver an MRTF-B siRNA into human conjunctival fibroblasts. We prepared two lipid nanoparticle (LNP) formulations, incorporating targeting cleavable peptide cY in one of them, and measured their physicochemical properties and silencing effect in human conjunctival fibroblasts. Both proved to be non-cytotoxic at a concentration of 50 nM and effectively silenced the MRTF-B gene in vitro, with the targeting cleavable peptide not affecting the silencing efficiency [LNP with cY: 62.1% and 81.5% versus LNP without cY: 77.7% and 80.2%, at siRNA concentrations of 50 nM (p = 0.06) and 100 nM (p = 0.09), respectively]. On the other hand, the addition of the targeting cleavable peptide significantly increased the encapsulation efficiency of the LNPs from 92.5% to 99.3% (p = 0.0005). In a 3D fibroblast-populated collagen matrix model, both LNP formulations significantly decreased fibroblast contraction after a single transfection. We conclude that the novel PEGylated CL4H6-MRTF-B siRNA-loaded LNPs represent a promising therapeutic approach to prevent conjunctival fibrosis after glaucoma filtration surgery.
  • Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo.
    Mahmoud A Younis; Ikramy A Khalil; Yaser H A Elewa; Yasuhiro Kon; Hideyoshi Harashima
    Journal of controlled release : official journal of the Controlled Release Society, 331, 335, 349, 2021年03月10日, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Hepatocellular carcinoma (HCC) is a fatal disease with limited therapeutic choices. The stroma-rich tumor microenvironment hinders the in vivo delivery of most nanomedicines. Ultra-small lipid nanoparticles (usLNPs) were designed for the selective co-delivery of the cytotoxic drug, sorafenib (SOR), and siRNA against the Midkine gene (MK-siRNA) to HCC in mice. The usLNPs composed of a novel pH-sensitive lipid, a diversity of phospholipids and a highly-selective targeting peptide. A microfluidic device, iLiNP, was used and a variety of factors were controlled to tune particle size aiming at maximizing tumor penetration efficiency. Optimizing the composition and physico-chemical properties of the usLNPs resulted in an enhanced tumor accumulation, selectivity and in vivo gene silencing. The optimized usLNPs exerted potent gene silencing in the tumor (median effective dose, ED50~0.1 mg/Kg) with limited effect on the healthy liver. The novel combination synergistically-eradicated HCC in mice (~85%) at a surprisingly-low dose of SOR (2.5 mg/Kg) which could not be achieved via individual monotherapy. Toxicity studies revealed the biosafety of the usLNPs upon either acute or chronic treatment. Furthermore, the SOR-resistant HCC established in mice was eradicated by 70% using this approach. We conclude that our strategy is promising for potential clinical applications in HCC treatment.
  • リポソームを応用した末梢組織から脊髄への低侵襲薬物輸送システムの開発
    福井 隆史; 角家 健; 舘野 寛直; 中村 孝司; 山田 勇磨; 佐藤 悠介; 岩崎 倫政; 原島 秀吉
    日本整形外科学会雑誌, 95, 2, S123, S123, (公社)日本整形外科学会, 2021年03月
    日本語
  • ミトコンドリア強化ヒト心筋幹細胞(hMITO Cell)の製造および心虚血再灌流モデルを用いた細胞移植療法の検証
    後藤 悠太; 山田 勇磨; 日比野 光恵; 佐々木 大輔; 武田 充人; 真栄城 正寿; 渡慶次 学; 原島 秀吉
    日本薬学会年会要旨集, 141年会, 29V09, pm09S, (公社)日本薬学会, 2021年03月
    日本語
  • GALA-Modified Lipid Nanoparticles for the Targeted Delivery of Plasmid DNA to the Lungs.
    Yuta Hagino; Ikramy A Khalil; Seigo Kimura; Kenji Kusumoto; Hideyoshi Harashima
    Molecular pharmaceutics, 18, 3, 878, 888, 2021年03月01日, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), This study describes the development of lipid nanoparticles (LNPs) for the efficient and selective delivery of plasmid DNA (pDNA) to the lungs. The GALA peptide was used as a ligand to target the lung endothelium and as an endosomal escape device. Transfection activity in the lungs was significantly improved when pDNA was encapsulated in double-coated LNPs. The inner coat was composed of dioleoylphsophoethanolamine and a stearylated octaarginine (STR-R8) peptide, while the outer coat was largely a cationic lipid, di-octadecenyl-trimethylammonium propane, mixed with YSK05, a pH-sensitive lipid, and cholesterol. Optimized amounts of YSK05 and GALA were used to achieve an efficient and lung-selective system. The optimized system produced a high gene expression level in the lungs (>107 RLU/mg protein) with high lung/liver and lung/spleen ratios. GALA/R8 modification and the double-coating design were indispensable for efficient gene expression in the lungs. Despite the fact that NPs prepared with 1-step or 2-step coating have the same lipid amount and composition and the same pDNA dose, the transfection activity was dramatically higher in the lungs in the case of 2-step coating. Surprisingly, 1-step or 2-step coatings had no effect on the amount of nanoparticles that were delivered to the lungs, suggesting that the double-coating strategy substantially improved the efficiency of gene expression at the intracellular level.
  • Lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition.
    Yuichi Suzuki; Haruno Onuma; Risa Sato; Yusuke Sato; Akari Hashiba; Masatoshi Maeki; Manabu Tokeshi; Mohammad Enamul Hoque Kayesh; Michinori Kohara; Kyoko Tsukiyama-Kohara; Hideyoshi Harashima
    Journal of controlled release : official journal of the Controlled Release Society, 330, 61, 71, 2021年02月10日, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), The clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) system has considerable therapeutic potential for use in treating a wide range of intractable genetic and infectious diseases including hepatitis B virus (HBV) infections. While non-viral delivery technologies for the CRISPR/Cas system are expected to have clinical applications, difficulties associated with the clinically relevant synthesis of formulations and the poor efficiency of delivery severely hinder therapeutic genome editing. We report herein on the production of a lipid nanoparticle (LNP)-based CRISPR/Cas ribonucleoprotein (RNP) delivery nanoplatform synthesized using a clinically relevant mixer-equipped microfluidic device. DNA cleavage activity and the aggregation of Cas enzymes was completely avoided under the optimized synthetic conditions. The optimized formulation, which was identified through 2 steps of design of experiments, exhibited excellent gene disruption (up to 97%) and base substitution (up to 23%) without any apparent cytotoxicity. The addition of negative charges to the RNPs by complexing single-stranded oligonucleotide (ssON) significantly enhanced the delivery of both Cas9 and Cpf1 RNPs. The optimized formulation significantly suppressed both HBV DNA and covalently closed circular DNA (cccDNA) in HBV-infected human liver cells compared to adeno-associated virus type 2 (AAV2). These findings represent a significant contribution to the development of CRISPR/Cas RNP delivery technology and its practical applications in genome editing therapy.
  • The nanomedicine rush: New strategies for unmet medical needs based on innovative nano DDS.
    Yusuke Sato; Takashi Nakamura; Yuma Yamada; Hideyoshi Harashima
    Journal of controlled release : official journal of the Controlled Release Society, 330, 305, 316, 2021年02月10日, [査読有り], [招待有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), The era of Nanomedicine has arrived with the approval of ONPATTRO™ by the FDA in 2018. Lipid nanoparticle (LNP) technology has succeeded in delivering siRNA to the human liver in genetic diseases and has also been applied to mRNA vaccinations for COVID-19 using a similar LNP technology. In this review, we focus on the current status of new lipids for use in LNP formulations including our original lipids (CL4H6/CL4C6/CL4D6) as well as mechanisms of targeting without a ligand. Clinical applications of nano DDS are moving forward rapidly in the field of cancer immunology since the successful introduction of OPDIVO™ in 2014. Antigen presentation and the maturation of immune cells can be controlled by nano DDS for cancer immunotherapy. YSK12-C4, a newly designed ionizable amino lipid can induce successful immune activation by silencing mRNA in DC and NK cells, which are expected to be evaluated for clinical use. Finally, new cancer therapy by targeting mitochondria involving the use of a MITO-Porter, a membrane fusion-type mitochondrial delivery system, has been introduced. The importance of delivering a photo sensitizer to mitochondria was clearly demonstrated in photodynamic cancer therapy. Clinical applications of MITO-Porters started in collaborative efforts with LUCA Science Co., Ltd. And was established in 2018. The future direction of Nanomedicine is discussed.
  • Novel lipid combination for delivery of plasmid DNA to immune cells in the spleen.
    Seigo Kimura; Ikramy A Khalil; Yaser H A Elewa; Hideyoshi Harashima
    Journal of controlled release : official journal of the Controlled Release Society, 330, 753, 764, 2021年02月10日, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), This study reports on the development of a novel lipid combination that permits the efficient and highly selective delivery of plasmid DNA (pDNA) to immune cells in the spleen. Using DODAP, an ionizable lipid that was previously thought to be inefficient for gene delivery, we show for the first time, that this ignored lipid can be successfully used for efficient and targeted gene delivery in vivo, but only when combined with DOPE, a specific helper lipid. Using certain DODAP and DOPE ratios resulted in the formation of lipid nanoparticles (LNPs) with a ~ 1000-fold higher gene expression, and this expression was specific for the spleen, making it the most spleen-selective system for transfection using pDNA. The developed DODAP/DOPE-LNPs target immune cells in the spleen via receptors for complement C3 and this pathway is critical for efficient gene expression. We hypothesize that the high spleen transfection activity of DODAP/DOPE-LNPs is caused by the promotion of gene expression associated with B cell activation via complement receptors. LNPs encapsulating tumor-antigen encoding pDNA showed both prophylactic and therapeutic anti-tumor effects. The optimized LNPs resulted in the production of different cytokines and antigen-specific antibodies as well as exerting antigen-specific cytotoxic effects. This study revives the use of DODAP in gene delivery and highlights the importance of using appropriate lipid combinations for delivering genes to specific cells.
  • A novel dual-targeted rosiglitazone-loaded nanoparticle for the prevention of diet-induced obesity via the browning of white adipose tissue.
    Ryu Hiradate; Ikramy A Khalil; Aya Matsuda; Mika Sasaki; Kyoko Hida; Hideyoshi Harashima
    Journal of controlled release : official journal of the Controlled Release Society, 329, 665, 675, 2021年01月10日, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Adipose tissue in the body is classified as white adipose tissue (WAT); a fat-accumulating tissue, or brown adipose tissue (BAT); an energy-dissipating tissue. Transforming WAT-to-BAT (browning) is a promising strategy for the treatment of obesity, since it would lead to an increase in energy expenditure. Rosiglitazone (Rosi), an agonist of the peroxisome proliferator-activated receptor γ (PPARγ), is known to be a potent browning inducer in subcutaneous WAT. However, the effectiveness of Rosi has been quite limited because of several off-target effects. The objective of this study was to develop locally administered Rosi-loaded nanoparticles (Rs-NPs) with the ability to target adipocytes to achieve the adipose tissue-specific activation of PPARγ, thus causing the browning of WAT. We prepared dual targeted Rs-NPs that were modified with a specific peptide that targets prohibitin that are expressed in adipocytes, and a cell penetrating peptide for enhancing cellular uptake and controlling intracellular trafficking. The Rs-NPs modified with a single ligand were internalized into mature adipocytes and induced browning activity in vitro but they failed to significantly affect the body weight of the diet-induced obese mice model. The dual-targeted Rs-NPs induced a strong browning activity, both in vitro and in vivo, and successfully inhibited the progression of obesity, as evidenced by the shrinkage of hypertrophied adipocytes without any detectable systemic adverse effects. Meanwhile, free Rosi aggravated hepatic steatosis and did not cause adipose tissue browning nor the inhibition of body weight gain. We conclude that the increased energy expenditure via adipose tissue browning using dual-targeted Rs-NP is a promising strategy for the treatment of obesity and its related metabolic syndrome.
  • Engineered ε-decalactone lipomers bypass the liver to selectively in vivo deliver mRNA to the lungs without targeting ligands
    Mahmoud M. Abd Elwakil; Tianle Gao; Takuya Isono; Yusuke Sato; Yaser H. A. Elewa; Toshifumi Satoh; Hideyoshi Harashima
    Materials Horizons, Royal Society of Chemistry (RSC), 2021年
    研究論文(学術雑誌),

    Engineered lipomers coming from sustainable sources can efficiently bypass the liver to deliver a genetic message to the lungs after systemic administration without targeting ligands.

  • Three-dimensional, symmetrically assembled microfluidic device for lipid nanoparticle production
    Niko Kimura; Masatoshi Maeki; Kosuke Sasaki; Yusuke Sato; Akihiko Ishida; Hirofumi Tani; Hideyoshi Harashima; Manabu Tokeshi
    RSC ADVANCES, 11, 3, 1430, 1439, 2021年01月
    英語, 研究論文(学術雑誌)
  • Targeting the Mitochondrial Genome Via a MITO-Porter : Evaluation of mtDNA and mtRNA Levels and Mitochondrial Function.
    Yuma Yamada; Hideyoshi Harashima
    Methods in molecular biology (Clifton, N.J.), 2275, 227, 245, 2021年, [査読有り], [最終著者], [国際誌]
    英語, 研究論文(学術雑誌), Genetic mutations and defects in mitochondrial DNA (mtDNA) are associated with certain types of mitochondrial dysfunctions, ultimately resulting in the emergence of a variety of human diseases. To achieve an effective mitochondrial gene therapy, it will be necessary to deliver therapeutic agents to the innermost mitochondrial space (the mitochondrial matrix), which contains the mtDNA pool. We recently developed a MITO-Porter, a liposome-based nanocarrier that delivers cargo to mitochondria via a membrane-fusion mechanism. In this chapter, we discuss the methodology used to deliver bioactive molecules to the mitochondrial matrix using a Dual Function (DF)-MITO-Porter, a liposome-based nanocarrier that delivers it cargo by means of a stepwise process, and an evaluation of mtDNA levels and mitochondrial activities in living cells. We also discuss mitochondrial gene silencing by the mitochondrial delivery of antisense RNA oligonucleotide (ASO) targeting mtDNA-encoded mRNA using the MITO-Porter system.
  • Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB.
    Seigo Kimura; Hideyoshi Harashima
    Pharmaceutics, 12, 12, 2020年12月15日, [査読有り], [招待有り], [最終著者], [国際誌]
    英語, 研究論文(学術雑誌), The era of the aging society has arrived, and this is accompanied by an increase in the absolute numbers of patients with neurological disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD). Such neurological disorders are serious costly diseases that have a significant impact on society, both globally and socially. Gene therapy has great promise for the treatment of neurological disorders, but only a few gene therapy drugs are currently available. Delivery to the brain is the biggest hurdle in developing new drugs for the central nervous system (CNS) diseases and this is especially true in the case of gene delivery. Nanotechnologies such as viral and non-viral vectors allow efficient brain-targeted gene delivery systems to be created. The purpose of this review is to provide a comprehensive review of the current status of the development of successful drug delivery to the CNS for the treatment of CNS-related disorders especially by gene therapy. We mainly address three aspects of this situation: (1) blood-brain barrier (BBB) functions; (2) adeno-associated viral (AAV) vectors, currently the most advanced gene delivery vector; (3) non-viral brain targeting by non-invasive methods.
  • The use of design of experiments with multiple responses to determine optimal formulations for in vivo hepatic mRNA delivery.
    Akari Hashiba; Manaya Toyooka; Yusuke Sato; Masatoshi Maeki; Manabu Tokeshi; Hideyoshi Harashima
    Journal of controlled release : official journal of the Controlled Release Society, 327, 467, 476, 2020年11月10日, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Although great advances have been made in the delivery of short RNAs by lipid nanoparticles (LNPs), the optimal formulation composition and physicochemical properties of LNPs for long RNA (including mRNA) remain unclear. In the present study, we optimized the lipid composition of liver-targeted mRNA-loaded LNPs that were prepared with pH-sensitive cationic lipids that had been previously designed for siRNA delivery through a two stepped design of experiment (DoE). Multiple responses including physicochemical properties, gene expression, and liver-specificity were analyzed in order, not only to understand the role of each formulation parameter, but also to examine parameters that would be difficult to predict. We found that particle size and the PEG-to-phospholipid (PEG/PL) ratio were additional key factors for liver-specific gene expression in addition to the other formulation factors. The optimized formulation showed a better gene expression compared to other lipid formulations from industry leaders. These findings suggest that a "DoE with multiple responses" approach can be used to predict significant parameters and permit optimized formulations to be prepared more efficiently.
  • Evolution of drug delivery system from viewpoint of controlled intracellular trafficking and selective tissue targeting toward future nanomedicine.
    Yuma Yamada; Yusuke Sato; Takashi Nakamura; Hideyoshi Harashima
    Journal of controlled release : official journal of the Controlled Release Society, 327, 533, 545, 2020年11月10日, [査読有り], [招待有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Due to the rapid changes that have occurred in the field of drug discovery and the recent developments in the early 21st century, the role of drug delivery systems (DDS) has become increasingly more important. For the past 20 years, our laboratory has been developing gene delivery systems based on lipid-based delivery systems. One of our efforts has been directed toward developing a multifunctional envelope-type nano device (MEND) by modifying the particle surface with octaarginine, which resulted in a remarkably enhanced cellular uptake and improved intracellular trafficking of plasmid DNA (pDNA). When we moved to in vivo applications, however, we were faced with the PEG-dilemma and we shifted our strategy to the incorporation of ionizable cationic lipids into our system. This resulted in some dramatic improvements over our original design and this can be attributed to the development of a new lipid library. We have also developed a mitochondrial targeting system based on a membrane fusion mechanism using a MITO-Porter, which can deliver nucleic acids/pDNA into the matrix of mitochondria. After the appearance of antibody medicines, Opdivo, an immune checkpoint inhibitor, has established cancer immunology as the 4th strategy in cancer therapy. Our DDS technologies can also be applied to this new field of cancer therapy to cure cancer by controlling our immune mechanisms. The latest studies are summarized in this review article.
  • ミトコンドリア病(Leigh脳症)モデルマウスの心機能の評価とモデルマウス由来心筋前駆細胞のミトコンドリア機能の検討
    佐々木 大輔; 武田 充人; 山田 勇磨; 原島 秀吉
    日本小児循環器学会雑誌, 36, Suppl.2, s2, 358, (NPO)日本小児循環器学会, 2020年11月
    日本語
  • The use of a MITO-Porter to deliver exogenous therapeutic RNA to a mitochondrial disease's cell with a A1555G mutation in the mitochondrial 12S rRNA gene results in an increase in mitochondrial respiratory activity.
    Yuma Yamada; Minako Maruyama; Tomoko Kita; Shin-Ichi Usami; Shin-Ichiro Kitajiri; Hideyoshi Harashima
    Mitochondrion, 55, 134, 144, 2020年11月, [査読有り], [最終著者], [国際誌]
    英語, 研究論文(学術雑誌), We report on validating a mitochondrial gene therapeutic strategy using fibroblasts derived from patients with an A1555G point mutation in mitochondrial DNA coding 12S ribosomal RNA (rRNA (12S)). Wild-type rRNA (12S) as a therapeutic RNA was encapsulated in a mitochondrial targeting liposome, a MITO-Porter (rRNA-MITO-Porter), and an attempt was made to deliver the MITO-Porter to mitochondria of the diseased cells. It was confirmed that the rRNA-MITO-Porter treatment significantly decreased the ratio of the mutant rRNA content. Moreover, it was shown that the mitochondrial respiratory activities of the diseased cells were improved as the result of the mitochondrial transfection of the rRNA-MITO-Porter.
  • New Design Strategies for Controlling the Rate of Hydrophobic Drug Release from Nanoemulsions in Blood Circulation.
    Saed Abbasi; Yusuke Sato; Kazuaki Kajimoto; Hideyoshi Harashima
    Molecular pharmaceutics, 17, 10, 3773, 3782, 2020年10月05日, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), The intravenous administration of drug-loaded nanoparticles (NPs) is needed to achieve passive or active targeting in disease tissues. However, when the loaded drug is a hydrophobic small molecule, the NPs fail to reach adequate plasma drug concentrations mainly because of premature drug release. The pharmacokinetics of such drugs can be controlled by covalent modification, but this approach could compromise the safety or potency of the drug. In this study, we investigated two formulation parameters that could be used to improve the plasma concentrations of unmodified drugs that are loaded in a nanoemulsion (NE), a core-shell type NP. The first parameter is the loading ratio, and the second is the affinity of the drug to the core. Optimized NEs with reduced drug loading and with a high drug-core affinity resulted in a 12.4- and 11.2-fold increase in the plasma retention of curcumin and paclitaxel, respectively. Our strategy for enhancing the drug-core interaction affinity relied on mixing oils and surfactants to achieve cooperativity in noncovalent interactions, such as hydrophobic interactions, hydrogen bonding, and π-π stacking, which was further confirmed by theoretical calculations of interaction affinities. Finally, we report on the development of a cinnamic acid-derived oil-like material as a novel drug vehicle with exceptional solubilizing ability that could be used in intravenous formulations of NEs.
  • リポソームsiRNAデリバリーシステムを用いた腫瘍血管biglycanを標的とした新規血管新生阻害療法
    間石 奈湖; 櫻井 遊; 畠山 浩人; Li Cong; Alam Mohammad T.; 菊地 央; 森本 浩史; 森本 真弘; 樋田 泰浩; 原島 秀吉; 樋田 京子
    日本癌学会総会記事, 79回, OE16, 5, (一社)日本癌学会, 2020年10月
    英語
  • 核酸医薬とナノメディシン 多機能性エンベロープ型ナノ構造体の開発とナノ医療への展開
    原島 秀吉; 佐藤 悠介; 中村 孝司; 山田 勇磨
    日本癌学会総会記事, 79回, ML13, ML13, (一社)日本癌学会, 2020年10月
    英語
  • Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy.
    Nour Shobaki; Yusuke Sato; Yuichi Suzuki; Nana Okabe; Hideyoshi Harashima
    Journal of controlled release : official journal of the Controlled Release Society, 325, 235, 248, 2020年09月10日, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), The tumor-microenvironment contains large numbers of tumor-associated macrophages (TAMs) which are largely M2 phenotypes and are involved in pro-tumorous functions. Targeting TAMs so as to manipulate them and to modify their functions could be a novel immunotherapy for the treatment of cancer. Such a strategy would involve targeting TAMs with short interfering RNA (siRNA) to modify their functions by silencing certain genes that are responsible for their M2 polarization. In this study, a lipid nanoparticle (LNP) formulation was used to target and deliver siRNA to TAMs. The LNP was mainly composed of a novel, pH-sensitive cationic lipid, referred to as the CL4H6 lipid, which had previously been optimized to target hepatocytes. The optimized siRNA-loaded CL4H6-LNPs were selectively and efficiently taken up and showed strong gene silencing activity in TAMs in a human tumor xenograft model in nude mice. Furthermore, an anti-tumor therapeutic response in the same tumor model was obtained by targeting TAMs using the optimized siRNA-loaded CL4H6-LNPs. The anti-tumor therapeutic response was obtained through the silencing of the signal transducer and activator of transcription 3 (STAT3) and hypoxia inducible factor 1 α (HIF-1α), which resulted in an increase in the level of infiltrated macrophage (CD11b+ cells) into the tumor-microenvironment (TME) as well as a tendency to increase the concentration of M1 macrophages (CD169+ cells). The treatment also resulted in reversing the pro-tumorous functions of TAMs -mainly angiogenesis and tumor cell activation-, as evidenced by a decrease in the related gene expression at the mRNA level. This research has promising clinical and pharmaceutical applications for achieving novel macrophage-based cancer immunotherapy.
  • Challenges in Promoting Mitochondrial Transplantation Therapy.
    Yuma Yamada; Momo Ito; Manae Arai; Mitsue Hibino; Takao Tsujioka; Hideyoshi Harashima
    International journal of molecular sciences, 21, 17, 2020年09月02日, [査読有り], [最終著者], [国際誌]
    英語, 研究論文(学術雑誌), Mitochondrial transplantation therapy is an innovative strategy for the treatment of mitochondrial dysfunction. The approach has been reported to be useful in the treatment of cardiac ischemic reperfusion injuries in human clinical trials and has also been shown to be useful in animal studies as a method for treating mitochondrial dysfunction in various tissues, including the heart, liver, lungs, and brain. On the other hand, there is no methodology for using preserved mitochondria. Research into the pharmaceutical formulation of mitochondria to promote mitochondrial transplantation therapy as the next step in treating many patients is urgently needed. In this review, we overview previous studies on the therapeutic effects of mitochondrial transplantation. We also discuss studies related to immune responses that occur during mitochondrial transplantation and methods for preserving mitochondria, which are key to their stability as medicines. Finally, we describe research related to mitochondrial targeting drug delivery systems (DDS) and discuss future perspectives of mitochondrial transplantation.
  • ミトコンドリアDDSを用いたビタミンB1の脳内送達・治療効果の検証
    山田 勇磨; 石丸 拓也; 原島 秀吉
    日本DDS学会学術集会プログラム予稿集, 36回, 169, 169, 日本DDS学会, 2020年08月
    日本語
  • Mitochondrial Delivery of an Anticancer Drug Via Systemic Administration Using a Mitochondrial Delivery System That Inhibits the Growth of Drug-Resistant Cancer Engrafted on Mice.
    Yuma Yamada; Reina Munechika; Satrialdi; Fumika Kubota; Yusuke Sato; Yu Sakurai; Hideyoshi Harashima
    Journal of pharmaceutical sciences, 109, 8, 2493, 2500, 2020年08月, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Mitochondrial delivery of an anticancer drug targeting cancer cells would eventually result in cell death. To achieve this, a drug delivery system targeting mitochondria is needed. We recently developed a MITO-Porter, a liposome that delivers its cargo to mitochondria. We reported that such a MITO-Porter could deliver doxorubicin (DOX), an anticancer drug, to mitochondria in OS-RC-2 cells, a drug resistant cancer cell, resulting in inhibiting the cell growth, based in in vitro experiments. Herein, we report on validating the benefit of such a therapeutic strategy for treating drug resistant cancers by the in vivo targeting of mitochondria. We prepared a DOX-MITO-Porter, in which DOX was encapsulated in the MITO-Porter and optimized its retention in blood circulation. When the DOX-MITO-Porter was administered to mice bearing OS-RC-2 cells via tail vein injection, tumor size was significantly decreased, compared to DOX itself and to the DOX-encapsulated polyethylene glycol-modified liposome (DOX-PEG-LP). Intracellular observation confirmed that the DOX-MITO-Porter had accumulated in tumor mitochondria. It was also found a relationship between anti-tumor effect and the mitochondrial function, as indicated by the depolarization of mitochondrial membrane potential. This study provides support for the utility of an in vivo mitochondrial delivery system in drug resistant cancer therapies.
  • Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
    Niko Kimura; Masatoshi Maeki; Yusuke Sato; Akihiko Ishida; Hirofumi Tani; Hideyoshi Harashima; Manabu Tokeshi
    ACS applied materials & interfaces, 12, 30, 34011, 34020, 2020年07月29日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Microfluidic methodologies for preparation of lipid nanoparticles (LNPs) based on an organic solvent injection method enable precise size control of the LNPs. After preparation of LNPs, the organic solvent injection method needs some post-treatments, such as overnight dialysis or direct dilution with a buffer solution. LNP production using the microfluidic-based organic solvent injection method is dominated by kinetics rather than thermodynamics. Kinetics of ethanol removal from the inner and outer membranes of LNPs could induce a structural change in the membrane that could lead to fusion of LNPs. However, the effects of microfluidic post-treatment on the final size of LNPs have not been sufficiently understood. Herein, we investigated the effect of the post-treatment processes on the final product size of LNPs in detail. A simple baffle device and a model lipid system composed of a neutral phospholipid (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, POPC) and cholesterol were used to produce the LNPs. We demonstrated that flow conditions of the post-treatment diluting the remaining ethanol in the LNP suspension affected the final product size of LNPs. Based on the findings, we developed an integrated baffle device composed of an LNP production region and a post-treatment region for a microfluidic-based LNP production system; this integrated baffle device prevented the undesirable aggregation or fusion of POPC LNPs even for the high-lipid-concentration condition. Finally, we applied our concept to small interfering RNA (siRNA) delivery and confirmed that no significant effects due to the continuous process occurred on the siRNA encapsulation efficiency, biological distribution, and knockdown activity. The microfluidic post-treatment method is expected to contribute to the production of LNPs for practical applications and the development of novel LNP-based nanomedicines.
  • Lipid nanoparticles fuse with cell membranes of immune cells at low temperatures leading to the loss of transfection activity.
    Takashi Nakamura; Koharu Yamada; Yusuke Sato; Hideyoshi Harashima
    International journal of pharmaceutics, 587, 119652, 119652, 2020年07月17日, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Delivering nucleic acid using a non-viral vector is a potent strategy for gene modification and controlling gene expression in immune cell therapy. Since the low-temperature storage (0-4 °C) or cryopreservation of cells are indispensable for performing immune cell therapy, we investigated the interactions between an siRNA-loaded lipid nanoparticle (LNP), a multifunctional envelope-type nanodevice (MEND) containing YSK12-C4 (YSK12-MEND), and human immune cell lines (NK-92 and Jurkat) at low-temperature and its effect on transfection activity. The YSK12-MEND readily bound to the cell membrane of NK-92 cells at low-temperature, but no internalization of the YSK12-MEND by cells was observed, even after returning the temperature to 37 °C. Gene silencing activity was completely impaired. The cause of this inhibition appears to be membrane fusion between the YSK12-MEND and cell membrane at the low-temperature. Collectively, our results suggest that the exposure of siRNA-loaded LNPs to cells at low-temperature should be avoided in defining transfection protocols in immune cell therapy.
  • Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E/low density lipoprotein receptor and the N-acetyl-D-galactosamine/asialoglycoprotein receptor pathway
    Yusuke Sato; Yoshiyuki Kinami; Kazuki Hashiba; Hideyoshi Harashima
    Journal of Controlled Release, 322, 217, 226, Elsevier B.V., 2020年06月10日
    英語, 研究論文(学術雑誌)
  • Erratum: The optimization of cancer photodynamic therapy by utilization of a pi-extended porphyrin-type photosensitizer in combination with MITO-Porter (Chem. Commun. (2020) 56 (1145–1148) DOI: 10.1039/C9CC08563G)
    Satrialdi; Reina Munechika; Vasudevanpillai Biju; Yuta Takano; Hideyoshi Harashima; Yuma Yamada
    Chemical Communications, 56, 45, 6153, Royal Society of Chemistry, 2020年06月07日
    英語, 研究論文(学術雑誌)
  • Dawn of lipid nanoparticles in lymph node targeting: Potential in cancer immunotherapy.
    Takashi Nakamura; Hideyoshi Harashima
    Advanced drug delivery reviews, 167, 78, 88, 2020年06月06日, [査読有り], [招待有り], [最終著者], [国際誌]
    英語, 研究論文(学術雑誌), It is generally known that the lymph nodes (LNs) are important tissues in cancer immunotherapy. Therefore, delivering immune functional compounds to LNs is a useful strategy for enhancing cancer immunotherapy. Lipid-based nanocarriers have been widely used as delivery systems that target LNs, but lipid nanoparticle (LNP) technology has recently attracted increased interest. High levels of nucleic acids can be efficiently loaded in LNPs, they can be used to actively deliver nucleic acids into the cytoplasm, and they can be produced on an industrial scale. The use of microfluidic devices has been particularly valuable for producing small-sized LNPs, thus paving the way for successful LN targeting. In the review, we focus on the potential of LNP technology for targeting LNs.
  • Validation of Gene Therapy for Mutant Mitochondria by Delivering Mitochondrial RNA Using a MITO-Porter.
    Eriko Kawamura; Minako Maruyama; Jiro Abe; Akira Sudo; Atsuhito Takeda; Shingo Takada; Takashi Yokota; Shintaro Kinugawa; Hideyoshi Harashima; Yuma Yamada
    Molecular therapy. Nucleic acids, 20, 687, 698, 2020年06月05日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Here, we report on validating a mitochondrial gene therapy by delivering nucleic acids to mitochondria of diseased cells by a MITO-Porter, a liposome-based carrier for mitochondrial delivery. We used cells derived from a patient with a mitochondrial disease with a G625A heteroplasmic mutation in the tRNAPhe of the mitochondrial DNA (mtDNA). It has been reported that some mitochondrial gene diseases are caused by heteroplasmic mutations, in which both mutated and wild-type (WT) genes are present, and the accumulation of pathological mutations leads to serious, intractable, multi-organ diseases. Therefore, the decrease of the mutated gene rate is considered to be a useful gene therapy strategy. To accomplish this, wild-type mitochondrial pre-tRNAPhe (pre-WT-tRNAPhe), prepared by in vitro transcription, was encapsulated in the MITO-Porter. The pre-WT-tRNAPhe encapsulated in the MITO-Porter was transfected into diseased mitochondrial cells, and the resulting mutant levels were examined by an amplification refractory mutation system (ARMS)-quantitative PCR. The mutation rate of tRNAPhe was decreased, and this therapeutic effect was sustained even on the 8th day after transfection. Furthermore, mitochondrial respiratory activity of the disease cells was increased after the transfection of therapeutic pre-WT-tRNAPhe. These results support the conclusion that the mitochondrial delivery of therapeutic nucleic acids represents a viable strategy for mitochondrial gene therapy.
  • Distribution of BCG-CWS-Loaded Nanoparticles in the Spleen After Intravenous Injection Affects Cytotoxic T Lymphocyte Activity.
    Hideyuki Masuda; Takashi Nakamura; Hideyoshi Harashima
    Journal of pharmaceutical sciences, 109, 6, 1943, 1950, 2020年06月, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Interest has developed in the bacillus Calmette-Guerin (BCG) cell wall skeleton (BCG-CWS) as a noninfectious adjuvant. Although BCG-CWS readily undergoes aggregation, in a previous study, we applied it to cancer immunotherapy via intravenous administration by encapsulating the BCG-CWS into nanoparticles (CWS-NPs). The CWS-NPs were taken up by major histocompatibility complex (MHC) class II+ (MHC-II+) cells and induced antigen-specific cytotoxic T lymphocyte (CTL) activity. However, the nature of the contribution of MHC-II+ cells to the CTL response continues to be unclear. In this study, we investigated the relationship between the distribution of CWS-NPs in the spleen and CTL activity. The main MHC-II+ cells that internalized the CWS-NPs were B cells. Decreasing the level of polyethylene glycol modification increased the uptake of CWS-NPs by B cells, leading to an increased CTL activity. A comparison of CWS-NPs with different uptake efficiencies into dendritic cells and B cells suggested that the DCs with internalized CWS-NPs may contribute to CTL activation compared with B cells. We succeeded in enhancing CTL activity by the CWS-NPs, and the findings reported herein should provide important information regarding target cells for the development of CWS-NP.
  • Validation of a mitochondrial RNA therapeutic strategy using fibroblasts from a Leigh syndrome patient with a mutation in the mitochondrial ND3 gene.
    Yuma Yamada; Kana Somiya; Akihiko Miyauchi; Hitoshi Osaka; Hideyoshi Harashima
    Scientific reports, 10, 1, 7511, 7511, 2020年05月05日, [国際誌]
    英語, 研究論文(学術雑誌), We report on the validation of a mitochondrial gene therapeutic strategy using fibroblasts from a Leigh syndrome patient by the mitochondrial delivery of therapeutic mRNA. The treatment involves delivering normal ND3 protein-encoding mRNA as a therapeutic RNA to mitochondria of the fibroblasts from a patient with a T10158C mutation in the mtDNA coding the ND3 protein, a component of the mitochondrial respiratory chain complex I. The treatment involved the use of a liposome-based carrier (a MITO-Porter) for delivering therapeutic RNA to mitochondria via membrane fusion. The results confirmed that the mitochondrial transfection of therapeutic RNA by the MITO-Porter system resulted in a decrease in the levels of mutant RNA in mitochondria of diseased cells based on reverse transcription quantitative PCR. An evaluation of mitochondrial respiratory activity by respirometry also showed that transfection using the MITO-Porter resulted in an increase in maximal mitochondrial respiratory activity in the diseased cells.
  • 脂質ナノ粒子の特性がリンパ節送達とリンパ節内分布へ与える影響
    中村 孝司; 河合 美典; 佐藤 悠介; 真栄城 正寿; 渡慶次 学; 原島 秀吉
    日本薬剤学会年会講演要旨集, 35年会, 171, 171, (公社)日本薬剤学会, 2020年05月
    日本語
  • MELAS A3243G変異型ミトコンドリアDNAを標的とした遺伝子治療戦略の検証
    山田 勇磨; 宗宮 加奈; 佐々木 大輔; 武田 充人; 原島 秀吉
    日本薬剤学会年会講演要旨集, 35年会, 169, 169, (公社)日本薬剤学会, 2020年05月
    日本語
  • Involvement of Caveolin-1-mediated transcytosis in the intratumoral accumulation of liposomes.
    Yu Sakurai; Akari Kato; Hideyoshi Harashima
    Biochemical and biophysical research communications, 525, 2, 313, 318, 2020年04月30日, [国際誌]
    英語, 研究論文(学術雑誌), For achieving efficient cancer treatment, it is important to elucidate the mechanism responsible for the accumulation of nanoparticles in tumor tissue. Recent studies suggest that nanoparticles are not delivered merely through gaps between tumor endothelial cells. We previously reported that the maturation of the vascular structure by the vascular endothelial cell growth factor receptor 2 (VEGFR2) using a previously developed siRNA delivery technology (RGD-MEND) significantly enhanced the accumulation of nanoparticles in types of cancers that area vessel-rich (renal cell carcinoma). This result was completely inconsistent with the generally accepted theory of the enhanced permeability and retention (EPR) effect. We hypothesized that a caveolin-1 (Cav1)-mediated transcellular route would be involved with the penetration of nanoparticles into tumor vasculature. To reveal the exact mechanism responsible for this enhancement, we observed the delivery of long-circulating liposomes (LPs) after Cav1 was co-suppressed by RGD-MEND with VEGFR2. The enhanced delivery of LPs by siRNA against VEGFR2 (siVEGFR2) was accompanied by the elevated expression of the Cav1 protein. In addition, Cav1 knockdown by siRNA against Cav1 (siCav1) canceled the enhanced delivery of LPs by siVEGFR2. The injection of siCav1 had no effect on the formation of alpha smooth muscle actin or vascular endothelial cell adhesion molecules. These results suggest that a Cav1-induced transcellular route and not a paracellular route, at least partially, contributes to the accumulation of nanoparticles in tumors.
  • Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery.
    Yu Sakurai; Wataru Mizumura; Kenichiro Ito; Kazuhiro Iwasaki; Takayuki Katoh; Yuki Goto; Hiroaki Suga; Hideyoshi Harashima
    Molecular pharmaceutics, 17, 4, 1397, 1404, 2020年04月06日, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Peptide modification is a popular strategy for developing an active targeting lipid nanoparticle (LNP). In modifying the surface of an LNP with a peptide, the sequence and structure of the peptide strongly affects the formation of the LNP. Specifically, a peptide with a high hydrophobicity can induce coarsening and aggregation of the LNP. In an attempt to prevent this from occurring, we incorporated monoacyl and diacyl group-conjugated poly(ethylene glycol) (PEG) into a LNP. We previously developed an original LNP, a multifunctional envelope type nanodevice (MEND) modified with an Epi-1 peptide, a ligand with a high affinity for the epithelial cell adhesion molecule (EpCAM). Using this peptide-modified MEND, the efficiency of delivery of a small interfering RNA (siRNA) encapsulated in the MEND was significantly improved. Although increasing the ratio of modification enhanced cellular uptake, the increase also induced aggregation of the LNP, particularly in the case of a large scale preparation. Our results indicate that a monoacyl PEG-lipid can prevent aggregation, even when the LNP is modified with higher molar ratios of peptide, but that this also results in a decrease in delivery efficiency. Moreover, the Epi-1-modified MEND exhibited a strong silencing effect in an ovarian cancer peritoneal dissemination model. Our results suggest that the simple incorporation of a monoacyl derivative into the PEG-lipid resulted in the formation of a peptide-modified LNP with improved characteristics.
  • Vitamin E Scaffolds of pH-Responsive Lipid Nanoparticles as DNA Vaccines in Cancer and Protozoan Infection.
    Mio Maeta; Naoya Miura; Hiroki Tanaka; Takashi Nakamura; Ryo Kawanishi; Yoshifumi Nishikawa; Kenichi Asano; Masato Tanaka; Shinya Tamagawa; Yuta Nakai; Kota Tange; Hiroki Yoshioka; Hideyoshi Harashima; Hidetaka Akita
    Molecular pharmaceutics, 17, 4, 1237, 1247, 2020年04月06日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), DNA vaccinations are promising strategies for treating diseases that require cellular immunity (i.e., cancer and protozoan infection). Here, we report on the use of a liposomal nanocarrier (lipid nanoparticles (LNPs)) composed of an SS-cleavable and pH-activated lipidlike material (ssPalm) as an in vivo DNA vaccine. After subcutaneous administration, the LNPs containing an ssPalmE, an ssPalm with vitamin E scaffolds, elicited a higher gene expression activity in comparison with the other LNPs composed of the ssPalms with different hydrophobic scaffolds. Immunization with the ssPalmE-LNPs encapsulating plasmid DNA that encodes ovalbumin (OVA, a model tumor antigen) or profilin (TgPF, a potent antigen of Toxoplasma gondii) induced substantial antitumor or antiprotozoan effects, respectively. Flow cytometry analysis of the cells that had taken up the LNPs in draining lymph nodes (dLNs) showed that the ssPalmE-LNPs were largely taken up by macrophages and a small number of dendritic cells. We found that the transient deletion of CD169+ macrophages, a subpopulation of macrophages that play a key role in cancer immunity, unexpectedly enhanced the activity of the DNA vaccine. These data suggest that the ssPalmE-LNPs are effective DNA vaccine carriers, and a strategy for avoiding their being trapped by CD169+ macrophages will be a promising approach for developing next-generation DNA vaccines.
  • Lipid Nanoparticles for Cell-Specific in Vivo Targeted Delivery of Nucleic Acids
    Ikramy A. Khalil; Mahmoud A. Younis; Seigo Kimura; Hideyoshi Harashima
    Biological and Pharmaceutical Bulletin, 43, 4, 584, 595, Pharmaceutical Society of Japan, 2020年04月01日, [査読有り]
    英語, 研究論文(学術雑誌)
  • The Effect of Size and Charge of Lipid Nanoparticles Prepared by Microfluidic Mixing on Their Lymph Node Transitivity and Distribution.
    Takashi Nakamura; Minori Kawai; Yusuke Sato; Masatoshi Maeki; Manabu Tokeshi; Hideyoshi Harashima
    Molecular pharmaceutics, 17, 3, 944, 953, 2020年03月02日, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Because the lymph node (LN) is a critical organ for inducing immune responses against pathogens and cancers, the transport of immune functional molecules such as antigens and adjuvants to LNs by delivery systems is a useful strategy for the effective outcome of an immune response. The size and charge of a delivery system largely affect the transitivity to and distribution within LN. Although pH-sensitive lipid nanoparticles (LNPs) prepared by microfluidic mixing are the latest delivery system to be applied clinically, the effects of their size and charge on the transitivity to and distribution within LN are currently unknown. We investigated the size and charge effect of LNPs prepared by microfluidic mixing on transitivity to and distribution within LNs. A 30 nm-sized LNP (30-LNP) was efficiently translocated to LNs and was taken up by CD8+ dendritic cells, while the efficiency was drastically decreased in the cases of 100 and 200 nm-sized LNPs. Furthermore, a comparative study between neutral, positively, and negatively charged 30-LNP revealed that the negative 30-LNP moved to the LN more efficiently than the other LNPs. Interestingly, the negative 30-LNP reached the deep cortex, namely, the T cell zone. Our findings provide informative insights for designing LN-targeting LNPs prepared by microfluidic mixing and for the translocation of nanoparticles in LNs.
  • The gala peptide: multiple roles in drug and gene delivery
    Ikramy A. Khalil; Hideyoshi Harashima
    Bulletin of Pharmaceutical Sciences, 43, 1, 39, 51, Assiut University, 2020年03月01日
    英語, 研究論文(学術雑誌)
  • 光増感分子rTPAを搭載したミトコンドリア標的型ナノカプセルの構築および担癌モデルマウスを用いた癌光治療戦略の検証
    山田 勇磨; Satrialdi; 高野 勇太; Biju Vasudevanpillai; 原島 秀吉
    日本薬学会年会要旨集, 140年会, 26X, am11, (公社)日本薬学会, 2020年03月
    日本語
  • Development of a nanoparticle that releases nucleic acids in response to a mitochondrial environment.
    Yuma Yamada; Yutaka Fukuda; Daisuke Sasaki; Minako Maruyama; Hideyoshi Harashima
    Mitochondrion, 52, 67, 74, 2020年02月22日, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, The delivery of nucleic acids targeting mutant mtDNA represent a potential strategy for addressing a variety of mitochondria-related diseases. We previously developed a MITO-Porter, a nano carrier that is capable of delivering nanoparticles of nucleic acids to mitochondria of human cells. Here, we report on an investigation of a series of nanoparticles formed with various poly cationic peptides that can release nucleic acids in response to a mitochondrial environment. A significant relationship was found between the number of and the location of arginine and histidine residues in the peptide sequence and the release of nucleic acids in a mitochondrial environment.
  • The optimization of cancer photodynamic therapy by utilization of a pi-extended porphyrin-type photosensitizer in combination with MITO-Porter.
    Satrialdi; Reina Munechika; Vasudevanpillai Biju; Yuta Takano; Hideyoshi Harashima; Yuma Yamada
    Chemical communications (Cambridge, England), 56, 7, 1145, 1148, 2020年01月23日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), The uncontrolled production of reactive oxygen species during photodynamic therapy (PDT) induces oxidative stress. The full potential of PDT is accomplished by delivery of a pi-extended porphyrin-type photosensitizer into mitochondria of tumor cells using a MITO-Porter, a mitochondrial targeting nanodevice. This strategy can be implemented for innovative cancer therapy.
  • Therapeutic Strategies for Regulating Mitochondrial Oxidative Stress.
    Yuma Yamada; Yuta Takano; Satrialdi; Jiro Abe; Mitsue Hibino; Hideyoshi Harashima
    Biomolecules, 10, 1, 2020年01月05日, [査読有り], [最終著者], [国際誌]
    英語, 研究論文(学術雑誌), There have been many reports on the relationship between mitochondrial oxidative stress and various types of diseases. This review covers mitochondrial targeting photodynamic therapy and photothermal therapy as a therapeutic strategy for inducing mitochondrial oxidative stress. We also discuss other mitochondrial targeting phototherapeutic methods. In addition, we discuss anti-oxidant therapy by a mitochondrial drug delivery system (DDS) as a therapeutic strategy for suppressing oxidative stress. We also describe cell therapy for reducing oxidative stress in mitochondria. Finally, we discuss the possibilities and problems associated with clinical applications of mitochondrial DDS to regulate mitochondrial oxidative stress.
  • A small-sized lipid nanoparticles production method using microfluidic devices with baffle structures
    Niko Kimura; Masatoshi Maeki; Yusuke Note; Yusuke Sato; Akihiko Ishida; Hirofumi Tani; Hideyoshi Harashima; Manabu Tokeshi
    21st International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2017, 965, 966, 2020年
    研究論文(国際会議プロシーディングス)
  • Power of mitochondrial drug delivery systems to produce innovative nanomedicines.
    Yuma Yamada; Satrialdi; Mitsue Hibino; Daisuke Sasaki; Jiro Abe; Hideyoshi Harashima
    Advanced drug delivery reviews, 154-155, 187, 209, 2020年, [査読有り], [招待有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Mitochondria carry out various essential functions including ATP production, the regulation of apoptosis and possess their own genome (mtDNA). Delivering target molecules to this organelle, it would make it possible to control the functions of cells and living organisms and would allow us to develop a better understanding of life. Given the fact that mitochondrial dysfunction has been implicated in a variety of human disorders, delivering therapeutic molecules to mitochondria for the treatment of these diseases is an important issue. To date, several mitochondrial drug delivery system (DDS) developments have been reported, but a generalized DDS leading to therapy that exclusively targets mitochondria has not been established. This review focuses on mitochondria-targeted therapeutic strategies including antioxidant therapy, cancer therapy, mitochondrial gene therapy and cell transplantation therapy based on mitochondrial DDS. A particular focus is on nanocarriers for mitochondrial delivery with the goal of achieving mitochondria-targeting therapy. We hope that this review will stimulate the accelerated development of mitochondrial DDS.
  • Editorial: Advanced Liposome Research.
    Hideyoshi Harashima; Tatsuhiro Ishida
    Advanced drug delivery reviews, 154-155, 1, 1, 2020年, [招待有り], [筆頭著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌)
  • Hydrophobic scaffolds of pH-sensitive cationic lipids contribute to miscibility with phospholipids and improve the efficiency of delivering short interfering RNA by small-sized lipid nanoparticles
    Yusuke Sato; Nana Okabe; Yusuke Note; Kazuki Hashiba; Masatoshi Maeki; Manabu Tokeshi; Hideyoshi Harashima
    Acta Biomaterialia, 102, 341, 350, 2020年01月, [査読有り], [最終著者, 責任著者]
    英語, 研究論文(学術雑誌)
  • Spleen selective enhancement of transfection activities of plasmid DNA driven by octaarginine and an ionizable lipid and its implications for cancer immunization
    Seigo Kimura; Ikramy A. Khalil; Yaser H.A. Elewa; Hideyoshi Harashima
    Journal of Controlled Release, 313, 70, 79, Elsevier BV, 2019年11月
    研究論文(学術雑誌)
  • Targeting Tumor Endothelial Cells with Nanoparticles.
    Sakurai Y; Akita H; Harashima H
    International journal of molecular sciences, 20, 23, 2019年11月, [査読有り], [最終著者, 責任著者]
  • Innovative nanotechnologies for enhancing nucleic acids/gene therapy: Controlling intracellular trafficking to targeted biodistribution.
    Nakamura T; Yamada Y; Sato Y; Khalil IA; Harashima H
    Biomaterials, 218, 119329, 119329, 2019年10月, [査読有り], [招待有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Nanomedicine promises to play an important role in next generation therapy, including Nucleic acid/Gene therapy. To accomplish this, innovative nanotechnologies will be needed to support nanomedicine by controlling not only the biodistribution but also the intracellular trafficking of macromolecules such as RNA/DNA. A multifunctional envelope-type nano device (MEND) was developed to meet this requirement. We herein provide an update regarding the functions of the MEND system focusing on the introduction of different functional biomaterials that enhance efficiency. The octaarginine (R8) peptide enhances cellular uptake and controls intracellular trafficking to induce synergism in transgene expression. The R8 was also used for developing a MITO-Porter system for mitochondrial targeting. The function of the MITO-Porter system was extended by developing a mitochondrial reporter gene for mitochondrial gene therapy. For efficient in vivo gene delivery, new pH-sensitive lipids have been introduced to achieve controlled biodistribution and to enhance endosomal escape. For example, the CL4H6 lipid exerts a more efficient in vivo gene silencing than that of ONPATTROTM, a preparation that has been approved by the US Food and Drug Administration. We further summarize new technologies that have been successfully applied to cancer immunotherapy leading to the introduction of a new strategy based on the concept of the Cancer-Immunity Cycle.
  • A nanocarrier for the mitochondrial delivery of nucleic acids to cardiomyocytes.
    Yamada Y; Fujishita N; Harashima H
    Nucleosides, nucleotides & nucleic acids, 1, 15, 2019年10月, [査読有り], [最終著者]
  • Synergistic Enhancement of Cellular Uptake With CD44-Expressing Malignant Pleural Mesothelioma by Combining Cationic Liposome and Hyaluronic Acid-Lipid Conjugate.
    Yu Sakurai; Akari Kato; Yasuhiro Hida; Junichi Hamada; Nako Maishi; Kyoko Hida; Hideyoshi Harashima
    Journal of pharmaceutical sciences, 108, 10, 3218, 3224, 2019年10月, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Malignant pleural mesothelioma (MPM) is a highly aggressive form of cancer, with a median survival of less than 1 year. It is well known that the hyaluronan (HA) receptor CD44 is highly expressed by MPM cells and is reported to be correlated with a poor prognosis. We herein report on the development of a new type if drug delivery system against CD44 that involves the use of lipid nanoparticles (LNPs) equipped with a new type of HA derivative. In this study, we evaluated HA-lipid conjugation (HAL) via the end of the HA molecule through reductive amination, a process that allowed the carboxylate group to remain intact. As a result, the HAL-modified LNP appears to be a potent nanoparticle for dealing with MPM. Surprisingly, the use of a combination of a cationic lipid and HAL had a synergistic effect on cellular uptake in MPM and consequently permitted an anti-cancer drug such as cis-diamminedichloro-platinum(II) (CDDP). Intrapleural injection of CDDP-loaded HAL-LNP (1.5 mg/kg as CDDP) per week significantly suppressed the progression of this type of cancer in an MPM orthotopic model. These results suggest that HAL-modified LNP represents a potent delivery system for MPM cells that express high levels of CD44.
  • A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells
    Mahmoud A. Younis; Ikramy A. Khalil; Mahmoud M. Abd Elwakil; Hideyoshi Harashima
    Molecular Pharmaceutics, 16, 9, 4031, 4044, 2019年09月03日
    研究論文(学術雑誌)
  • Hyaluronan-modified nanoparticles for tumor-targeting.
    Yu Sakurai; Hideyoshi Harashima
    Expert opinion on drug delivery, 16, 9, 915, 936, 2019年09月, [国際誌]
    英語, 研究論文(学術雑誌), Introduction: Hyaluronan (HA), a natural polysaccharide, is produced in large amounts by the human body. Since its receptor CD44 is highly expressed in many types of cancers, HA is a promising ligand for cancer-targeting nanoparticles (NPs). Since the enhanced permeability and retention (EPR) effect-based strategy faces difficulties in terms of efficiency in clinical studies, studies focusing on HA-modified NPs that can actively target cancer cells should be prominent for further progress in NP-based cancer treatment. Areas covered: Various materials combined with HA composed of lipid nanoparticles and polymers as well as iron, gold and other metals have been examined. In addition, their cargos have been quite diverse and include small molecule drugs, imaging agents, proteins and nucleic acids. We summarize recent studies on varieties of NPs and describe the properties of HA as a ligand of CD44. Expert opinion: In spite of a number of studies on HA-based NPs, there is few examples of HA-based NPs in clinical. In order to make a progress in clinical study, an evaluation methodology of HA-NPs should be unified and normalized.
  • The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy.
    Endo R; Nakamura T; Kawakami K; Sato Y; Harashima H
    Scientific reports, 9, 1, 11335, 11335, 2019年08月, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Cell-based therapy using dendritic cells (DC) represents a potent cancer immunotherapy. However, activated DC express indoleamine 2,3-dioxygenase 1 (IDO1), a counter-regulatory and tolerogenic molecule, leading to the inhibition of T cell activation and the promotion of T cell differentiation into regulatory T cells. Silencing the IDO1 gene in DC by small interfering RNA (siRNA) represents a potent therapeutic strategy. We report on the successful and efficient introduction of a siRNA targeting IDO1 into mouse DCs by a means of a multifunctional envelope-type nanodevice (MEND) containing a YSK12-C4 (YSK12-MEND). The YSK12-C4 has both fusogenic and cationic properties. The YSK12-MEND induced an effective level of gene silencing of IDO1 at siRNA doses in the range of 1-20 nM, a concentration that commercially available transfection reagents are not able to silence. The YSK12-MEND mediated IDO1 silencing had no effect on the characteristic determinants of DC phenotype such as CD11c, CD80 and MHC class II. The silencing of IDO1 in DC by the YSK12-MEND significantly enhanced the antitumor effect against E.G7-OVA tumor. Moreover, a decrease in the numbers of regulatory T cells in the tumor was observed in mice that were treated with the IDO1-silenced DC. The YSK12-MEND appears to be a potent delivery system for IDO1-silenced DC based cancer immunotherapy.
  • Targeted mitochondrial delivery of antisense RNA-containing nanoparticles by a MITO-Porter for safe and efficient mitochondrial gene silencing.
    Kawamura E; Hibino M; Harashima H; Yamada Y
    Mitochondrion, 49, 178, 188, 2019年08月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Mitochondrial gene therapy will be needed to treat mitochondrial diseases. We previously demonstrated mitochondrial gene silencing by the mitochondrial delivery of antisense RNA oligonucleotide (ASO) targeting mtDNA-encoded mRNA using a MITO-Porter, a liposomal nano carrier system designed for mitochondrial delivery. Here, we report on the efficient packaging of ASO in the MITO-Porter via a nanoparticle packaging method, which showed a 10-fold higher packaging efficiency than the conventional method. The constructed carrier showed a decrease in the target mRNA levels and ATP production. These results indicate that such a MITO-Porter has potential for use in therapies designed to regulate mitochondrial function.
  • A study of the endocytosis mechanism and transendothelial activity of lung-targeted GALA-modified liposomes.
    Santiwarangkool S; Akita H; Khalil IA; Abd Elwakil MM; Sato Y; Kusumoto K; Harashima H
    Journal of controlled release : official journal of the Controlled Release Society, 307, 55, 63, 2019年08月, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), The GALA peptide (WEAALAEALAEALAEHLAEALAEALEALAA) was originally designed to induce the destabilization of endosomal membranes based on its ability to undergo a pH-dependent conformational change from a random coil to an α-helix. We recently found that liposomes modified with GALA peptide (GALA-LPs) extensively accumulate in lung endothelial cells (ECs) after intravenous injection. However, the uptake mechanism of GALA-LPs and their ability to reach alveolar epithelium was unclear. We report herein that GALA-LPs are internalized into ECs via a clathrin-mediated pathway. Surprisingly, GALA-LPs had the ability to pass lung ECs and reach other cells through transcytosis. GALA-LPs were taken up by >70% of lung ECs, while they also accumulated in ~30% of type I alveolar epithelium (ATI). GALA-modified gold nanoparticles were detected in ECs, in the basement membrane and in other cells such as ATI, type II alveolar epithelium (ATII) and alveolar macrophages. Consistent with this result, a significant gene knockdown was achieved in lung epithelium cells using GALA-LPs encapsulating anti-podoplanin siRNA. This indicates that GALA-LPs can be used as a carrier for delivering macromolecules to parenchymal as well as to endothelial cells in the lung. Although caveolae are commonly linked to the transendothelial transport of proteins and antibodies, our data indicate that clathrin-mediated endocytosis might also participate in the transcytosis process.
  • The Use of a Microfluidic Device to Encapsulate a Poorly Water-Soluble Drug CoQ(10) in Lipid Nanoparticles and an Attempt to Regulate Intracellular Trafficking to Reach Mitochondria
    Hibino Mitsue; Yamada Yuma; Fujishita Naoki; Sato Yusuke; Maeki Masatoshi; Tokeshi Manabu; Harashima Hideyoshi
    JOURNAL OF PHARMACEUTICAL SCIENCES, 108, 8, 2668, 2676, 2019年08月, [査読有り], [最終著者, 責任著者]
    研究論文(学術雑誌)
  • A mitochondrial delivery system using liposome-based nanocarriers that target myoblast cells.
    Katayama T; Kinugawa S; Takada S; Furihata T; Fukushima A; Yokota T; Anzai T; Hibino M; Harashima H; Yamada Y
    Mitochondrion, 49, 66, 72, 2019年07月, [査読有り]
  • Enhanced autophagy induction via the mitochondrial delivery of methylated β-cyclodextrins-threaded polyrotaxanes by a MITO-Porter
    Yuma Yamada; Shinnosuke Daikuhara; Atsushi Tamura; Kei Nishida; Nobuhiko Yui; Hideyoshi Harashima
    Chemical Communications, 55, 50, 7203, 7206, 2019年06月, [査読有り], [最終著者]
    英語, 研究論文(学術雑誌)
  • Lung-Endothelium-Targeted Nanoparticles Based on a pH-Sensitive Lipid and the GALA Peptide Enable Robust Gene Silencing and the Regression of Metastatic Lung Cancer
    Mahmoud M. Abd Elwakil; Ikramy A. Khalil; Yaser H. A. Elewa; Kenji Kusumoto; Yusuke Sato; Nour Shobaki; Yasuhiro Kon; Hideyoshi Harashima
    Advanced Functional Materials, 29, 18, Wiley-VCH Verlag, 2019年05月02日
    英語, 研究論文(学術雑誌)
  • MITO-Porterを用いた治療用mRNA送達によるミトコンドリア遺伝子治療戦略の検証
    山田 勇磨; 宗宮 加奈; 原島 秀吉
    日本薬剤学会年会講演要旨集, 34年会, 179, 179, (公社)日本薬剤学会, 2019年05月
    日本語
  • Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo
    Sato Yusuke; Hashiba Kazuki; Sasaki Kosuke; Maeki Masatoshi; Tokeshi Manabu; Harashima Hideyoshi
    JOURNAL OF CONTROLLED RELEASE, 295, 140, 152, 2019年02月, [査読有り], [最終著者, 責任著者]
    英語, 研究論文(学術雑誌)
  • Development of a three-dimensional micromixer device for production of various lipid-based nucleic acid nanocarriers
    Niko Kimura; Masatoshi Maeki; Yusuke Sato; Kosuke Sasaki; Akihiko Ishida; Hirofumi Tani; Hideyoshi Harashima; Manabu Tokeshi
    23rd International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2019, 368, 369, 2019年
    研究論文(国際会議プロシーディングス)
  • Two modes of toxicity of lipid nanoparticles containing a pH-sensitive cationic lipid on human A375 and A375-SM melanoma cell lines,
    樋田 京子
    BPB Reports, 2, 48, 55, 2019年, [査読有り], [最終著者, 責任著者]
    英語, 研究論文(学術雑誌)
  • Critical parameters dictating efficiency of membrane-mediated drug transfer using nanoparticles.
    Abbasi S; Kajimoto K; Harashima H
    International journal of pharmaceutics, 553, 1-2, 398, 407, 2018年12月, [査読有り], [最終著者, 責任著者]
  • Effective Therapy Using a Liposomal siRNA that Targets the Tumor Vasculature in a Model Murine Breast Cancer with Lung Metastasis.
    Sakurai Y; Hada T; Kato A; Hagino Y; Mizumura W; Harashima H
    Molecular therapy oncolytics, 11, 102, 108, 2018年12月, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Although metastatic cancer is a major cause of death for cancer patients, no efficacious treatment for metastasis is available. We previously showed that the growth of a primary tumor could be inhibited by the administration of an anti-angiogenic small interfering RNA (siRNA) that is encapsulated in an RGD peptide-modified lipid nanoparticle (RGD-LNP). We herein report on the delivery of siRNA by an RGD-LNP to the vasculature is also effective for treating metastatic tumors. We compared the RGD-LNP with the polyethylene glycol (PEG)ylated LNP (PEG-LNP) in terms of accumulation in a lung-metastasized model. Despite malformed structure of vasculature in the metastasized lung, the accumulation of the PEG-LNP in the metastasized lung was lower than that for the RGD-LNP, which suggests that the delivery strategy based on vascular permeability is not completely effective for targeting metastasis tumors. The systemic injection of the RGD-LNP induced a significant silencing in the metastasized vasculature, but not in the normal lung. In addition, the continuous injection of the RGD-LNP encapsulating siRNA against a delta-like ligand 4 (DLL4) drastically prolonged the overall survival of metastasized model mice. Accordingly, our current findings suggest that vasculature targeting would be more effective than enhanced permeability and retention effect-based therapy for the treatment of metastatic cancer.
  • The delivery of mRNA to colon inflammatory lesions by lipid-nano-particles containing environmentally-sensitive lipid-like materials with oleic acid scaffolds.
    Tanaka H; Watanabe A; Konishi M; Nakai Y; Yoshioka H; Ohkawara T; Takeda H; Harashima H; Akita H
    Heliyon, 4, 12, e00959, 2018年12月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), An mRNA gene therapy represents a potentially promising therapeutic for curing inflammatory diseases. The transient nature of the gene expression of mRNA would be expected to be beneficial for avoiding undesired side effects. Since the mRNA is a vulnerable molecule, a development of a carrier that can deliver the mRNA to the cytoplasm has a high priority. We report herein on the development of a system for delivering mRNA to the inflammatory lesion in a dextran sulfate sodium (DSS)-induced colitis model. We modulated molecular structures of an ionizable lipid, an SS-cleavable and pH-activated lipid-like material (ssPalm). Among the fatty acids investigated, oleic acid scaffolds (ssPalmO) appeared to be more biocompatible than either myristic acid or linoleic acid scaffolds with the colitis model. The structural modification of the hydrophilic head groups from linear tertiary amines to piperazine rings (ssPalmO-Paz4-C2) resulted in a more than 10-fold higher increasing in the transgene activity in inflammatory colon. The most notable observation is that the transgene activity in the inflammatory colon is significantly higher than that in liver, the major clearance organ of lipid nanoparticles. Collectively, the ssPalmO-Paz4-C2 represents a promising material for the delivery of an mRNA to inflammatory lesions.
  • ミトコンドリア強化幹細胞(MITO Cell)を用いた細胞移植療法の検証
    山田 勇磨; 阿部 二郎; 佐々木 大輔; 武田 充人; 原島 秀吉
    日本バイオマテリアル学会大会予稿集, 40回, 180, 180, 日本バイオマテリアル学会, 2018年11月
    日本語
  • DNA-loaded nano-adjuvant formed with a vitamin E-scaffold intracellular environmentally-responsive lipid-like material for cancer immunotherapy.
    Kawai M; Nakamura T; Miura N; Maeta M; Tanaka H; Ueda K; Higashi K; Moribe K; Tange K; Nakai Y; Yoshioka H; Harashima H; Akita H
    Nanomedicine : nanotechnology, biology, and medicine, 14, 8, 2587, 2597, 2018年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Cytoplasmic DNA triggers cellular immunity via activating the stimulator of interferon genes pathway. Since DNA is degradable and membrane impermeable, delivery system would permit cytoplasmic delivery by destabilizing the endosomal membrane for the use as an adjuvant. Herein, we report on the development of a plasmid DNA (pDNA)-encapsulating lipid nanoparticle (LNP). The structural components include an SS-cleavable and pH-activated lipid-like material that mounts vitamin E as a hydrophobic scaffold, and dual sensing motifs that are responsive to the intracellular environment (ssPalmE). The pDNA-encapsulating LNP (ssPalmE-LNP) induced a high interferon-β production in Raw 264.7 cells. The subcutaneous injection of ssPalmE-LNP strongly enhanced antigen-specific cytotoxic T cell activity. The ssPalmE-LNP treatment efficiently induced antitumor effects against E.G7-OVA tumor and B16-F10 melanoma metastasis. Furthermore, when combined with an anti-programmed death 1 antibody, an extensive therapeutic antitumor effect was observed. Therefore, the ssPalmE-LNP is a promising carrier of adjuvants for cancer immunotherapy.
  • Optimization of siRNA delivery to target sites: issues and future directions.
    Khalil IA; Yamada Y; Harashima H
    Expert opinion on drug delivery, 15, 11, 1053, 1065, 2018年11月, [査読有り], [招待有り], [最終著者, 責任著者]
  • Application of BCG-CWS as a Systemic Adjuvant by Using Nanoparticulation Technology.
    Masuda H; Nakamura T; Noma Y; Harashima H
    Molecular pharmaceutics, 15, 12, 5762, 5771, 2018年11月, [査読有り], [最終著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), The intravesical instillation of live Bacillus Calmette-Guerin (BCG) for treating bladder cancer is a powerful cancer immunotherapy. The BCG cell wall skeleton (BCG-CWS) is the main component of the adjuvant, leading to the induction of antitumor immunity. However, the use of live BCG and BCG-CWS is currently limited to local administration because of the infectiousness of live BCG and the insolubility of BCG-CWS. We previously developed a water-dispersible nanoparticle (NP) formulation of BCG-CWS (CWS-NP), which could be used to apply BCG components for use as a systemically injected adjuvant for the treatment of cancers other than bladder cancer. In the present study, we examined the possible use of CWS-NP for cancer immunotherapy, when intravenously administered. The CWS-NP was a highly uniform dispersion and showed no aggregation in serum. The intravenously injected CWS-NP accumulated in the spleen and was efficiently taken up by dendritic cells, leading to their maturation. The coadministration of CWS-NP and ovalbumin (OVA) loaded NP resulted in the generation of OVA-specific cytotoxic T cells and inhibited the growth of E.G7-OVA tumors. These results represent the first findings related to the use of systemically injected CWS-NP as an adjuvant for cancer immunotherapy.
  • Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA
    Yusuke Sato; Hideki Matsui; Risa Sato; Hideyoshi Harashima
    Journal of Controlled Release, 284, 179, 187, Elsevier B.V., 2018年08月28日, [査読有り], [最終著者, 責任著者]
    英語, 研究論文(学術雑誌)
  • The use of cardiac progenitor cells for transplantation in congenital heart disease and an innovative strategy for activating mitochondrial function in such cells.
    Abe J; Yamada Y; Harashima H
    Journal of thoracic disease, 10, Suppl 18, S2119, S2121, 2018年07月, [査読有り], [最終著者, 責任著者]
  • A hepatic pDNA delivery system based on an intracellular environment sensitive vitamin E-scaffold lipid-like material with the aid of an anti-inflammatory drug
    Ryohei Togashi; Hiroki Tanaka; Sakiko Nakamura; Hideo Yokota; Kota Tange; Yuta Nakai; Hiroki Yoshioka; Hideyoshi Harashima; Hidetaka Akita
    Journal of Controlled Release, 279, 262, 270, Elsevier B.V., 2018年06月10日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core
    Takashi Nakamura; Koharu Yamada; Yuki Fujiwara; Yusuke Sato; Hideyoshi Harashima
    Molecular Pharmaceutics, 15, 6, 2142, 2150, American Chemical Society, 2018年06月04日, [査読有り], [最終著者, 責任著者]
    英語, 研究論文(学術雑誌)
  • Development of the iLiNP Device: Fine Tuning the Lipid Nanoparticle Size within 10 nm for Drug Delivery
    Niko Kimura; Masatoshi Maeki; Yusuke Sato; Yusuke Note; Akihiko Ishida; Hirofumi Tani; Hideyoshi Harashima; Manabu Tokeshi
    ACS Omega, 3, 5, 5044, 5051, American Chemical Society, 2018年05月09日, [査読有り]
    英語, 研究論文(学術雑誌)
  • In Vivo Introduction of mRNA Encapsulated in Lipid Nanoparticles to Brain Neuronal Cells and Astrocytes via Intracerebroventricular Administration.
    Hiroki Tanaka; Taichi Nakatani; Tomomi Furihata; Kota Tange; Yuta Nakai; Hiroki Yoshioka; Hideyoshi Harashima; Hidetaka Akita
    Molecular pharmaceutics, 15, 5, 2060, 2067, 2018年05月07日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Gene therapy is a promising strategy for curing certain types of brain diseases. Supplementation of therapeutic proteins such as aromatic amino acid decarboxylase (AADC) or nerve growth factor (NGF) have been reported to be successful examples of such treatments. However, there are safety concerns because these systems are based on virus-based gene vectors. A safe and efficient artificial carrier is thus urgently needed as an alternative. In this study, an mRNA based artificial gene carrier was introduced into the mouse brain via intracerebroventricular administration. As a carrier, a lipid nanoparticle (LNP) composed of environmentally sensitive lipid-like materials called an SS-cleavable proton-activated lipid-like material is used. The apolipoprotein E mediated cellular uptake of the lipid nanoparticles is one of the key features for its superior and homogeneous transfection activity compared to commercially available transfection reagents in both in vitro and in vivo situations. Immunostaining of brain specimens suggested that exogenous proteins can be introduced into neuronal cells as well as astrocytes using the mRNA-based gene carrier. This cannot be achieved using DNA-based artificial gene carriers. The findings suggest that a combination of an mRNA and a lipid based delivery system have great promise as a platform for the treatment of brain disorders.
  • 微小化脂質ナノ粒子によるアジュバントのリンパ節送達
    中村 孝司; 河合 美典; 佐藤 悠介; 真栄城 正寿; 渡慶次 学; 原島 秀吉
    日本薬剤学会年会講演要旨集, 33年会, 193, 193, (公社)日本薬剤学会, 2018年05月
    日本語
  • Synergism between a cell penetrating peptide and a pH-sensitive cationic lipid in efficient gene delivery based on double-coated nanoparticles
    Ikramy A. Khalil; Seigo Kimura; Yusuke Sato; Hideyoshi Harashima
    Journal of Controlled Release, 275, 107, 116, Elsevier B.V., 2018年04月10日, [査読有り], [最終著者, 責任著者]
    英語, 研究論文(学術雑誌)
  • Mitochondrial transgene expression via an artificial mitochondrial DNA vector in cells from a patient with a mitochondrial disease
    Takuya Ishikawa; Kana Somiya; Reina Munechika; Hideyoshi Harashima; Yuma Yamada
    Journal of Controlled Release, 274, 109, 117, Elsevier B.V., 2018年03月28日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Targeting the mitochondrial genome through a nanocarrier and the regulation of mitochondrial gene expression
    Yuma Yamada; Hideyoshi Harashima
    Mitochondrial Biology and Experimental Therapeutics, 491, 498, Springer International Publishing, 2018年03月21日, [査読有り], [最終著者]
    英語, 論文集(書籍)内論文
  • Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems
    Masatoshi Maeki; Niko Kimura; Yusuke Sato; Hideyoshi Harashima; Manabu Tokeshi
    Advanced Drug Delivery Reviews, 128, 84, 100, Elsevier B.V., 2018年03月15日, [査読有り]
    英語
  • がん組織における浸潤性向上を目指した極小脂質ナノ粒子の開発
    岡部 奈々; 佐藤 悠介; 真栄城 正寿; 渡慶次 学; 原島 秀吉
    日本薬学会年会要旨集, 138年会, 4, 78, 78, (公社)日本薬学会, 2018年03月
    日本語
  • An efficient PEGylated gene delivery system with improved targeting: Synergism between octaarginine and a fusogenic peptide
    Ikramy A. Khalil; Hideyoshi Harashima
    International Journal of Pharmaceutics, 538, 1-2, 179, 187, Elsevier B.V., 2018年03月01日, [査読有り], [最終著者, 責任著者]
    英語, 研究論文(学術雑誌)
  • In Vivo Transgene Expression in the Pancreas by the Intraductal Injection of Naked Plasmid DNA.
    Yamada Y; Tabata M; Abe J; Nomura M; Harashima H
    Journal of pharmaceutical sciences, 107, 2, 647, 653, Elsevier B.V., 2018年02月01日, [査読有り], [最終著者]
    英語, 研究論文(学術雑誌)
  • Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption
    Shoshiro Yamamoto; Yu Sakurai; Hideyoshi Harashima
    International Journal of Pharmaceutics, 536, 1, 42, 49, Elsevier B.V., 2018年01月30日, [査読有り], [最終著者, 責任著者]
    英語, 研究論文(学術雑誌)
  • Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting
    Nour Shobaki; Yusuke Sato; Hideyoshi Harashima
    International Journal of Nanomedicine, 13, 8395, 8410, Dove Medical Press Ltd., 2018年
    英語, 研究論文(学術雑誌)
  • A post-treatment methodology for precise size control of lipid nanoparticles by stepwise and rapid ethanol dilution
    Niko Kimura; Masatoshi Maeki; Nana Okabe; Yusuke Sato; Akihiko Ishida; Hirofumi Tani; Hideyoshi Harashima; Manabu Tokeshi
    22nd International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2018, 3, 1404, 1405, 2018年
    研究論文(国際会議プロシーディングス)
  • EPR effect and development of new strategy for nanoparticle delivery via remodeling tumor microenvironment based on tumor vasculature targeting
    Yu Sakurai; Hideyoshi Harashima
    Drug Delivery System, 33, 2, 98, 104, Japan Society of Drug Delivery System, 2018年, [査読有り], [招待有り], [最終著者, 責任著者]
    日本語, 研究論文(学術雑誌)
  • Liposome Microencapsulation for the Surface Modification and Improved Entrapment of Cytochrome c for Targeted Delivery
    Kazuaki Kajimoto; Tatsuhito Katsumi; Takashi Nakamura; Masatoshi Kataoka; Hideyoshi Harashima
    JAOCS, Journal of the American Oil Chemists' Society, 95, 1, 101, 109, 2018年01月01日, [査読有り], [最終著者, 責任著者]
    英語, 研究論文(学術雑誌)
  • Cardiac progenitor cells activated by mitochondrial delivery of resveratrol enhance the survival of a doxorubicin-induced cardiomyopathy mouse model via the mitochondrial activation of a damaged myocardium
    Jiro Abe; Yuma Yamada; Atsuhito Takeda; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 269, 177, 188, 2018年01月, [査読有り], [最終著者, 責任著者]
    英語, 研究論文(学術雑誌)
  • Nano-sized drug carriers: Extravasation, intratumoral distribution, and their modeling
    Joseph W. Nichols; Yu Sakurai; Hideyoshi Harashima; You Han Bae
    JOURNAL OF CONTROLLED RELEASE, 267, 31, 46, 2017年12月, [査読有り], [招待有り]
    英語, 研究論文(学術雑誌)
  • Preparation of envelope-type lipid nanoparticles containing gold nanorods for photothermal cancer therapy
    West Kristian D. Paraiso; Hiroki Tanaka; Yusuke Sato; Daiki Shirane; Noriyuki Suzuki; Yasumitsu Ogra; Kota Tange; Yuta Nakai; Hiroki Yoshioka; Hideyoshi Harashima; Hidetaka Akita
    COLLOIDS AND SURFACES B-BIOINTERFACES, 160, 715, 723, 2017年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Optical control of mitochondrial reductive reactions in living cells using an electron donor-acceptor linked molecule
    Yuta Takano; Reina Munechika; Vasudevanpillai Biju; Hideyoshi Harashima; Hiroshi Imahori; Yuma Yamada
    NANOSCALE, 9, 47, 18690, 18698, 2017年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Packaging of the Coenzyme Q(10) into a Liposome for Mitochondrial Delivery and the Intracellular Observation in Patient Derived Mitochondrial Disease Cells
    Yuma Yamada; Laila Burger; Eriko Kawamura; Hideyoshi Harashima
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40, 12, 2183, 2190, 2017年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus
    Yusuke Sato; Hideki Matsui; Naoki Yamamoto; Risa Sato; Tsubasa Munakata; Michinori Kohara; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 266, 216, 225, 2017年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Integration of nano drug-delivery system with cancer immunotherapy
    Takashi Nakamura; Hideyoshi Harashima
    Therapeutic Delivery, 8, 11, 987, 1000, Future Medicine Ltd., 2017年11月01日, [査読有り]
    英語
  • Understanding the formation mechanism of lipid nanoparticles in microfluidic devices with chaotic micromixers
    Masatoshi Maeki; Yuka Fujishima; Yusuke Sato; Takao Yasui; Noritada Kaji; Akihiko Ishida; Hirofumi Tani; Yoshinobu Baba; Hideyoshi Harashima; Manabu Tokeshi
    PLOS ONE, 12, 11, e0187962, 2017年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Identification and Evaluation of the Minimum Unit of a KALA Peptide Required for Gene Delivery and Immune Activation
    Naoya Miura; Kota Tange; Yuta Nakai; Hiroki Yoshioka; Hideyoshi Harashima; Hidetaka Akita
    JOURNAL OF PHARMACEUTICAL SCIENCES, 106, 10, 3113, 3119, 2017年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting
    Yu Sakurai; Wataru Mizumura; Manami Murata; Tomoya Hada; Shoshiro Yamamoto; Kenichiro Ito; Kazuhiro Iwasaki; Takayuki Katoh; Yuki Goto; Asako Takagi; Michinori Kohara; Hiroaki Suga; Hideyoshi Harashima
    MOLECULAR PHARMACEUTICS, 14, 10, 3290, 3298, 2017年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Mitochondrial Delivery of Doxorubicin Using MITO-Porter Kills Drug-Resistant Renal Cancer Cells via Mitochondrial Toxicity
    Yuma Yamada; Reina Munechika; Eriko Kawamura; Yu Sakurai; Yusuke Sato; Hideyoshi Harashima
    JOURNAL OF PHARMACEUTICAL SCIENCES, 106, 9, 2428, 2437, 2017年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • PEGylation of the GALA Peptide Enhances the Lung-Targeting Activity of Nanocarriers That Contain Encapsulated siRNA
    Sarochin Santiwarangkool; Hidekata Akita; Taichi Nakatani; Kenji Kusumoto; Hiroki Kimura; Masaru Suzuki; Masaharu Nishimura; Yusuke Sato; Hideyoshi Harashima
    JOURNAL OF PHARMACEUTICAL SCIENCES, 106, 9, 2420, 2427, 2017年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes
    Kazuki Hashiba; Yusuke Sato; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 262, 239, 246, 2017年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Validation of the use of an artificial mitochondrial reporter DNA vector containing a Cytomegalovirus promoter for mitochondrial transgene expression
    Yuma Yamada; Takuya Ishikawa; Hideyoshi Harashima
    BIOMATERIALS, 136, 56, 66, 2017年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • ドキソルビシン心筋症に対するミトコンドリアドラッグデリバリーシステムを用いた心筋前駆細胞移植の検討
    阿部 二郎; 山田 勇磨; 武田 充人; 原島 秀吉
    日本小児循環器学会雑誌, 33, Suppl.1, s1, 175, (NPO)日本小児循環器学会, 2017年07月
    日本語
  • Size-Dependency of the Surface Ligand Density of Liposomes Prepared by Post-insertion
    Shang-Hsuan Lee; Yusuke Sato; Mamoru Hyodo; Hideyoshi Harashima
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40, 7, 1002, 1009, 2017年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • リンパ節内樹状細胞を標的とした極小ナノキャリアシステムの開発
    河合 美典; 中村 孝司; 佐藤 悠介; 真栄城 正寿; 原島 秀吉
    日本DDS学会学術集会プログラム予稿集, 33回, 175, 175, 日本DDS学会, 2017年06月
    日本語
  • オートファジー誘導能を有する超分子構造ポリマー搭載ミトコンドリアDDSの構築
    大工原 伸之輔; 山田 勇磨; 田村 篤志; 西田 慶; 由井 伸彦; 原島 秀吉
    日本DDS学会学術集会プログラム予稿集, 33回, 173, 173, 日本DDS学会, 2017年06月, [査読有り]
    日本語
  • Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles
    Shoshiro Yamamoto; Akari Kato; Yu Sakurai; Tomoya Hada; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 251, 1, 10, 2017年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Modifying Antigen-Encapsulating Liposomes with KALA Facilitates MHC Class I Antigen Presentation and Enhances Anti-tumor Effects
    Naoya Miura; Hidetaka Akita; Naho Tateshita; Takashi Nakamura; Hideyoshi Harashima
    MOLECULAR THERAPY, 25, 4, 1003, 1013, 2017年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Enhanced transgene expression by plasmid-specific recruitment of histone acetyltransferase
    Mika Nishihara; Genki N. Kanda; Tetsuya Suzuki; Shin'ichiro Yamakado; Hideyoshi Harashima; Hiroyuki Kamiya
    JOURNAL OF BIOSCIENCE AND BIOENGINEERING, 123, 3, 277, 280, 2017年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Temperature and pH sensitivity of a stabilized self-nanoemulsion formed using an ionizable lipid-like material via an oil-to-surfactant transition
    Hiroki Tanaka; Sho Oasa; Masataka Kinjo; Kota Tange; Yuta Nakai; Hideyoshi Harashima; Hidetaka Akita
    COLLOIDS AND SURFACES B-BIOINTERFACES, 151, 95, 101, 2017年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Modifying Cationic Liposomes with Cholesteryl-PEG Prevents Their Aggregation in Human Urine and Enhances Cellular Uptake by Bladder Cancer Cells
    Takashi Nakamura; Yosuke Noma; Yu Sakurai; Hideyoshi Harashima
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40, 2, 234, 237, 2017年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • MITO-Porter, multifunctional envelope-type nano device for mitochondrial delivery toward innovative nano medicine
    Yuma Yamada; Hideyoshi Harashima
    Journal of the Society of Powder Technology, Japan, 54, 3, 158, 166, Society of Powder Technology, 2017年, [査読有り]
    日本語, 研究論文(学術雑誌)
  • Innovative Technologies in Nanomedicines: From Passive Targeting to Active Targeting/From Controlled Pharmacokinetics to Controlled Intracellular Pharmacokinetics
    Yusuke Sato; Yu Sakurai; Kazuaki Kajimoto; Takashi Nakamura; Yuma Yamada; Hidetaka Akita; Hideyoshi Harashima
    MACROMOLECULAR BIOSCIENCE, 17, 1, 2017年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • MITO-porter for mitochondrial delivery and mitochondrial functional analysis
    Yuma Yamada; Hideyoshi Harashima
    Handbook of Experimental Pharmacology, 240, 457, 472, Springer New York LLC, 2017年, [査読有り]
    英語, 論文集(書籍)内論文
  • Drug Delivery Research for the Future: Expanding the Nano Horizons and Beyond
    Samir Mitragotri; Twan Lammers; You Han Bae; Steven Schwendeman; Stefaan De Smedt; Jean-Christophe Leroux; Dan Peer; Ick Chan Kwon; Hideyoshi Harashima; Akihiko Kikuchi; Yu-Kyoung Oh; Vladmir Torchilin; Wim Hennink; Justin Hanes; Kinam Park
    JOURNAL OF CONTROLLED RELEASE, 246, 183, 184, 2017年01月, [査読有り]
    英語
  • Scalable preparation of poly(ethyleneglycol)-grafted siRNA-loaded lipid nanoparticles using a commercially available fluidic device and tangential flow filtration
    Yu Sakurai; Tomoya Hada; Hideyoshi Harashima
    JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, 28, 10-12, 1086, 1096, 2017年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Remodeling of the extracellular matrix by endothelial cell-targeting siRNA improves the EPR-based delivery of 100 nm particles
    Yu Sakurai; Tomoya Hada; Shoshiro Yamamoto; Akari Kato; Wataru Mizumura; Hideyoshi Harashima
    Molecular Therapy, 24, 12, 2090, 2099, Nature Publishing Group, 2016年12月01日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Development of a multifunctional envelope-type nano device and its application to nanomedicine
    Yusuke Sato; Takashi Nakamura; Yuma Yamada; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 244, Pt B, 194, 204, 2016年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Remodeling of the Extracellular Matrix by Endothelial Cell-Targeting siRNA Improves the EPR-Based Delivery of 100 nm Particles.
    Sakurai Y; Hada T; Yamamoto S; Kato A; Mizumura W; Harashima H
    Molecular therapy : the journal of the American Society of Gene Therapy, 24, 12, 2090, 2099, 2016年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Topology of Surface Ligands on Liposomes: Characterization Based on the Terms, Incorporation Ratio, Surface Anchor Density, and Reaction Yield
    Shang-Hsuan Lee; Yusuke Sato; Mamoru Hyodo; Hideyoshi Harashima
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 39, 12, 1983, 1994, 2016年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Small-sized, stable lipid nanoparticle for the efficient delivery of siRNA to human immune cell lines
    Takashi Nakamura; Moeka Kuroi; Yuki Fujiwara; Shota Warashina; Yusuke Sato; Hideyoshi Harashima
    SCIENTIFIC REPORTS, 6, 37849, 2016年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Identification of a Nucleoporin358-Specific RNA Aptamer for Use as a Nucleus-Targeting Liposomal Delivery System
    Garima Shrivastava; Mamoru Hyodo; Shige H. Yoshimura; Hidetaka Akita; Hideyoshi Harashima
    NUCLEIC ACID THERAPEUTICS, 26, 5, 286, 298, 2016年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Liver-Specific Silencing of Lipin1 Reduces Fat Mass as Well as Hepatic Triglyceride Biosynthesis in Mice
    Kazuaki Kajimoto; Erina Suemitsu; Yusuke Sato; Yu Sakurai; Hideyoshi Harashima
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 39, 10, 1653, 1661, 2016年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • ミトコンドリア薬物送達システムを用いた心筋炎に対する新たな治療戦略
    阿部 二郎; 山田 勇磨; 武田 充人; 原島 秀吉
    日本小児循環器学会雑誌, 32, Suppl.1, s1, 208, (NPO)日本小児循環器学会, 2016年07月, [査読有り]
    日本語
  • Effect of particle size on their accumulation in an inflammatory lesion in a dextran sulfate sodium (DSS)-induced colitis model
    Ayaka Watanabe; Hiroki Tanaka; Yu Sakurai; Kota Tange; Yuta Nakai; Tatsuya Ohkawara; Hiroshi Takeda; Hideyoshi Harashima; Hidetaka Akita
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 509, 1-2, 118, 122, 2016年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors
    Golam Kibria; Hiroto Hatakeyama; Yusuke Sato; Hideyoshi Harashima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 509, 1-2, 178, 187, 2016年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Elimination of the biphasic pharmacodynamics of 15d-PGJ2 by controlling its release from a nanoemulsion
    Saed Abbasi; Kazuaki Kajimoto; Hideyoshi Harashima
    International Journal of Nanomedicine, 11, 2685, 2694, Dove Medical Press Ltd., 2016年06月08日, [査読有り]
    英語, 研究論文(学術雑誌)
  • プラスミドDNA結合ヒストンの特異的アセチル化による外来遺伝子発現上昇
    紙谷 浩之; 西原 実香; 神田 元紀; 鈴木 哲矢; 山門 振一郎; 原島 秀吉
    日本DDS学会学術集会プログラム予稿集, 32回, 153, 153, 日本DDS学会, 2016年06月
    日本語
  • Protecting liver sinusoidal endothelial cells suppresses apoptosis in acute liver damage
    Tomohito Tanoi; Takafumi Tamura; Naoki Sano; Ken Nakayama; Kiyoshi Fukunaga; Yun-Wen Zheng; Afsana Akhter; Yu Sakurai; Yasuhiro Hayashi; Hideyoshi Harashima; Nobuhiro Ohkohchi
    HEPATOLOGY RESEARCH, 46, 7, 697, 706, 2016年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • In vivo selection of active deoxyribonucleoside kinase by a mutagenic nucleoside analog
    Hiroyuki Kamiya; Mana Ito; Kosuke Nishi; Hideyoshi Harashima
    JOURNAL OF BIOTECHNOLOGY, 228, 52, 57, 2016年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery
    Yusuke Sato; Yusuke Note; Masatoshi Maeki; Noritada Kaji; Yoshinobu Baba; Manabu Tokeshi; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 229, 48, 57, 2016年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A Dual-Ligand Liposomal System Composed of a Cell-Penetrating Peptide and a Mitochondrial RNA Aptamer Synergistically Facilitates Cellular Uptake and Mitochondrial Targeting
    Yuma Yamada; Ryo Furukawa; Hideyoshi Harashima
    JOURNAL OF PHARMACEUTICAL SCIENCES, 105, 5, 1705, 1713, 2016年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Heterogeneity of tumor endothelial cells and drug delivery
    Kyoko Hida; Nako Maishi; Yu Sakurai; Yasuhiro Hida; Hideyoshi Harashima
    ADVANCED DRUG DELIVERY REVIEWS, 99, Pt B, 140, 147, 2016年04月, [査読有り]
    英語
  • Relationship Between the Physicochemical Properties of Lipid Nanoparticles and the Quality of siRNA Delivery to Liver Cells
    Yusuke Sato; Hiroto Hatakeyama; Mamoru Hyodo; Hideyoshi Harashima
    MOLECULAR THERAPY, 24, 4, 788, 795, 2016年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Tri-membrane nanoparticles produced by combining liposome fusion and a novel patchwork of bicelles to overcome endosomal and nuclear membrane barriers to cargo delivery
    Asako Yamada; Asako Mitsueda; Mahadi Hasan; Miho Ueda; Susumu Hama; Shota Warashina; Takashi Nakamura; Hideyoshi Harashima; Kentaro Kogure
    Biomaterials Science, 4, 3, 439, 447, Royal Society of Chemistry, 2016年03月01日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Transcytosis-Targeting Peptide: A Conductor of Liposomal Nanoparticles through the Endothelial Cell Barrier
    Hidetaka Akita; Takahiro Fujiwara; Sarochin Santiwarangkool; Nazir Hossen; Kazuaki Kajimoto; Ayman El-Sayed; Yasuhiko Tabata; Hideyoshi Harashima
    SMALL, 12, 9, 1212, 1221, 2016年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection
    Naoki Yamamoto; Yusuke Sato; Tsubasa Munakata; Masakazu Kakuni; Chise Tateno; Takahiro Sanada; Yuichi Hirata; Shuko Murakami; Yasuhito Tanaka; Kazuaki Chayama; Hiroto Hatakeyama; Mamoru Hyodo; Hideyoshi Harashima; Michinori Kohara
    JOURNAL OF HEPATOLOGY, 64, 3, 547, 555, 2016年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • FoxO1 Plays an Important Role in Regulating β-Cell Compensation for Insulin Resistance in Male Mice.
    Zhang T; Kim DH; Xiao X; Lee S; Gong Z; Muzumdar R; Calabuig-Navarro V; Yamauchi J; Harashima H; Wang R; Bottino R; Alvarez-Perez JC; Garcia-Ocaña A; Gittes G; Dong HH
    Endocrinology, 157, 3, 1055, 1070, 2016年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells
    Shota Warashina; Takashi Nakamura; Yusuke Sato; Yuki Fujiwara; Mamoru Hyodo; Hiroto Hatakeyama; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 225, 183, 191, 2016年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Validation of a Strategy for Cancer Therapy: Delivering Aminoglycoside Drugs to Mitochondria in HeLa Cells
    Jiro Abe; Yuma Yamada; Hideyoshi Harashima
    JOURNAL OF PHARMACEUTICAL SCIENCES, 105, 2, 734, 740, 2016年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • PEG dilemma- nucleic acids delivery to cancers by controlling biodistribution and intracellular trafficking
    Hiroto Hatakeyama; Hideyoshi Harashima
    Drug Delivery System, 31, 4, 293, 299, Japan Society of Drug Delivery System, 2016年, [査読有り]
    日本語, 研究論文(学術雑誌)
  • Elimination of the biphasic pharmacodynamics of 15d-PGJ2 by controlling its release from a nanoemulsion
    Saed Abbasi; Kazuaki Kajimoto; Hideyoshi Harashima
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 11, 2685, 2694, 2016年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Preparation of a Cyclic RGD: Modified Liposomal SiRNA Formulation for Use in Active Targeting to Tumor and Tumor Endothelial Cells.
    Sakurai Y; Hada T; Harashima H
    Methods in molecular biology (Clifton, N.J.), 1364, 63, 69, 2016年, [査読有り]
  • A Multifunctional Envelope-Type Nano Device Containing a pH-Sensitive Cationic Lipid for Efficient Delivery of Short Interfering RNA to Hepatocytes In Vivo.
    Sato Y; Harashima H; Kohara M
    Methods in molecular biology (Clifton, N.J.), 1364, 71, 78, 2016年, [査読有り]
  • Tri-membrane nanoparticles produced by combining liposome fusion and a novel patchwork of bicelles to overcome endosomal and nuclear membrane barriers to cargo delivery
    Asako Yamada; Asako Mitsueda; Mahadi Hasan; Miho Ueda; Susumu Hama; Shota Warashina; Takashi Nakamura; Hideyoshi Harashima; Kentaro Kogure
    BIOMATERIALS SCIENCE, 4, 3, 439, 447, 2016年, [査読有り]
    英語, 研究論文(学術雑誌)
  • In Vivo Inverse Correlation in the Activation of Natural Killer T Cells Through Dual-Signal Stimulation via a Combination of α-Galactosylceramide-Loaded Liposomes and Interleukin-12.
    Abdelmegeed H; Nakamura T; Harashima H
    Journal of pharmaceutical sciences, 105, 1, 250, 256, 2016年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Cellular environment-responsive nanomaterials for use in gene and siRNA delivery: molecular design for biomembrane destabilization and intracellular collapse
    Hiroki Tanaka; Yusuke Sato; Hideyoshi Harashima; Hidetaka Akita
    EXPERT OPINION ON DRUG DELIVERY, 13, 7, 1015, 1027, 2016年, [査読有り]
    英語
  • Insertion and Deletion Mismatches Distant from the Target Position Improve Gene Correction with a Tailed Duplex
    Hiroyuki Kamiya; Natsuki Nishigaki; Akihiro Ikeda; Seiya Yukawa; Yukiko Morita; Yoshimichi Nakatsu; Teruhisa Tsuzuki; Hideyoshi Harashima
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 35, 7, 379, 388, 2016年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Validation of Mitochondrial Gene Delivery in Liver and Skeletal Muscle via Hydrodynamic Injection Using an Artificial Mitochondrial Reporter DNA Vector
    Yukari Yasuzaki; Yuma Yamada; Takuya Ishikawa; Hideyoshi Harashima
    MOLECULAR PHARMACEUTICS, 12, 12, 4311, 4320, 2015年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • New drug delivery system for liver sinusoidal endothelial cells for ischemia-reperfusion injury
    Naoki Sano; Takafumi Tamura; Naoyuki Toriyabe; Takeshi Nowatari; Ken Nakayama; Tomohito Tanoi; Soichiro Murata; Yu Sakurai; Mamoru Hyodo; Kiyoshi Fukunaga; Hideyoshi Harashima; Nobuhiro Ohkohchi
    WORLD JOURNAL OF GASTROENTEROLOGY, 21, 45, 12778, 12786, 2015年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Size-dependent specific targeting and efficient gene silencing in peritoneal macrophages using a pH-sensitive cationic liposomal siRNA carrier
    Hideki Matsui; Yusuke Sato; Hiroto Hatakeyama; Hidetaka Akita; Hideyoshi Harashima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 495, 1, 171, 178, 2015年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • The intracellular pharmacodynamics of siRNA is responsible for the low gene silencing activity of siRNA-loaded nanoparticles in dendritic cells
    Takashi Nakamura; Yuki Fujiwara; Shota Warashina; Hideyoshi Harashima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 494, 1, 271, 277, 2015年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma
    Takashi Nakamura; Hiroko Miyabe; Mamoru Hyodo; Yusuke Sato; Yoshihiro Hayakawa; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 216, 149, 157, 2015年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Molecular Tuning of a Vitamin E-Scaffold pH-Sensitive and Reductive Cleavable Lipid-like Material for Accelerated in Vivo Hepatic siRNA Delivery
    Hidetaka Akita; Yuki Noguchi; Hiroto Hatakeyama; Yusuke Sato; Kota Tange; Yuta Nakai; Hideyoshi Harashima
    ACS BIOMATERIALS SCIENCE & ENGINEERING, 1, 9, 834, 844, 2015年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Mitochondrial delivery of Coenzyme Q(10) via systemic administration using a MITO-Porter prevents ischemia/reperfusion injury in the mouse liver
    Yuma Yamada; Kohei Nakamura; Jiro Abe; Mamoru Hyodo; Sanae Haga; Michitaka Ozaki; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 213, 86, 95, 2015年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • An analysis of membrane fusion between mitochondrial double membranes and MITO-Porter, mitochondrial fusogenic vesicles
    Yuma Yamada; Yutaka Fukuda; Hideyoshi Harashima
    MITOCHONDRION, 24, 50, 55, 2015年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Efficient and High-Speed Transduction of an Antibody into Living Cells Using a Multifunctional Nanocarrier System to Control Intracellular Trafficking
    Yuma Yamada; Sandra Milena Vergara Perez; Mai Tabata; Jiro Abe; Yukari Yasuzaki; Hideyoshi Harashima
    JOURNAL OF PHARMACEUTICAL SCIENCES, 104, 9, 2845, 2854, 2015年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Efficient Packaging of Plasmid DNA Using a pH Sensitive Cationic Lipid for Delivery to Hepatocytes
    Yu Sakurai; Takashi Matsuda; Tomoya Hada; Hideyoshi Harashima
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 38, 8, 1185, 1191, 2015年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Influence of endosomal escape and degradation of α-galactosylceramide loaded liposomes on CD1d antigen presentation.
    Nakamura T; Kuroi M; Harashima H
    Molecular pharmaceutics, 12, 8, 2791, 2799, 2015年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Mitochondrial delivery of antisense RNA by MITO-Porter results in mitochondrial RNA knockdown, and has a functional impact on mitochondria.
    Furukawa R; Yamada Y; Kawamura E; Harashima H
    Biomaterials, 57, 107, 115, 2015年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Multifunctional Envelope-Type Nano Device: Evolution from Nonselective to Active Targeting System
    Yasuhiro Hayashi; Hiroto Hatakeyama; Kazuaki Kajimoto; Mamoru Hyodo; Hidetaka Akita; Hideyoshi Harashima
    BIOCONJUGATE CHEMISTRY, 26, 7, 1266, 1276, 2015年07月, [査読有り]
    英語
  • General considerations regarding the in vitro and in vivo properties of block copolymer micelle products and their evaluation
    Kumiko Sakai-Kato; Nobuhiro Nishiyama; Masato Kozaki; Takeshi Nakanishi; Yoshihiro Matsuda; Mai Hirano; Hiroyuki Hanada; Shigeru Hisada; Hiroshi Onodera; Hideyoshi Harashima; Yasuhiro Matsumura; Kazunori Kataoka; Yukihiro Goda; Haruhiro Okuda; Toru Kawanishi
    JOURNAL OF CONTROLLED RELEASE, 210, 76, 83, 2015年07月, [査読有り]
    英語
  • Effect of hydrophobic scaffold on the cellular uptake and gene transfection activities of DNA-encapsulating liposomal nanoparticles via intracerebroventricular administration
    Hidetaka Akita; Taichi Nakatani; Kimiko Kuroki; Katsumi Maenaka; Kota Tange; Yuta Nakai; Hideyoshi Harashima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 490, 1-2, 142, 145, 2015年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Hyaluronic acid controls the uptake pathway and intracellular trafficking of an octaarginine-modified gene vector in CD44 positive- and CD44 negative-cells
    Yuma Yamada; Masahiro Hashida; Hideyoshi Harashima
    BIOMATERIALS, 52, 189, 198, 2015年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Forkhead Box O6 (FoxO6) Depletion Attenuates Hepatic Gluconeogenesis and Protects against Fat-induced Glucose Disorder in Mice
    Virtu Calabuig-Navarro; Jun Yamauchi; Sojin Lee; Ting Zhang; Yun-Zi Liu; Kelsey Sadlek; Gina M. Coudriet; Jon D. Piganelli; Chun-Lei Jiang; Rita Miller; Mark Lowe; Hideyoshi Harashima; H. Henry Dong
    JOURNAL OF BIOLOGICAL CHEMISTRY, 290, 25, 15581, 15594, 2015年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Effect of the Compaction and the Size of DNA on the Nuclear Transfer Efficiency after Microinjection in Synchronized Cells
    Hidetaka Akita; Dai Kurihara; Marco Schmeer; Martin Schleef; Hideyoshi Harashima
    PHARMACEUTICS, 7, 2, 64, 73, 2015年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Action-at-a-Distance Mutagenesis Induced by Oxidized Guanine in Werner Syndrome Protein-Reduced Human Cells
    Hiroyuki Kamiya; Daiki Yamazaki; Eri Nakamura; Tetsuaki Makino; Miwako Kobayashi; Ichiro Matsuoka; Hideyoshi Harashima
    CHEMICAL RESEARCH IN TOXICOLOGY, 28, 4, 621, 628, 2015年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma
    Hidetaka Akita; Ryohei Ishiba; Ryohei Togashi; Kota Tange; Yuta Nakai; Hiroto Hatakeyama; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 200, 97, 105, 2015年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A KALA-modified lipid nanoparticle containing CpG-free plasmid DNA as a potential DNA vaccine carrier for antigen presentation and as an immune-stimulative adjuvant
    Naoya Miura; Sharif M. Shaheen; Hidetaka Akita; Takashi Nakamura; Hideyoshi Harashima
    NUCLEIC ACIDS RESEARCH, 43, 3, 1317, 1331, 2015年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Targeting the mitochondrial genome via a dual function MITO-porter: Evaluation of mtDNA levels and mitochondrial function
    Yuma Yamada; Hideyoshi Harashima
    Mitochondrial Medicine, 2, 123, 133, Springer New York, 2015年01月29日, [査読有り]
    英語, 論文集(書籍)内論文
  • Optimization of a siRNA carrier modified with a ph-sensitive cationic lipid and a cyclic RGD peptide for efficiently targeting tumor endothelial cells
    Tomoya Hada; Yu Sakurai; Hideyoshi Harashima
    Pharmaceutics, 7, 3, 320, 333, MDPI AG, 2015年, [査読有り]
    英語, 研究論文(学術雑誌)
  • A strategy for synthesis of lipid nanoparticles using microfluidic devices with a mixer structure
    Masatoshi Maeki; Tatsuyoshi Saito; Yusuke Sato; Takao Yasui; Noritada Kaji; Akihiko Ishida; Hirofumi Tani; Yoshinobu Baba; Hideyoshi Harashima; Manabu Tokeshi
    RSC ADVANCES, 5, 57, 46181, 46185, 2015年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Advances in an active and passive targeting to tumor and adipose tissues
    Yu Sakurai; Kazuaki Kajimoto; Hiroto Hatakeyama; Hideyoshi Harashima
    EXPERT OPINION ON DRUG DELIVERY, 12, 1, 41, 52, 2015年01月, [査読有り]
    英語
  • The RNA Sensor RIG-I Dually Functions as an Innate Sensor and Direct Antiviral Factor for Hepatitis B Virus
    Seiichi Sato; Kai Li; Takeshi Kameyama; Takaya Hayashi; Yuji Ishida; Shuko Murakami; Tsunamasa Watanabe; Sayuki Iijima; Yu Sakurai; Koichi Watashi; Susumu Tsutsumi; Yusuke Sato; Hidetaka Akita; Takaji Wakita; Charles M. Rice; Hideyoshi Harashima; Michinori Kohara; Yasuhito Tanaka; Akinori Takaoka
    IMMUNITY, 42, 1, 123, 132, 2015年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Mechanism responsible for the antitumor effect of BCG-CWS using the LEEL method in a mouse bladder cancer model
    Takashi Nakamura; Masafumi Fukiage; Yoshiteru Suzuki; Ikuya Yano; Jun Miyazaki; Hiroyuki Nishiyama; Hideyuki Akaza; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 196, 161, 167, 2014年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Comparative Study of the Sensitivities of Cancer Cells to Doxorubicin, and Relationships between the Effect of the Drug-Efflux Pump P-gp
    Golam Kibria; Hiroto Hatakeyama; Kosuke Akiyama; Kyoko Hida; Hideyoshi Harashima
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 37, 12, 1926, 1935, 2014年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • "Programmed packaging" for gene delivery
    M. Hyodo; Y. Sakurai; H. Akita; H. Harashima
    JOURNAL OF CONTROLLED RELEASE, 193, 316, 323, 2014年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Ligand density at the surface of a nanoparticle and different uptake mechanism: Two important factors for successful siRNA delivery to liver endothelial cells
    Afsana Akhter; Yasuhiro Hayashi; Yu Sakurai; Noritaka Ohga; Kyoko Hida; Hideyoshi Harashima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 475, 1-2, 227, 237, 2014年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • The Screening of RNA Aptamers Specific for Carbonic Anhydrase I Using the Systematic Evolution of Ligands by an Exponential Enrichment Method (SELEX)
    Garima Shrivastava; Mamoru Hyodo; Mst Naznin Ara; Hideyoshi Harashima
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 33, 11, 697, 708, 2014年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Construction of an Aptamer Modified Liposomal System Targeted to Tumor Endothelial Cells
    Mst Naznin Ara; Takashi Matsuda; Mamoru Hyodo; Yu Sakurai; Noritaka Ohga; Kyoko Hida; Hideyoshi Harashima
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 37, 11, 1742, 1749, 2014年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Advantages of ethanol dilution method for preparing GALA-modified liposomal siRNA carriers on the in vivo gene knockdown efficiency in pulmonary endothelium
    Kenji Kusumoto; Hidetaka Akita; Sarochin Santiwarangkool; Hideyoshi Harashima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 473, 1-2, 144, 147, 2014年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Multifunctional envelope-type nano device for controlled intracellular trafficking and selective targeting in vivo
    Kazuaki Kajimoto; Yusuke Sato; Takashi Nakamura; Yuma Yamada; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 190, 593, 606, 2014年09月, [査読有り]
    英語
  • Condensation of plasmid DNA enhances mitochondrial association in skeletal muscle following hydrodynamic limb vein injection
    Yukari Yasuzaki; Yuma Yamada; Yutaka Fukuda; Hideyoshi Harashima
    Pharmaceuticals, 7, 8, 881, 893, 2014年08月21日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Neutralized Nanoparticle Composed of SS-Cleavable and pH-Activated Lipid-Like Material as a Long-Lasting and Liver-Specific Gene Delivery System
    Masami Ukawa; Hidetaka Akita; Yasuhiro Hayashi; Ryohei Ishiba; Kota Tange; Masaya Arai; Kazuhiro Kubo; Yuriko Higuchi; Kazunori Shimizu; Satoshi Konishi; Mitsuru Hashida; Hideyoshi Harashima
    ADVANCED HEALTHCARE MATERIALS, 3, 8, 1222, 1229, 2014年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Improvement of Doxorubicin Efficacy Using Liposornal Anti-Polo-like Kinase 1 siRNA in Human Renal Cell Carcinomas
    Yu Sakurai; Hiroto Hatakeyama; Hidetaka Akita; Hideyoshi Harashima
    MOLECULAR PHARMACEUTICS, 11, 8, 2713, 2719, 2014年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Comparative assessments of crucial factors for a functional ligand-targeted nanocarrier
    Md. Nazir Hossen; Kazuaki Kajimoto; Ryo Tatsumi; Mamoru Hyodo; Hideyoshi Harashima
    JOURNAL OF DRUG TARGETING, 22, 7, 600, 609, 2014年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Identification and expression of troponin T, a new marker on the surface of cultured tumor endothelial cells by aptamer ligand
    Mst. Naznin Ara; Mamoru Hyodo; Noritaka Ohga; Kosuke Akiyama; Kyoko Hida; Yasuhiro Hida; Nobuo Shinohara; Hideyoshi Harashima
    CANCER MEDICINE, 3, 4, 825, 834, 2014年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A nanocarrier system for the delivery of nucleic acids targeted to a pancreatic beta cell line
    Yuma Yamada; Mai Tabata; Yukari Yasuzaki; Masatoshi Nomura; Atsushi Shibata; Yuta Ibayashi; Yosuke Taniguchi; Shigeki Sasaki; Hideyoshi Harashima
    BIOMATERIALS, 35, 24, 6430, 6438, 2014年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells
    Mst Naznin Ara; Takashi Matsuda; Mamoru Hyodo; Yu Sakurai; Hiroto Hatakeyama; Noritaka Ohga; Kyoko Hida; Hideyoshi Harashima
    BIOMATERIALS, 35, 25, 7110, 7120, 2014年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Octaarginine-Modified Liposomes Enhance Cross-Presentation by Promoting the C-Terminal Trimming of Antigen Peptide
    Takashi Nakamura; Kouhei Ono; Yoshiteru Suzuki; Rumiko Moriguchi; Kentaro Kogure; Hideyoshi Harashima
    MOLECULAR PHARMACEUTICS, 11, 8, 2787, 2795, 2014年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • RNA Aptamers for Targeting Mitochondria Using a Mitochondria-Based SELEX Method
    Yuri Tawaraya; Mamoru Hyodo; Mst Naznin Ara; Yuma Yamada; Hideyoshi Harashima
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 37, 8, 1411, 1415, 2014年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • プラスミドDNA特異的ヒストン修飾による導入遺伝子発現上昇
    西原 実香; 神田 元紀; 山門 振一郎; 原島 秀吉; 紙谷 浩之
    日本DDS学会学術集会プログラム予稿集, 30回, 165, 165, 日本DDS学会, 2014年07月
    日本語
  • Mono-cationic detergents play a critical role in the development of liposome-based gene vector via controlling its lamellarity
    Ryosuke Suzuki; Yuma Yamada; Eriko Kawamura; Hideyoshi Harashima
    JOURNAL OF NANOPARTICLE RESEARCH, 16, 8, 2014年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A new adjuvant delivery system 'cyclic di-GMP/YSK05 liposome' for cancer immunotherapy
    Hiroko Miyabe; Mamoru Hyodo; Takashi Nakamura; Yusuke Sato; Yoshihiro Hayakawa; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 184, 20, 27, 2014年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Glycerol Monomycolate Is a Novel Ligand for the Human, but Not Mouse Macrophage Inducible C-type Lectin, Mincle
    Yuki Hattori; Daisuke Morita; Nagatoshi Fujiwara; Daiki Mori; Takashi Nakamura; Hideyoshi Harashima; Sho Yamasaki; Masahiko Sugita
    JOURNAL OF BIOLOGICAL CHEMISTRY, 289, 22, 15405, 15412, 2014年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Anatomy of plasmid DNAs with anti-silencing elements
    Genki N. Kanda; Shiho Miyamoto; Miwako Kobayashi; Ichiro Matsuoka; Hideyoshi Harashima; Hiroyuki Kamiya
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 464, 1-2, 27, 33, 2014年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • An apolipoprotein E modified liposomal nanoparticle: Ligand dependent efficiency as a siRNA delivery carrier for mouse-derived brain endothelial cells
    Mina Tamaru; Hidetaka Akita; Kazuaki Kajimoto; Yusuke Sato; Hiroto Hatakeyama; Hideyoshi Harashima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 465, 1-2, 77, 82, 2014年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus.
    Tsunamasa Watanabe; Hiroto Hatakeyama; Chiho Matsuda-Yasui; Yusuke Sato; Masayuki Sudoh; Asako Takagi; Yuichi Hirata; Takahiro Ohtsuki; Masaaki Arai; Kazuaki Inoue; Hideyoshi Harashima; Michinori Kohara
    SCIENTIFIC REPORTS, 4, 4750, 2014年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Hepatic Monoacylglycerol O-acyltransferase 1 as a Promising Therapeutic Target for Steatosis, Obesity, and Type 2 Diabetes
    Yasuhiro Hayashi; Erina Suemitsu; Kazuaki Kajimoto; Yusuke Sato; Afsana Akhter; Yu Sakurai; Hiroto Hatakeyama; Mamoru Hyodo; Noritada Kaji; Yoshinobu Baba; Hideyoshi Harashima
    MOLECULAR THERAPY-NUCLEIC ACIDS, 3, e154, 2014年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Effects of Silencing the RET/PTC1 Oncogene in Papillary Thyroid Carcinoma by siRNA-Squalene Nanoparticles With and Without Fusogenic Companion GALA-Cholesterol
    Hafiz Muhammad Ali; Andrei Maksimenko; Giorgia Urbinati; Hubert Chapuis; Mouna Raouane; Didier Desmaele; Hayashi Yasuhiro; Hideyoshi Harashima; Patrick Couvreur; Liliane Massaad-Massade
    THYROID, 24, 2, 327, 338, 2014年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Neutral biodegradable lipid-envelope-type nanoparticle using vitamin A-Scaffold for nuclear targeting of plasmid DNA
    Hiroki Tanaka; Hidetaka Akita; Ryohei Ishiba; Kota Tange; Masaya Arai; Kazuhiro Kubo; Hideyoshi Harashima
    BIOMATERIALS, 35, 5, 1755, 1761, 2014年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Nanoparticulation of BCG-CWS for application to bladder cancer therapy
    Takashi Nakamura; Masafumi Fukiage; Megumi Higuchi; Akihiro Nakaya; Ikuya Yano; Jun Miyazaki; Hiroyuki Nishiyama; Hideyuki Akaza; Toshihiro Ito; Hiroyuki Hosokawa; Toshinori Nakayama; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 176, 44, 53, 2014年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • 創薬におけるゼンメルワイス
    原島 秀吉
    薬剤学, 74, 1, 1, 1, The Academy of Pharmaceutical Science and Technology, Japan, 2014年
    日本語
  • The initiatives for regulatory science researches of nanomedicines
    Harashima Hideyoshi; Hidetaka Akita; Kumiko Sakai-Kato; Takehiko Ishii; Yasuhiro Matsumura; Kazunori Kataoka
    Drug Delivery System, 29, 3, 217, 225, Japan Society of Drug Delivery System, 2014年, [査読有り]
    日本語, 研究論文(学術雑誌)
  • Application of apolipoprotein E-modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid in the brain
    Mina Tamaru; Hidetaka Akita; Taichi Nakatani; Kazuaki Kajimoto; Yusuke Sato; Hiroto Hatakeyama; Hideyoshi Harashima
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 9, 4267, 4276, 2014年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Neutralized nanoparticle composed of SS-cleavable and pH-activated lipid-like material as a long-lasting and liver-specific gene delivery system
    Masami Ukawa; Hidetaka Akita; Yasuhiro Hayashi; Ryohei Ishiba; Kota Tange; Masaya Arai; Kazuhiro Kubo; Yuriko Higuchi; Kazunori Shimizu; Satoshi Konishi; Mitsuru Hashida; Hideyoshi Harashima
    Advanced Healthcare Materials, 3, 8, 1222, 1229, Wiley-VCH Verlag, 2014年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Suppression of short tract gene conversion in episomal DNA by p53 reduction
    Hiroyuki Kamiya; Tetsuya Suzuki; Hideyoshi Harashima
    Genes and Environment, 36, 2, 65, 68, The Japanese Environmental Mutagen Society, 2014年, [査読有り]
    英語, 研究論文(学術雑誌)
  • RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system
    Yu Sakurai; Hiroto Hatakeyama; Yusuke Sato; Mamoru Hyodo; Hidetaka Akita; Noritaka Ohga; Kyoko Hida; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 173, 110, 118, 2014年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system
    Golam Kibria; Hiroto Hatakeyama; Hideyoshi Harashima
    ARCHIVES OF PHARMACAL RESEARCH, 37, 1, 4, 15, 2014年01月, [査読有り]
    英語
  • The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice
    Hiroto Hatakeyama; Manami Murata; Yusuke Sato; Mayumi Takahashi; Noriaki Minakawa; Akira Matsuda; Hideyoshi Harashima
    Journal of Controlled Release, 173, 1, 43, 50, 2014年, [査読有り]
    英語, 研究論文(学術雑誌)
  • The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice
    Hiroto Hatakeyama; Manami Murata; Yusuke Sato; Mayumi Takahashi; Noriaki Minakawa; Akira Matsuda; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 173, 43, 50, 2014年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A method for screening mitochondrial fusogenic envelopes for use in mitochondrial drug delivery
    Yuma Yamada; Hideyoshi Harashima
    Methods in Molecular Biology, 1141, 57, 66, Humana Press Inc., 2014年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Cytoprotective role of the fatty acid binding protein 4 against oxidative and endoplasmic reticulum stress in 3T3-L1 adipocytes
    Kazuaki Kajimoto; Yoshitaka Minami; Hideyoshi Harashima
    FEBS OPEN BIO, 4, 602, 610, 2014年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Application of apolipoprotein E-modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid in the brain.
    Tamaru M; Akita H; Nakatani T; Kajimoto K; Sato Y; Hatakeyama H; Harashima H
    International journal of nanomedicine, 9, 4267, 4276, 2014年, [査読有り]
  • Multifunctional Enveloped Nanodevices (MENDs)
    Yusuke Sato; Takashi Nakamura; Yuma Yamada; Hidetaka Akita; Hideyoshi Harashima
    NONVIRAL VECTORS FOR GENE THERAPY LIPID- AND POLYMER-BASED GENE TRANSFER, 88, 139, 204, 2014年, [査読有り]
    英語, 論文集(書籍)内論文
  • In vitro optimization of 2′-OMe-4′-thioribonucleoside-modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle
    Mayumi Takahashi; Naoki Yamada; Hiroto Hatakeyama; Manami Murata; Yusuke Sato; Noriaki Minakawa; Hideyoshi Harashima; Akira Matsuda
    Nucleic Acids Research, 41, 22, 10659, 10667, 2013年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • In vitro optimization of 2 '-OMe-4 '-thioribonucleoside-modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle
    Mayumi Takahashi; Naoki Yamada; Hiroto Hatakeyama; Manami Murata; Yusuke Sato; Noriaki Minakawa; Hideyoshi Harashima; Akira Matsuda
    NUCLEIC ACIDS RESEARCH, 41, 22, 10659, 10667, 2013年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Reduced Plasma Glucose by Asparagine Synthetase Knockdown in the Mouse Liver
    Shinya Iida; Hiroyuki Kamiya; Akihiro Nakaya; Yasuhiro Hayashi; Akihiro Sawada; Noritada Kaji; Yoshinobu Baba; Hideyoshi Harashima
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 36, 12, 2009, 2011, 2013年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Intracellular observation of nanocarriers modified with a mitochondrial targeting signal peptide
    Eriko Kawamura; Yuma Yamada; Yukari Yasuzaki; Mamoru Hyodo; Hideyoshi Harashima
    JOURNAL OF BIOSCIENCE AND BIOENGINEERING, 116, 5, 634, 637, 2013年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Development of a Novel Nanoparticle by Dual Modification With the Pluripotential Cell-Penetrating Peptide PepFect6 for Cellular Uptake, Endosomal Escape, and Decondensation of an siRNA Core Complex
    Asako Mitsueda; Yuri Shimatani; Masahiro Ito; Takashi Ohgita; Asako Yamada; Susumu Hama; Astrid Graslund; Staffan Lindberg; Ulo Langel; Hideyoshi Harashima; Ikuhiko Nakase; Shiroh Futaki; Kentaro Kogure
    BIOPOLYMERS, 100, 6, 698, 704, 2013年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A liposomal delivery system that targets liver endothelial cells based on a new peptide motif present in the ApoB-100 sequence.
    Akhter A; Hayashi Y; Sakurai Y; Ohga N; Hida K; Harashima H
    International journal of pharmaceutics, 456, 1, 195, 201, Elsevier science bv, 2013年11月, [査読有り]
    英語, Liver dysfunction is associated with a variety of liver diseases, including viral or alcoholic hepatitis, fibrosis, cirrhosis, and portal hypertension. A targeted drug delivery system would be very useful in the treatment of these diseases. We herein describe the development of a system comprised of a new peptide-lipid conjugate for the efficient delivery of molecules to LEC. The RLTRKRGLK sequence (3359-3367), which mediates the association of LDL with arterial CSPG and an LDL receptor, was utilized as a ligand for achieving this goal. The peptide modified PEG-LPs (RLTR-PEG-LPs) were efficiently taken up by primary liver endothelial cells (liver ECs) and other types of cells. In vivo biodistribution and confocal microscopy analysis showed that RLTR-PEG-LPs became widely accumulated in LECs within a short time. Distribution of RLTR-PEG-LPs was greatly reduced with a pretreatment of unlabeled RLTR-PEG-LPs, not cationic LPs, indicating that the sequence is important for LECs. The findings indicate that a reverse sequence of RLTR (KLGR) modified PEG-LPs (KLGR-PEG-LP) did the same pattern compared with RLTR-PEG- LPs, suggesting that the RKR or RXXR sequence might be essential for LECs targeting. Collectively RLTR-PEG-LPs and KLGR-PEG-LPs have the potential for delivering drugs to LECs. (C) 2013 Elsevier B.V. All rights reserved.
  • A DNA microarray-based analysis of immune-stimulatory and transcriptional responses of dendritic cells to KALA-modified nanoparticles
    Hidetaka Akita; Soichiro Ishii; Naoya Miura; Sharif Mohammad Shaheen; Yasuhiro Hayashi; Takashi Nakamura; Noritada Kaji; Yoshinobu Baba; Hideyoshi Harashima
    BIOMATERIALS, 34, 35, 8979, 8990, 2013年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Mitochondrial targeting functional peptides as potential devices for the mitochondrial delivery of a DF-MITO-Porter
    Eriko Kawamura; Yuma Yamada; Hideyoshi Harashima
    MITOCHONDRION, 13, 6, 610, 614, 2013年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Th1-skewed tissue responses to a mycolyl glycolipid in mycobacteria-infected rhesus macaques
    Daisuke Morita; Ayumi Miyamoto; Yuki Hattori; Takaya Komori; Takashi Nakamura; Tatsuhiko Igarashi; Hideyoshi Harashima; Masahiko Sugita
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 441, 1, 108, 113, 2013年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Investigation of siRNA Nanoparticle Formation Using Mono-Cationic Detergents and Its Use in Gene Silencing in Human HeLa Cells.
    Yamada Y; Suzuki R; Harashima H
    Cancers, 5, 4, 1413, 1425, 2013年11月, [査読有り]
  • Production of small nano-sized particles by complex formation between polycations and linearized plasmid DNA at a low pH
    Ryohei Togashi; Hidetaka Akita; Hideyoshi Harashima
    JOURNAL OF BIOSCIENCE AND BIOENGINEERING, 116, 4, 528, 531, 2013年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication
    Md. Nazir Hossen; Kazuaki Kajimoto; Hidetaka Akita; Mamoru Hyodo; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 171, 2, 104, 112, 2013年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier
    Yuma Yamada; Hideyoshi Harashima
    Mitochondrion, 13, 5, 526, 532, 2013年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • An Approach to Transgene Expression in Liver Endothelial Cells Using a Liposome-Based Gene Vector Coated with Hyaluronic Acid
    Yuma Yamada; Masahiro Hashida; Yasuhiro Hayashi; Mai Tabata; Mamoru Hyodo; Mst Naznin Ara; Noritaka Ohga; Kyoko Hida; Hideyoshi Harashima
    JOURNAL OF PHARMACEUTICAL SCIENCES, 102, 9, 3119, 3127, 2013年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Lipid Envelope-Type Nanoparticle Incorporating a Multifunctional Peptide for Systemic siRNA Delivery to the Pulmonary Endothelium
    Kenji Kusumoto; Hidetaka Akita; Taichi Ishitsuka; Yu Matsumoto; Takahiro Nomoto; Ryo Furukawa; Ayman El-Sayed; Hiroto Hatakeyama; Kazuaki Kajimoto; Yuma Yamada; Kazunori Kataoka; Hideyoshi Harashima
    ACS NANO, 7, 9, 7534, 7541, 2013年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A Neutral envelope-type nanoparticle containing pH-responsive and ss-cleavable lipid-like material as a carrier for plasmid DNA
    Hidetaka Akita; Ryohei Ishiba; Hiroto Hatakeyama; Hiroki Tanaka; Yusuke Sato; Kota Tange; Masaya Arai; Kazuhiro Kubo; Hideyoshi Harashima
    Advanced Healthcare Materials, 2, 8, 1120, 1125, 2013年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
    Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
    Biomaterials, 34, 22, 5617, 5627, 2013年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Endocytosis of Gene Delivery Vectors: From Clathrin-dependent to Lipid Raft-mediated Endocytosis
    Ayman El-Sayed; Hideyoshi Harashima
    MOLECULAR THERAPY, 21, 6, 1118, 1130, 2013年06月, [査読有り]
    英語
  • The polyethyleneglycol dilemma: Advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors
    Hiroto Hatakeyama; Hidetaka Akita; Hideyoshi Harashima
    Biological and Pharmaceutical Bulletin, 36, 6, 892, 899, 2013年06月, [査読有り]
    英語
  • Correlation between transgen expression and plasmid DNA loss in mouse liver
    Ryohei Togashi; Hideyoshi Harashima; Hiroyuki Kamiya
    Journal of Gene Medicine, 15, 6-7, 242, 248, 2013年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Antiangiogenic nanotherapy for the control of obesity
    Kazuaki Kajimoto; Md. Nazir Hossen; Hideyoshi Harashima
    NANOMEDICINE, 8, 5, 671, 673, 2013年05月, [査読有り]
    英語
  • Therapeutic Assessment of Cytochrome C for the Prevention of Obesity Through Endothelial Cell-targeted Nanoparticulate System
    Md. Nazir Hossen; Kazuaki Kajimoto; Hidetaka Akita; Mamoru Hyodo; Taichi Ishitsuka; Hideyoshi Harashima
    MOLECULAR THERAPY, 21, 3, 533, 541, 2013年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Mitochondrial delivery of bongkrekic acid using a MITO-porter prevents the induction of apoptosis in human hela cells
    Yuma Yamada; Kohei Nakamura; Ryo Furukawa; Eriko Kawamura; Takuya Moriwaki; Kenji Matsumoto; Katsuhiro Okuda; Mitsuru Shindo; Hideyoshi Harashima
    JOURNAL OF PHARMACEUTICAL SCIENCES, 102, 3, 1008, 1015, 2013年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Enhanced transgene expression from chromatinized plasmid DNA in mouse liver
    Hiroyuki Kamiya; Shiho Miyamoto; Hitomi Goto; Genki N. Kanda; Miwako Kobayashi; Ichiro Matsuoka; Hideyoshi Harashima
    International Journal of Pharmaceutics, 441, 1-2, 146, 150, 2013年01月30日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Major T Cell Response to a Mycolyl Glycolipid Is Mediated by CD1c Molecules in Rhesus Macaques
    Daisuke Morita; Yuki Hattori; Takashi Nakamura; Tatsuhiko Igarashi; Hideyoshi Harashima; Masahiko Sugita
    INFECTION AND IMMUNITY, 81, 1, 311, 316, 2013年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • The transfection activity of R8-modified nanoparticles and siRNA condensation using pH sensitive stearylated-octahistidine
    Naoyuki Toriyabe; Yasuhiro Hayashi; Hideyoshi Harashima
    Biomaterials, 34, 4, 1337, 1343, 2013年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Incorporation of polyinosine-polycytidylic acid enhances cytotoxic T cell activity and antitumor effects by octaarginine-modified liposomes encapsulating antigen, but not by octaarginine-modified antigen complex
    Takashi Nakamura; Rumiko Moriguchi; Kentaro Kogure; Hideyoshi Harashima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 441, 1-2, 476, 481, 2013年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Particle tracking analysis for the intracellular trafficking of nanoparticles modified with african swine fever virus protein p54-derived peptide
    Hidetaka Akita; Kaoru Enoto; Hiroki Tanaka; Hideyoshi Harashima
    Molecular Therapy, 21, 2, 309, 317, Nature Publishing Group, 2013年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system
    Yu Sakurai; Hiroto Hatakeyama; Yusuke Sato; Mamoru Hyodo; Hidetaka Akita; Hideyoshi Harashima
    Molecular Therapy, 21, 6, 1195, 1203, Nature Publishing Group, 2013年, [査読有り]
    英語, 研究論文(学術雑誌)
  • The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration.
    Nakamura T; Yamazaki D; Yamauchi J; Harashima H
    Journal of controlled release : official journal of the Controlled Release Society, 171, 2, 216, 224, Elsevier B.V., 2013年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage.
    Kuraya D; Watanabe M; Koshizuka Y; Ogura M; Yoshida T; Asahi Y; Kamachi H; Nakamura T; Harashima H; Ozaki M; Umezawa K; Matsushita M; Yamashita K; Todo S
    Transplantation, 96, 5, 445, 453, 2013年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Localization of exogenous DNA to mitochondria in skeletal muscle following hydrodynamic limb vein injection
    Yukari Yasuzaki; Yuma Yamada; Tsutomu Kanefuji; Hideyoshi Harashima
    Journal of Controlled Release, 172, 3, 805, 811, 2013年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Development of an Efficient Short Interference RNA (siRNA) Delivery System with a New pH-Sensitive Cationic Lipid
    Yusuke Sato; Hiroto Hatakeyama; Mamoru Hyodo; Hidetaka Akita; Hideyoshi Harashima
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 132, 12, 1355, 1363, 2012年12月, [査読有り]
    日本語
  • MITO-Porter; A Cutting-edge Technology for Mitochondrial Gene Therapy
    Ryo Furukawa; Yuma Yamada; Hideyoshi Harashima
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 132, 12, 1389, 1398, 2012年12月, [査読有り]
    日本語
  • Development of a Novel DNA Aptamer Ligand Targeting to Primary Cultured Tumor Endothelial Cells by a Cell-Based SELEX Method
    Mst. Naznin Ara; Mamoru Hyodo; Noritaka Ohga; Kyoko Hida; Hideyoshi Harashima
    PLOS ONE, 7, 12, e50174, 2012年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Neuronal injury induces microglial production of macrophage inflammatory protein-1α in rat corticostriatal slice cultures.
    Okamura T; Katayama T; Obinata C; Iso Y; Chiba Y; Kobayashi H; Yamada Y; Harashima H; Minami M
    Journal of neuroscience research, 90, 11, 2127, 2133, 2012年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo
    Yusuke Sato; Hiroto Hatakeyama; Yu Sakurai; Mamoru Hyodo; Hidetaka Akita; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 163, 3, 267, 276, 2012年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • RNA Interference-Based Silencing Reveals the Regulatory Role of Fatty Acid-Binding Protein 4 in the Production of IL-6 and Vascular Endothelial Growth Factor in 3T3-L1 Adipocytes
    Kazuaki Kajimoto; Shiharu Takayanagi; Shun Sasaki; Hidetaka Akita; Hideyoshi Harashima
    ENDOCRINOLOGY, 153, 11, 5629, 5636, 2012年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Vascular-targeted nanotherapy for obesity: Unexpected passive targeting mechanism to obese fat for the enhancement of active drug delivery
    Md Nazir Hossen; Kazuaki Kajimoto; Hidetaka Akita; Mamoru Hyodo; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 163, 2, 101, 110, 2012年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Targeting Mitochondria: Innovation from Mitochondrial Drug Delivery System (DDS) to Mitochondrial Medicine
    Yuma Yamada; Hideyoshi Harashima
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 132, 10, 1111, 1118, 2012年10月, [査読有り]
    日本語
  • Effects of Endogenous Proteins and microRNA Target Sequence in a Positive Feedback System
    Genki N. Kanda; Ryohei Togashi; Hideyoshi Harashima; Hiroyuki Kamiya
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 35, 9, 1534, 1538, 2012年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A designed curved DNA sequence remarkably enhances transgene expression from plasmid DNA in mouse liver
    S. Fukunaga; G. Kanda; J. Tanase; H. Harashima; T. Ohyama; H. Kamiya
    Gene Therapy, 19, 8, 828, 835, Nature Publishing, 2012年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Non-linear pharmacokinetics of octaarginine-modified lipid nanoparticles: Barriers from in vitro to in vivo
    Yasuhiro Hayashi; Yuki Noguchi; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 161, 3, 757, 762, 2012年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Intracellular stability of 2′-OMe-4′-thioribonucleoside modified siRNA leads to long-term RNAi effect
    Mayumi Takahashi; Chisato Nagai; Hiroto Hatakeyama; Noriaki Minakawa; Hideyoshi Harashima; Akira Matsuda
    Nucleic Acids Research, 40, 12, 5787, 5793, 2012年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Efficient Intracellular Delivery of Nucleic Acid Pharmaceuticals Using Cell-Penetrating Peptides
    Ikuhiko Nakase; Hidetaka Akita; Kentaro Kogure; Astrid Graslund; Ulo Langel; Hideyoshi Harashima; Shiroh Futaki
    ACCOUNTS OF CHEMICAL RESEARCH, 45, 7, 1132, 1139, 2012年07月, [査読有り]
    英語
  • クロマチン化プラスミドDNAによる発現上昇
    紙谷 浩之; 宮本 紫甫; 後藤 仁美; 神田 元紀; 小林 三和子; 松岡 一郎; 原島 秀吉
    日本DDS学会学術集会プログラム予稿集, 28回, 163, 163, 日本DDS学会, 2012年06月
    日本語
  • Fabrication of Functionalized Double-Lamellar Multifunctional Envelope-Type Nanodevices Using a Microfluidic Chip with a Chaotic Mixer Array
    Katsuma Kitazoe; Yeon-Su Park; Noritada Kaji; Yukihiro Okamoto; Manabu Tokeshi; Kentaro Kogure; Hideyoshi Harashima; Yoshinobu Baba
    PLOS ONE, 7, 6, e39057, 2012年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Post-nuclear gene delivery events for transgene expression by biocleavable polyrotaxanes
    Yuma Yamada; Taku Nomura; Hideyoshi Harashima; Atsushi Yamashita; Nobuhiko Yui
    Biomaterials, 33, 15, 3952, 3958, 2012年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Post-nuclear gene delivery events for transgene expression by biocleavable polyrotaxanes
    Yuma Yamada; Taku Nomura; Hideyoshi Harashima; Atsushi Yamashita; Nobuhiko Yui
    BIOMATERIALS, 33, 15, 3952, 3958, 2012年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • FRET from Quantum Dots to Photodecompose Undesired Acceptors and Report the Condensation and Decondensation of Plasmid DNA
    Vasudevanpillai Biju; Abdulaziz Anas; Hidetaka Akita; Edakkattuparambil Sidharthan Shibu; Tamitake Itoh; Hideyoshi Harashima; Mitsuru Ishikawa
    ACS NANO, 6, 5, 3776, 3788, 2012年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Efficient Intradermal Delivery of Superoxide Dismutase Using a Combination of Liposomes and Iontophoresis for Protection against UV-Induced Skin Damage
    Kaoru Kigasawa; Moeko Miyashita; Kazuaki Kajimoto; Kiyoshi Kanamura; Hideyoshi Harashima; Kentaro Kogure
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 35, 5, 781, 785, 2012年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Different mechanisms for nanoparticle formation between pDNA and siRNA using polyrotaxane as the polycation
    Yuma Yamada; Masahiro Hashida; Taku Nomura; Hideyoshi Harashima; Yuichi Yamasaki; Kazunori Kataoka; Atsushi Yamashita; Ryo Katoono; Nobuhiko Yui
    ChemPhysChem, 13, 5, 1161, 1165, 2012年04月10日, [査読有り]
    英語, 研究論文(学術雑誌)
  • 1H, 13C and 15N NMR assignments of the Escherichia coli Orf135 protein
    Kumiko Kawasaki; Momoko Yoneyama; Naoko Murata-Kamiya; Hideyoshi Harashima; Chojiro Kojima; Yutaka Ito; Hiroyuki Kamiya; Masaki Mishima
    Biomol NMR Assign, 6, 1, 1-4, 2012年04月, [査読有り]
    英語, 大腸菌Orf135蛋白質のNMR信号帰属
  • Different Mechanisms for Nanoparticle Formation between pDNA and siRNA Using Polyrotaxane as the Polycation
    Yuma Yamada; Masahiro Hashida; Taku Nomura; Hideyoshi Harashima; Yuichi Yamasaki; Kazunori Kataoka; Atsushi Yamashita; Ryo Katoono; Nobuhiko Yui
    CHEMPHYSCHEM, 13, 5, 1161, 1165, 2012年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Effect of the Anchor in Polyethylene Glycol-Lipids on the Transfection Activity of PEGylated Cationic Liposomes Encapsulating DNA
    Kenji Kusumoto; Hidetaka Akita; Ayman El-Sayed; Hideyoshi Harashima
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 35, 4, 445, 448, 2012年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Stearylated INF7 peptide enhances endosomal escape and gene expression of PEGylated nanoparticles both in vitro and in vivo
    Ayman El-Sayed; Tomoya Masuda; Hidetaka Akita; Hideyoshi Harashima
    JOURNAL OF PHARMACEUTICAL SCIENCES, 101, 2, 879, 882, 2012年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter
    Yuma Yamada; Hideyoshi Harashima
    BIOMATERIALS, 33, 5, 1589, 1595, 2012年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • High throughput purification device for gene delivery multifunctional envelope-type nanodevice
    Daisuke Shigenaka; Masami Ukawa; Noritada Kaji; Yukihiro Okamoto; Manabu Tokeshi; Hidetaka Akita; Hideyoshi Harashima; Yoshinobu Baba
    Proceedings of the 16th International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2012, 1546, 1548, 2012年, [査読有り]
    研究論文(国際会議プロシーディングス)
  • The manner in which DNA is packaged with TFAM has an impact on transcription activation and inhibition
    Ryo Furukawa; Yuma Yamada; Yuichi Matsushima; Yu-ichi Goto; Hideyoshi Harashima
    FEBS OPEN BIO, 2, 145, 150, 2012年, [査読有り]
    英語, 研究論文(学術雑誌)
  • CREB-binding protein transcription activation domain for enhanced transgene expression by a positive feedback system
    Genki Kanda; Hiroshi Ochiai; Hideyoshi Harashima; Hiroyuki Kamiya
    JOURNAL OF BIOTECHNOLOGY, 157, 1, 7, 11, 2012年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • MULTIFUNCTIONAL ENVELOPE-TYPE NANO DEVICE (MEND) FOR ORGANELLE TARGETING VIA A STEPWISE MEMBRANE FUSION PROCESS
    Yuma Yamada; Hidetaka Akita; Hideyoshi Harashima
    NANOMEDICINE: INFECTIOUS DISEASES, IMMUNOTHERAPY, DIAGNOSTICS, ANTIFIBROTICS, TOXICOLOGY AND GENE MEDICINE, 509, 301, 326, 2012年, [査読有り]
    英語, 論文集(書籍)内論文
  • Octaarginine- and pH sensitive fusogenic peptide-modified nanoparticles for liver gene delivery
    Ikramy A. Khalil; Yasuhiro Hayashi; Ryoichi Mizuno; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 156, 3, 374, 380, 2011年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guéin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands.
    Miyazaki J; Kawai K; Kojima T; Oikawa T; Joraku A; Shimazui T; Nakaya A; Yano I; Nakamura T; Harashima H; Akaza H
    BJU international, 108, 9, 1520, 1526, 2011年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Diverse substrate recognition and hydrolysis mechanisms of human NUDT5
    Takao Arimori; Haruhiko Tamaoki; Teruya Nakamura; Hiroyuki Kamiya; Shinji Ikemizu; Yasumitsu Takagi; Toru Ishibashi; Hideyoshi Harashima; Mutsuo Sekiguchi; Yuriko Yamagata
    NUCLEIC ACIDS RESEARCH, 39, 20, 8972, 8983, 2011年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Effects of insulator cHS4 on transgene expression from plasmid DNA in a positive feedback system
    Hiroshi Ochiai; Hideyoshi Harashima; Hiroyuki Kamiya
    JOURNAL OF BIOSCIENCE AND BIOENGINEERING, 112, 5, 432, 434, 2011年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Delivery of nucleic acids and gene delivery
    H. Akita; H. Hatakeyama; I. A. Khalil; Y. Yamada; H. Harashima
    Comprehensive Biomaterials, 4, 411, 444, Elsevier, 2011年10月
    英語, 論文集(書籍)内論文
  • Synthesis, Structure, and Biological Activity of Dumbbell-Shaped Nanocircular RNAs for RNA Interference
    Naoko Abe; Hiroshi Abe; Chisato Nagai; Mitsuru Harada; Hiroto Hatakeyama; Hideyoshi Harashima; Takahito Ohshiro; Mizuki Nishihara; Kazuhiro Furukawa; Mizuo Maeda; Satoshi Tsuneda; Yoshihiro Ito
    BIOCONJUGATE CHEMISTRY, 22, 10, 2082, 2092, 2011年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Mutagenicity of secondary oxidation products of 8-oxo-7,8-dihydro-2 '-deoxyguanosine 5 '-triphosphate (8-hydroxy-2 '- deoxyguanosine 5 '-triphosphate)
    Mika Hori; Tetsuya Suzuki; Noriaki Minakawa; Akira Matsuda; Hideyoshi Harashima; Hiroyuki Kamiya
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 714, 1-2, 11, 16, 2011年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Correction of Frameshift Mutations with Tailed Duplex DNAs
    Yukiko Morita; Hiroyuki Tsuchiya; Hideyoshi Harashima; Hiroyuki Kamiya
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 34, 9, 1465, 1468, 2011年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • KALA-modified multi-layered nanoparticles as gene carriers for MHC class-I mediated antigen presentation for a DNA vaccine
    Sharif M. Shaheen; Hidetaka Akita; Takashi Nakamura; Shota Takayama; Shiroh Futaki; Atsushi Yamashita; Ryo Katoono; Nobuhiko Yui; Hideyoshi Harashima
    Biomaterials, 32, 26, 6342, 6350, 2011年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • KALA-modified multi-layered nanoparticles as gene carriers for MHC class-I mediated antigen presentation for a DNA vaccine
    Sharif M. Shaheen; Hidetaka Akita; Takashi Nakamura; Shota Takayama; Shiroh Futaki; Atsushi Yamashita; Ryo Katoono; Nobuhiko Yui; Hideyoshi Harashima
    BIOMATERIALS, 32, 26, 6342, 6350, 2011年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A20 Silencing by Lipid Envelope-Type Nanoparticles Enhances the Efficiency of Lipopolysaccharide-Activated Dendritic Cells
    Shota Warashina; Takashi Nakamura; Hideyoshi Harashima
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 34, 8, 1348, 1351, 2011年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA
    Yu Sakurai; Hiroto Hatakeyama; Yusuke Sato; Hidetaka Akita; Kentaro Takayama; Sachiko Kobayashi; Shiroh Futaki; Hideyoshi Harashima
    BIOMATERIALS, 32, 24, 5733, 5742, 2011年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Synthesis and Evaluation of Stearylated Hyaluronic Acid for the Active Delivery of Liposomes to Liver Endothelial Cells
    Naoyuki Toriyabe; Yasuhiro Hayashi; Mamoru Hyodo; Hideyoshi Harashima
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 34, 7, 1084, 1089, 2011年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Improving in Vivo Hepatic Transfection Activity by Controlling Intracellular Trafficking: The Function of GALA and Maltotriose
    Hidetaka Akita; Tomoya Masuda; Takashi Nishio; Kenichi Niikura; Kuniharu Ijiro; Hideyoshi Harashima
    MOLECULAR PHARMACEUTICS, 8, 4, 1436, 1442, 2011年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • The Therapeutic Effects of R8-Liposome-BCG-CWS on BBN-Induced Rat Urinary Bladder Carcinoma
    Jun Miyazaki; Hiroyuki Nishiyama; Ikuya Yano; Akihiro Nakaya; Hideyasu Kohama; Koji Kawai; Akira Joraku; Takashi Nakamura; Hideyoshi Harashima; Hideyuki Akaza
    ANTICANCER RESEARCH, 31, 6, 2065, 2071, 2011年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid
    Hiroto Hatakeyama; Hidetaka Akita; Erika Ito; Yasuhiro Hayashi; Motoi Oishi; Yukio Nagasaki; Radostin Danev; Kuniaki Nagayama; Noritada Kaji; Hiroshi Kikuchi; Yoshinobu Baba; Hideyoshi Harashima
    BIOMATERIALS, 32, 18, 4306, 4316, 2011年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Glycerol monomycolate, a latent tuberculosis-associated mycobacterial lipid, induces eosinophilic hypersensitivity responses in guinea pigs
    Yuki Hattori; Isamu Matsunaga; Takaya Komori; Tetsuo Urakawa; Takashi Nakamura; Nagatoshi Fujiwara; Kenji Hiromatsu; Hideyoshi Harashima; Masahiko Sugita
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 409, 2, 304, 307, 2011年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A Microbial Glycolipid Functions as a New Class of Target Antigen for Delayed-type Hypersensitivity
    Takaya Komori; Takashi Nakamura; Isamu Matsunaga; Daisuke Morita; Yuki Hattori; Hirotaka Kuwata; Nagatoshi Fujiwara; Kenji Hiromatsu; Hideyoshi Harashima; Masahiko Sugita
    JOURNAL OF BIOLOGICAL CHEMISTRY, 286, 19, 16800, 16806, 2011年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Quantitative analysis of condensation/decondensation status of pDNA in the nuclear sub-domains by QD-FRET
    Sharif M. Shaheen; Hidetaka Akita; Atsushi Yamashita; Ryo Katoono; Nobuhiko Yui; Vasudevanpillai Biju; Mitsuru Ishikawa; Hideyoshi Harashima
    Nucleic Acids Research, 39, 7, e48, e48, 2011年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Quantitative analysis of condensation/decondensation status of pDNA in the nuclear sub-domains by QD-FRET
    Sharif M. Shaheen; Hidetaka Akita; Atsushi Yamashita; Ryo Katoono; Nobuhiko Yui; Vasudevanpillai Biju; Mitsuru Ishikawa; Hideyoshi Harashima
    NUCLEIC ACIDS RESEARCH, 39, 7, E48, U108, 2011年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Topology of octaarginines (R8) or IRQ ligand on liposomes affects the contribution of macropinocytosis- and caveolae-mediated cellular uptake
    Diky Mudhakir; Hidetaka Akita; Hideyoshi Harashima
    REACTIVE & FUNCTIONAL POLYMERS, 71, 3, 340, 343, 2011年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: A strategy for overcoming the PEG dilemma
    Hiroto Hatakeyama; Hidetaka Akita; Hideyoshi Harashima
    ADVANCED DRUG DELIVERY REVIEWS, 63, 3, 152, 160, 2011年03月, [査読有り]
    英語
  • Noninvasive and efficient transdermal delivery of CpG-oligodeoxynucleotide for cancer immunotherapy
    Kaoru Kigasawa; Kazuaki Kajimoto; Takashi Nakamura; Susumu Hama; Kiyoshi Kanamura; Hideyoshi Harashima; Kentaro Kogure
    JOURNAL OF CONTROLLED RELEASE, 150, 3, 256, 265, 2011年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Modulation of Endosomal Escape of IRQ-PEGylated Nano-carrier
    Diky Mudhakir; Hidetaka Akita; Hideyoshi Harashima
    4TH NANOSCIENCE AND NANOTECHNOLOGY SYMPOSIUM (NNS2011): AN INTERNATIONAL SYMPOSIUM, 1415, 2011年, [査読有り]
    英語, 研究論文(国際会議プロシーディングス)
  • Design of Smart Nano Device for Intracellular Targeting
    Diky Mudhakir; Erdal Tan; Hidetaka Akita; Hideyoshi Harashima
    4TH NANOSCIENCE AND NANOTECHNOLOGY SYMPOSIUM (NNS2011): AN INTERNATIONAL SYMPOSIUM, 1415, 2011年, [査読有り]
    英語, 研究論文(国際会議プロシーディングス)
  • Octaarginine-modified liposomes enhance the anti-oxidant effect of Lecithinized superoxide dismutase by increasing its cellular uptake
    Ryo Furukawa; Yuma Yamada; Mitsuko Takenaga; Rie Igarashi; Hideyoshi Harashima
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 404, 3, 796, 801, 2011年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Noninvasive and persistent transfollicular drug delivery system using a combination of liposomes and iontophoresis
    Kazuaki Kajimoto; Masahiko Yamamoto; Misuzu Watanabe; Kaoru Kigasawa; Kiyoshi Kanamura; Hideyoshi Harashima; Kentaro Kogure
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 403, 1-2, 57, 65, 2011年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A touch-and-go lipid wrapping technique in microfluidic channels for rapid fabrication of multifunctional envelope-type gene delivery nanodevices
    Katsuma Kitazoe; Jun Wang; Noritada Kaji; Yukihiro Okamoto; Manabu Tokeshi; Kentaro Kogure; Hideyoshi Harashima; Yoshinobu Baba
    LAB ON A CHIP, 11, 19, 3256, 3262, 2011年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Reprint of: Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation
    Hidetaka Akita; Kentaro Kogure; Rumiko Moriguchi; Yoshio Nakamura; Tomoko Higashi; Takashi Nakamura; Satoshi Serada; Minoru Fujimoto; Tetsuji Naka; Shiroh Futaki; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 149, 1, 58, 64, 2011年01月, [査読有り]
    英語
  • Special Issue: Recent Advancements of DDS research in japan
    Hideyoshi Harashima; Akihiko Kikuchi; Kazunori Kataoka
    JOURNAL OF CONTROLLED RELEASE, 149, 1, 1, 1, 2011年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • (Review) Application of a fusiogenic peptide GALA for intracellular delivery
    Ikuhiko Nakase; Kentaro Kogure; Hideyoshi Harashima; Shiroh Futaki
    Methods in Molecular Biology, 683, 525, 533, 2011年, [査読有り]
  • 内在性転写活性化因子を用いた細胞系における外来遺伝子発現の活性化
    神田 元紀; 落合 浩史; 原島 秀吉; 紙谷 浩之
    日本生化学会大会・日本分子生物学会年会合同大会講演要旨集, 83回・33回, 1P, 1247, (公社)日本生化学会, 2010年12月
    日本語
  • 2種類の「発現持続型」プラスミドの核内挙動の違い
    冨樫 亮平; 神田 元紀; 紙谷 浩之; 原島 秀吉
    日本生化学会大会・日本分子生物学会年会合同大会講演要旨集, 83回・33回, 1P, 1248, (公社)日本生化学会, 2010年12月
    日本語
  • Reporter gene expression at single-cell level characterized with real-time RT-PCR, chemiluminescence, fluorescence, and electrochemical imaging
    Hitoshi Shiku; Daisuke Okazaki; Junya Suzuki; Yasufumi Takahashi; Tatsuya Murata; Hidetaka Akita; Hideyoshi Harashima; Kosuke Ino; Tomokazu Matsue
    FEBS LETTERS, 584, 18, 4000, 4008, 2010年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • 2-Methacryloyloxyethyl phosphorylcholine polymer (MPC)-coating improves the transfection activity of GALA-modified lipid nanoparticles by assisting the cellular uptake and intracellular dissociation of plasmid DNA in primary hepatocytes
    Masami Ukawa; Hidetaka Akita; Tomoya Masuda; Yasuhiro Hayashi; Tomohiro Konno; Kazuhiko Ishihara; Hideyoshi Harashima
    BIOMATERIALS, 31, 24, 6355, 6362, 2010年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Intranuclear DNA Release Is a Determinant of Transfection Activity for a Non-viral Vector: Biocleavable Polyrotaxane as a Supramolecularly Dissociative Condenser for Efficient Intranuclear DNA Release
    Yuma Yamada; Taku Nomura; Hideyoshi Harashima; Atsushi Yamashita; Ryo Katoono; Nobuhiko Yui
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 33, 7, 1218, 1222, 2010年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Ornithine and Tryptophan Analogs as Efficient Polycations for Short Interference RNA Delivery to Tumor Cells
    Yusuke Sato; Hiroto Hatakeyama; Hideyoshi Harashima
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 33, 7, 1246, 1249, 2010年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Positive Feedback System Provides Efficient and Persistent Transgene Expression
    Hiroshi Ochiai; Hideyoshi Harashima; Hiroyuki Kamiya
    MOLECULAR PHARMACEUTICS, 7, 4, 1125, 1132, 2010年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes
    Yukari Yasuzaki; Yuma Yamada; Hideyoshi Harashima
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 397, 2, 181, 186, 2010年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Particle Tracking of Intracellular Trafficking of Octaarginine-modified Liposomes: A Comparative Study With Adenovirus
    Hidetaka Akita; Kaoru Enoto; Tomoya Masuda; Hiroyuki Mizuguchi; Tomomi Tani; Hideyoshi Harashima
    MOLECULAR THERAPY, 18, 5, 955, 964, 2010年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Effects of base excision repair proteins on mutagenesis by 8-oxo-7,8-dihydroguanine (8-hydroxyguanine) paired with cytosine and adenine
    Tetsuya Suzuki; Hideyoshi Harashima; Hiroyuki Kamiya
    DNA REPAIR, 9, 5, 542, 550, 2010年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation
    Hidetaka Akita; Kentaro Kogure; Rumiko Moriguchi; Yoshio Nakamura; Tomoko Higashi; Takashi Nakamura; Satoshi Serada; Minoru Fujimoto; Tetsuji Naka; Shiroh Futaki; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 143, 3, 311, 317, 2010年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Roles of specialized DNA polymerases in mutagenesis by 8-hydroxyguanine in human cells
    Hiroyuki Kamiya; Ayaka Yamaguchi; Tetsuya Suzuki; Hideyoshi Harashima
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 686, 1-2, 90, 95, 2010年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Leptin-derived peptide, a targeting ligand for mouse brain-derived endothelial cells via macropinocytosis
    Mina Tamaru; Hidetaka Akita; Takahiro Fujiwara; Kazuaki Kajimoto; Hideyoshi Harashima
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 394, 3, 587, 592, 2010年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Targeted sequence alteration of a chromosomal locus in mouse liver
    Hiroyuki Kamiya; Masayuki Uchiyama; Jingshu Piao; Yoshimichi Nakatsu; Teruhisa Tsuzuki; Hideyoshi Harashima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 387, 1-2, 180, 183, 2010年03月
    英語, 研究論文(学術雑誌)
  • An Improvement Delivery of siRNA by IRQ Ligand-Modified Double Membranous Nano-Carrier
    Diky Mudhakir; Erdal Tan; Hidetaka Akita; Hideyoshi Harashima
    THIRD NANOSCIENCE AND NANOTECHNOLOGY SYMPOSIUM 2010 - NNSB2010, 1284, 199, +, 2010年, [査読有り]
    英語, 研究論文(国際会議プロシーディングス)
  • A Novel Nonviral Gene Delivery System: Multifunctional Envelope-Type Nano Device
    Hiroto Hatakeyama; Hidetaka Akita; Kentaro Kogure; Hideyoshi Harashima
    NANO/MICRO BIOTECHNOLOGY, 119, 197, +, 2010年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Intranuclear DNA release is a determinant of transfection activity for a non-viral vector: Biocleavable polyrotaxane as a supramolecularly dissociative condenser for efficient intranuclear DNA release
    Yuma Yamada; Taku Nomura; Hideyoshi Harashima; Atsushi Yamashita; Ryo Katoono; Nobuhiko Yui
    Biological and Pharmaceutical Bulletin, 33, 7, 1218, 1222, 2010年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Roles of specialized DNA polymerases in mutagenesis by oxidized guanine.
    Hiroyuki Kamiya; Kazuya Satou; Mika Hori; Ayaka Yamaguchi; Hideyoshi Harashima
    Nucleic acids symposium series (2004), 53, 223, 224, 2009年12月01日
  • NUDT5 hydrolyzes oxidized deoxyribonucleoside diphosphates with broad substrate specificity
    Hiroyuki Kamiya; Mika Hori; Takao Arimori; Mutsuo Sekiguchi; Yuriko Yamagata; Hideyoshi Harashima
    DNA REPAIR, 8, 10, 1250, 1254, 2009年10月
    英語, 研究論文(学術雑誌)
  • A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo
    Hiroto Hatakeyama; Erika Ito; Hidetaka Akita; Motoi Oishi; Yukio Nagasaki; Shiroh Futaki; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 139, 2, 127, 132, 2009年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Effects of non-B DNA sequences on transgene expression
    Hiroyuki Kamiya; Hitomi Goto; Hideyoshi Harashima
    JOURNAL OF BIOSCIENCE AND BIOENGINEERING, 108, 1, 18, 21, 2009年07月
    英語, 研究論文(学術雑誌)
  • Effects of carriers on transgene expression from plasmids containing a DNA sequence with high histone affinity
    Hiroyuki Kamiya; Satoki Fukunaga; Takashi Ohyama; Hideyoshi Harashima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 376, 1-2, 99, 103, 2009年07月
    英語, 研究論文(学術雑誌)
  • Effect of Polyethyleneglycol Spacer on the Binding Properties of Nuclear Localization Signal-Modified Liposomes to Isolated Nucleus
    Dai Kurihara; Hidetaka Akita; Asako Kudo; Tomoya Masuda; Shiroh Futaki; Hideyoshi Harashima
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 32, 7, 1303, 1306, 2009年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Involvement of specialized DNA polymerases in mutagenesis by 8-hydroxy-dGTP in human cells
    Kazuya Satou; Mika Hori; Kazuaki Kawai; Hiroshi Kasai; Hideyoshi Harashima; Hiroyuki Kamiya
    DNA REPAIR, 8, 5, 637, 642, 2009年05月
    英語, 研究論文(学術雑誌)
  • A Novel Technique To Investigate the Decondensation of pc-DNA3.1-luc in Nuclear Sub-Domain with QD-FRET
    Sharif M. Shaheen; Hidetaka Akita; Atsushi Yamashita; Ryo Katoono; Nobuhiko Yui; Vasudevanpillai Biju; Mitsuru Ishikawa; Hideyoshi Harashima
    MOLECULAR THERAPY, 17, S330, S330, 2009年05月, [査読有り]
    英語
  • Multi-layered nanoparticles for penetrating the endosome and nuclear membrane via a step-wise membrane fusion process
    Hidetaka Akita; Asako Kudo; Arisa Minoura; Masaya Yamaguti; Ikrarny A. Khalil; Rumiko Moriguchi; Tomoya Masuda; Radostin Danev; Kuniaki Nagayama; Kentaro Kogure; Hideyoshi Harashima
    BIOMATERIALS, 30, 15, 2940, 2949, 2009年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Development of Efficient siRNA Delivery System to Tumor Cells by Combining Octaarginine, GALA and Enzymatically-Cleavable PEG-Lipid
    Yu Sakurai; Hiroto Hatakeyama; Hidetaka Akita; Motoi Oishi; Yukio Nagasaki; Shiro Futaki; Hideyoshi Harashima
    MOLECULAR THERAPY, 17, Suppl. 1, S388, S389, 2009年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A pH-Sensitive Fusogenic Peptide Facilitates Endosomal Escape and Greatly Enhanced the Gene Silencing of siRNA-Containing Nanoparticles In Vitro and In Vivo
    Hiroto Hatakeyama; Erika Itho; Hidetaka Akita; Motoi Oihi; Yukio Nagasaki; Shiroh Futaki; Hideyoshi Harashima
    MOLECULAR THERAPY, 17, S388, S388, 2009年05月, [査読有り]
    英語
  • Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin.
    Joraku A; Homhuan A; Kawai K; Yamamoto T; Miyazaki J; Kogure K; Yano I; Harashima H; Akaza H
    BJU international, 103, 5, 686, 693, 2009年03月, [査読有り]
  • Delivery of Macromolecules Using Arginine-Rich Cell-Penetrating Peptides: Ways to Overcome Endosomal Entrapment
    Ayman El-Sayed; Shiroh Futaki; Hideyoshi Harashima
    AAPS JOURNAL, 11, 1, 13, 22, 2009年03月, [査読有り]
    英語
  • Non-linear pharmacodynamics in the transfection efficiency of a non-viral gene delivery system
    Rumiko Moriguchi; Kentaro Kogure; Hideyoshi Harashima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 363, 1-2, 192, 198, 2008年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Oligosaccharide-Mediated Nuclear Transport of Nanoparticles
    Kenichi Niikura; Shota Sekiguchi; Takashi Nishio; Tomoya Masuda; Hidetaka Akita; Yasutaka Matsuo; Kentaro Kogure; Hideyoshi Harashima; Kuniharu Ijiro
    CHEMBIOCHEM, 9, 16, 2623, 2627, 2008年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Supramolecular control of polyplex dissociation and cell transfection: efficacy of amino groups and threading cyclodextrins in biocleavable polyrotaxanes.
    Atsushi Yamashita; Daizo Kanda; Ryo Katoono; Nobuhiko Yui; Tooru Ooya; Atsushi Maruyama; Hidetaka Akita; Kentaro Kogure; Hideyoshi Harashima
    J Control Release, 131, 2, 137, 144, 2008年10月, [査読有り]
    英語, 研究論文(学術雑誌), A novel strategy for gene delivery using biocleavable polyrotaxanes, in which dimethylaminoethyl-modified alpha-cyclodextrins (DMAE-alpha-CDs) are threaded onto a poly(ethylene glycol) (PEG) chain capped with benzyloxycarbonyl-L-tyrosine via disulfide linkages (DMAE-SS-PRX), involves the formation of a stable polyion complex (polyplex) against a counter polyanion and the intracellular plasmid DNA (pDNA) release from the polyplex accompanied by the supramolecular dissociation of DMAE-SS-PRXs. In this study, we prepared biocleavable polyrotaxanes with different numbers of threading alpha-CD and amino (DMAE) groups to enhance the transfection activity of DMAE-SS-PRXs. 29DMAE-alpha18-SS-PRX, in which the numbers of alpha-CD molecules and amino groups were 18 and 29 respectively, exhibited a high transfection activity compared with other PRXs. The transfection activity of DMAE-SS-PRXs seems to be related to the efficacy of pDNA release from those polyplexes, which was controlled by the number of alpha-CD and/or amino groups in the polyrotaxane carrier. Most of the DMAE-SS-PRX polyplexes released the pDNA only in the presence of both 10 mM DTT and of the counter-polyanion, as expected, e
  • Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases
    Yuma Yamada; Hideyoshi Harashima
    ADVANCED DRUG DELIVERY REVIEWS, 60, 13-14, 1439, 1462, 2008年10月, [査読有り]
    英語
  • Effects of target sequence and sense versus anti-sense strands on gene correction with single-stranded DNA fragments
    Hiroyuki Kamiya; Masayuki Uchiyama; Yoshimichi Nakatsu; Teruhisa Tsuzuki; Hideyoshi Harashima
    JOURNAL OF BIOCHEMISTRY, 144, 4, 431, 436, 2008年10月
    英語, 研究論文(学術雑誌)
  • Supramolecular control of polyplex dissociation and cell transfection: Efficacy of amino groups and threading cyclodextrins in biocleavable polyrotaxanes
    Atsushi Yamashita; Daizo Kanda; Ryo Katoono; Nobuhiko Yui; Tooru Ooya; Atsushi Maruyama; Hidetaka Akita; Kentaro Kogure; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 131, 2, 137, 144, 2008年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Efficient MHC class I presentation by controlled intracellular trafficking of antigens in octaarginine-modified liposomes
    Takashi Nakamura; Rumiko Moriguchi; Kentaro Kogure; Nilabh Shastri; Hideyoshi Harashima
    MOLECULAR THERAPY, 16, 8, 1507, 1514, 2008年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Advances in non-viral gene delivery: using multifunctional envelope-type nano-device
    Hidetaka Akita; Hideyoshi Harashima
    EXPERT OPINION ON DRUG DELIVERY, 5, 8, 847, 859, 2008年08月, [査読有り]
    英語
  • Photosensitized breakage and damage of DNA by CdSe-ZnS quantum dots
    AbdulAziz Anas; Hidetaka Akita; Hideyoshi Harashima; Tamitake Itoh; Mitsuru Ishikawa; Vasudevanpillai Biju
    JOURNAL OF PHYSICAL CHEMISTRY B, 112, 32, 10005, 10011, 2008年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Improved gene correction efficiency with a tailed duplex DNA fragment
    Hiroyuki Tsuchiya; Masayuki Uchiyarna; Kazuhiro Hara; Yoshimichi Nakatsu; Teruhisa Tsuzuki; Hideo Inoue; Hideyoshi Harashima; Hiroyuki Kamiya
    BIOCHEMISTRY, 47, 33, 8754, 8759, 2008年08月
    英語, 研究論文(学術雑誌)
  • On-chip fabrication of mutifunctional envelope-type nanodevices for gene delivery
    Hiroshi Kuramoto; Yeon-Su Park; Noritada Kaji; Manabu Tokeshi; Kentaro Kogure; Yasuo Shinohara; Hideyoshi Harashima; Yoshinobu Baba
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 391, 8, 2729, 2733, 2008年08月
    英語, 研究論文(学術雑誌)
  • An artificial virus-like nano carrier system: enhanced endosomal escape of nanoparticles via synergistic action of pH-sensitive fusogenic peptide derivatives
    Kentaro Sasaki; Kentaro Kogure; Shinji Chaki; Yoshio Nakamura; Rumiko Moriguchi; Hirofumi Hamada; Radostin Danev; Kuniaki Nagayama; Shiroh Futaki; Hideyoshi Harashima
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 391, 8, 2717, 2727, 2008年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Octaarginine- and octalysine-modified nanoparticles have different modes of endosomal escape
    Ayman El-Sayed; Ikramy A. Khalil; Kentaro Kogure; Shiroh Futaki; Hideyoshi Harashima
    JOURNAL OF BIOLOGICAL CHEMISTRY, 283, 34, 23450, 23461, 2008年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Cellular attachment and internalization of cationic liposomes containing mycobacterial cell wall
    Atthachai Homhuan; Hideyoshi Harashima; Ikuya Yano
    SCIENCEASIA, 34, 2, 179, 185, 2008年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Octaarginine-modified liposomes: Enhanced cellular uptake and controlled intracellular trafficking
    Krarny A. Khalil; Kentaro Kogure; Shiroh Futaki; Hideyoshi Harashima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 354, 1-2, 39, 48, 2008年04月, [査読有り]
    英語
  • Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system
    Kentaro Kogure; Hidetaka Akita; Yuma Yamada; Hideyoshi Harashima
    ADVANCED DRUG DELIVERY REVIEWS, 60, 4-5, 559, 571, 2008年03月, [査読有り]
    英語
  • Specificity of mutations induced by incorporation of oxidized dNTPs into DNA by human DNA polymerase eta.
    Katsuhiko Hidaka; Masami Yamada; Hiroyuki Kamiya; Chikahide Masutani; Hideyoshi Harashima; Fumio Hanaoka; Takehiko Nohmi
    DNA repair, 7, 3, 497, 506, 2008年03月01日, [査読有り], [国際誌]
    英語, Aberrant oxidation is a property of many tumor cells. Oxidation of DNA precursors, i.e., deoxynucleotide triphosphates (dNTPs), as well as DNA is a major cause of genome instability. Here, we report that human DNA polymerase eta (h Poleta) incorporates oxidized dNTPs, i.e., 2-hydroxy-2'-deoxyadenosine 5'-triphosphate (2-OH-dATP) and 8-hydroxy-2'-deoxyguanosine 5'-triphosphate (8-OH-dGTP), into DNA in an erroneous and efficient manner, thereby inducing various types of mutations during in vitro gap-filling DNA synthesis. When 2-OH-dATP was present at a concentration equal to those of the four normal dNTPs in the reaction mixture, DNA synthesis by h Poleta enhanced the frequency of G-to-T transversions eight-fold higher than that of the transversions in control where only the normal dNTPs were present. When 8-OH-dGTP was present at an equimolar concentration to the normal dNTPs, it enhanced the frequency of A-to-C transversions 17-fold higher than the control. It also increased the frequency of C-to-A transversions about two-fold. These results suggest that h Poleta incorporates 2-OH-dATP opposite template G and incorporates 8-OH-dGTP opposite template A and slightly opposite template C during DNA synthesis. Besides base substitutions, h Poleta enhanced the frequency of single-base frameshifts and deletions with the size of more than 100 base pairs when 8-OH-dGTP was present in the reaction mixture. Since h Poleta is present in replication foci even without exogenous DNA damage, we suggest that h Poleta may be involved in induction of various types of mutations through the erroneous and efficient incorporation of oxidized dNTPs into DNA in human cells.
  • Programmed Packaging: A New Drug Delivery System and its Application to Gene Therapy
    Kentaro Kogure; Hidetaka Akita; Hiroyuki Kamiya; Hideyoshi Harashima
    Modern Biopharmaceuticals: Design, Development and Optimization, 4, 1521, 1536, Wiley-VCH Verlag GmbH, 2008年02月05日
    英語, 論文集(書籍)内論文
  • MITO-Porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion.
    Yuma Yamada; Hidetaka Akita; Hiroyuki Kamiya; Kentaro Kogure; Takenori Yamamoto; Yasuo Shinohara; Kikuji Yamashita; Hideo Kobayashi; Hiroshi Kikuchi; Hideyoshi Harashima
    Biochimica et biophysica acta, 1778, 2, 423, 32, 2008年02月, [国際誌]
    英語, 研究論文(学術雑誌), Mitochondria are the principal producers of energy in higher cells. Mitochondrial dysfunction is implicated in a variety of human diseases, including cancer and neurodegenerative disorders. Effective medical therapies for such diseases will ultimately require targeted delivery of therapeutic proteins or nucleic acids to the mitochondria, which will be achieved through innovations in the nanotechnology of intracellular trafficking. Here we describe a liposome-based carrier that delivers its macromolecular cargo to the mitochondrial interior via membrane fusion. These liposome particles, which we call MITO-Porters, carry octaarginine surface modifications to stimulate their entry into cells as intact vesicles (via macropinocytosis). We identified lipid compositions for the MITO-Porter which promote both its fusion with the mitochondrial membrane and the release of its cargo to the intra-mitochondrial compartment in living cells. Thus, the MITO-Porter holds promise as an efficacious system for the delivery of both large and small therapeutic molecules into mitochondria.
  • Development of lipid particles targeted via sugar-lipid conjugates as novel nuclear gene delivery system
    Tomoya Masuda; Hidetaka Akita; Takashi Nishio; Kenichi Niikura; Kentaro Kogure; Kuniharu Ijiro; Hideyoshi Harashima
    BIOMATERIALS, 29, 6, 709, 723, 2008年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Nonviral gene delivery
    Hidetaka Akita; Hideyoshi Harashima
    GENE THERAPY FOR RENAL DISEASES AND TRANSPLANTATION, 159, 13, 29, 2008年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Effect of surface-modification with octaarginine versus octalysine on cellular uptake and endosomal escape of nanoparticles
    Ayman El-Sayed; Ikramy A. Khalil; Kentaro Kogure; Shiroh Futaki; Hideyoshi Harashima
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 128, 111, 112, 2008年, [査読有り]
    英語
  • Supramolecular control of polyplex dissociation and cell transfection: Efficacy of amine and threading cyclodextrin in biocleavable polyrotaxanes
    Yamashita A; Kanda D; Katoono R; Yui N; Ooya T; Maruyama A; Akita H; Kogure K; Harashima H
    8th World Biomaterials Congress 2008, 4, 2008年, [査読有り]
  • Base excision repair system suppresses mutagenesis caused by 8-hydroxy-dGTP in Escherichia coli.
    Tetsuya Suzuki; Kazuo Yamamoto; Hideyoshi Harashima; Hiroyuki Kamiya
    Nucleic acids symposium series (2004), 51, 52, 2007年12月01日
  • UvrAとUvrBは酸化損傷ヌクレオチドにより誘発される変異を促進する
    堀 美香; 石黒 智恵子; 鈴木 哲矢; 中川 紀子; 布柴 達男; 倉光 成紀; 山本 和生; 葛西 宏; 原島 秀吉; 紙谷 浩之
    日本放射線影響学会大会講演要旨集, 50回, 69, 69, (一社)日本放射線影響学会, 2007年11月
    日本語
  • Multifunctional envelope-type nano device for non-viral gene delivery: Concept and application of Programmed Packaging
    Kentaro Kogure; Hidetaka Akita; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 122, 3, 246, 251, 2007年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes
    Hiroto Hatakeyama; Hidetaka Akita; Emi Ishida; Koichi Hashimoto; Hideo Kobayashi; Takanori Aoki; Junko Yasuda; Kenichi Obata; Hiroshi Kikuchi; Tatsuhiro Ishida; Hiroshi Kiwada; Hideyoshi Harashima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 342, 1-2, 194, 200, 2007年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • New packaging method of mycobacterial cell wall using octaarginine-modified liposomes: Enhanced uptake by and immunostimulatory activity of dendritic cells
    Atthachal Homhuan; Kentaro Kogure; Hideyuki Akaza; Shiroh Futaki; Takashi Naka; Yukiko Fujita; Ikuya Yano; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 120, 1-2, 60, 69, 2007年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • 2-Hydroxy-2'-deoxyadenosine 5'-triphosphate enhances A.T --> C.G mutations caused by 8-hydroxy-2'-deoxyguanosine 5'-triphosphate by suppressing its degradation upon replication in a HeLa extract.
    Kazuya Satou; Hiroshi Kasai; Chikahide Masutani; Fumio Hanaoka; Hideyoshi Harashima; Hiroyuki Kamiya
    Biochemistry, 46, 22, 6639, 46, 2007年06月05日, [査読有り], [国際誌]
    英語, The coexistence effects of multiple kinds of oxidized deoxyribonucleotides were examined using an SV40 origin-dependent in vitro replication system with a HeLa extract. Oxidized dGTP and dATP, 8-hydroxy-2'-deoxyguanosine 5'-triphosphate (8-OH-dGTP) and 2-hydroxy-2'-deoxyadenosine 5'-triphosphate (2-OH-dATP), were used in this study. The mutation frequency synergistically increased when the two oxidized deoxyribonucleotides were together in the reaction. 2-OH-dATP enhanced the mutagenicity of 8-OH-dGTP, since the induced mutations were A.T --> C.G transversions. The contribution of the highly error-prone DNA polymerase eta was unlikely, since similar results were observed with an XP-V cell extract. The possible involvement of 2-hydroxyadenine in the complementary (template) strand was excluded on the basis of experiments using plasmids containing 2-hydroxyadenine as templates in the reactions with 8-OH-dGTP. 2-OH-dATP suppressed hydrolysis of 8-OH-dGTP, suggesting that the inhibition of the MTH1 protein played the major role in the enhancement. These results highlight the importance of specific hydrolysis of 8-OH-dGTP for the suppression of its induced mutation.
  • Octaarginine-modified multifunctional envelope-type nano device for siRNA
    Yoshio Nakamura; Kentaro Kogure; Shiroh Futaki; Hideyoshi Harashima
    JOURNAL OF CONTROLLED RELEASE, 119, 3, 360, 367, 2007年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Efficient and erroneous incorporation of oxidized DNA precursors by human DNA polymerase eta.
    Masatomi Shimizu; Petr Gruz; Hiroyuki Kamiya; Chikahide Masutani; Yan Xu; Yukio Usui; Hiroshi Sugiyama; Hideyoshi Harashima; Fumio Hanaoka; Takehiko Nohmi
    Biochemistry, 46, 18, 5515, 22, 2007年05月08日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Altered oxidative metabolism is a property of many tumor cells. Oxidation of DNA precursors, i.e., dNTP pool, as well as DNA is a major source of mutagenesis and carcinogenesis. Here, we report the remarkable nature of human DNA polymerase eta that incorporates oxidized dNTPs into a nascent DNA strand in an efficient and erroneous manner. The polymerase almost exclusively incorporated 8-hydroxy-dGTP (8-OH-dGTP) opposite template adenine (A) at 60% efficiency of normal dTTP incorporation, and incorporated 2-hydroxy-dATP (2-OH-dATP) opposite template thymine (T), guanine (G), or cytosine (C) at substantial rates. The synthetic primers having 8-hydroxy-G paired with template A or 2-hydroxy-A paired with template T, G, or C at the termini were efficiently extended. In contrast, human DNA polymerase iota incorporated 8-OH-dGTP opposite template A with much lower efficiency and did not incorporate 2-OH-dATP opposite any of the template bases. It did not extend the primers having the oxidized bases at the termini either. We propose that human DNA polymerase eta may participate in oxidative mutagenesis through the efficient and erroneous incorporation of oxidized dNTPs during DNA synthesis.
  • The location of the left-handedly curved DNA sequence affects exogenous DNA expression in vivo
    Hiroyuki Kamiya; Satoki Fukunaga; Takashi Ohyama; Hideyoshi Harashima
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 461, 1, 7, 12, 2007年05月
    英語, 研究論文(学術雑誌)
  • Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery
    I. A. Khalil; K. Kogure; S. Futaki; S. Hama; H. Akita; M. Ueno; H. Kishida; M. Kudoh; Y. Mishina; K. Kataoka; M. Yamada; H. Harashima
    GENE THERAPY, 14, 8, 682, 689, 2007年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Accumulation of O-GlcNAc-displaying CdTe quantum dots in cells in the presence of ATP
    Kenichi Niikura; Takashi Nishio; Hidetaka Akita; Yasutaka Matsuo; Ryosuke Kamitani; Kentaro Kogure; Hideyoshi Harashima; Kuniharu Ijiro
    CHEMBIOCHEM, 8, 4, 379, 384, 2007年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells
    Tomotaka Kobayashi; Tatsuhiro Ishida; Yurie Okada; Saori Ise; Hideyoshi Harashima; Hiroshi Kiwada
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 329, 1-2, 94, 102, 2007年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A more excellent construction method of a multi functional envelope-type nano device on microdevice for gene therapy
    Hiroshi Kuramoto; Noritada Kaji; Kentarou Kogure; Manabu Tokeshi; Yasuo Shinohara; Hideyoshi Harashima; Yoshinobu Baba
    Proceedings of the 11th International Conference on Miniaturized Systems for Chemistry and Life Sciences, uTAS 2007, 781, 783, 2007年
    研究論文(国際会議プロシーディングス)
  • Correlation between the Phosphohydrolase Activity of the Escherichia coli Orf135 (NudG) Protein and Mutation Suppression
    Hiroyuki Kamiya; Emiko Iida; Hideyoshi Harashima
    Genes and Environment, 29, 2, 63, 66, 2007年
    英語, 研究論文(学術雑誌)
  • Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid
    H. Hatakeyama; H. Akita; K. Kogure; M. Oishi; Y. Nagasaki; Y. Kihira; M. Ueno; H. Kobayashi; H. Kikuchi; H. Harashima
    GENE THERAPY, 14, 1, 68, 77, 2007年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Synthesis of a biocleavable polyrotaxane-plasmid DNA (pDNA) polyplex and its use for the rapid nonviral delivery of pDNA to cell nuclei.
    Atsushi Yamashita; Nobuhiko Yui; Tooru Ooya; Arihiro Kano; Atsushi Maruyama; Hidetaka Akita; Kentaro Kogure; Hideyoshi Harashima
    Nat Protoc, 1, 6, 2861, 2869, 2006年12月, [査読有り]
    英語, 研究論文(学術雑誌), This protocol provides a method for synthesizing a biocleavable polyrotaxane/plasmid DNA (pDNA) polyplex and for using it to deliver pDNA into cell nuclei. The biocleavable polyrotaxane is synthesized in four steps: (i) introduction of disulfide linkages at both terminals of PEG, (ii) preparation of an inclusion complex between disulfide-containing PEG and alpha-cyclodextrins (alpha-CDs), (iii) synthesis of polyrotaxane and (iv) modification of alpha-CDs in the polyrotaxane with dimethylethylenediamine. A polyplex of pDNA with the polyrotaxane is formed when the two compounds are dissolved together in a phosphate buffer. Subcellular localization of rhodamine-labeled pDNA in fluorescently labeled organelles is quantified by Z-series of confocal images captured by confocal laser scanning microscopy. Significant amounts of pDNA delivered to the nucleus can be expected as well as high transfection activity of the polyplex. This protocol can be completed in 23-32 d.
  • Mutagenic properties of oxidized GTP and ATP in in vitro transcription-reverse transcription.
    Hiroyuki Kamiya; Akihiro Suzuki; Kazuaki Kawai; Hiroshi Kasai; Hideyoshi Harashima
    Nucleic acids symposium series (2004), 99, 100, 2006年12月01日
  • Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin
    Tianzhi Yang; Alamdar Hussain; Shuhua Bai; Ikramy A. Khalil; Hideyoshi Harashima; Fakhrul Ahsan
    JOURNAL OF CONTROLLED RELEASE, 115, 3, 289, 297, 2006年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • 損傷ヌクレオチドによる遺伝情報不安定性誘発とその制御 酸化ヌクレオチド誘発変異とヌクレオチド除去修復酵素UvrABCとの関連
    堀 美香; 石黒 智恵子; 中川 紀子; 倉光 成紀; 山本 和生; 葛西 宏; 原島 秀吉; 紙谷 浩之
    日本放射線影響学会大会講演要旨集, 49回, 75, 75, (一社)日本放射線影響学会, 2006年09月
    日本語
  • Impact of convective flow on the cellular uptake and transfection activity of lipoplex and adenovirus
    Takahiro Fujiwara; Hidetaka Akita; Katsuko Furukawa; Takashi Ushida; Hiroyuki Mizuguchi; Hideyoshi Harashima
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 29, 7, 1511, 1515, 2006年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Involvement of Y-family DNA polymerases in mutagenesis caused by oxidized nucleotides in Escherichia coli
    M Yamada; T Nunoshiba; M Shimizu; P Gruz; H Kamiya; H Harashima; T Nohmi
    JOURNAL OF BACTERIOLOGY, 188, 13, 4992, 4995, 2006年07月
    英語, 研究論文(学術雑誌)
  • Cellular uptake and subsequent intracellular trafficking of R8-liposomes introduced at low temperature.
    Akitada Iwasa; Hidetaka Akita; Ikramy Khalil; Kentaro Kogure; Shiroh Futaki; Hideyoshi Harashima
    Biochimica et biophysica acta, 1758, 6, 713, 20, 2006年06月, [国際誌]
    英語, 研究論文(学術雑誌), Intracellular trafficking is a determining factor in the transgene expression efficiency of gene vectors. In the present study, the mechanism of the cellular uptake of octaarginine (R8)-modified liposomes, when introduced at 37 degrees C and 4 degrees C, was investigated in living cells. Compared with 37 degrees C, the uptake of R8-liposomes was only slightly reduced at 4 degrees C. Dual imaging of liposomes and plasma membranes revealed that R8-liposomes were internalized by vesicular transport, and partially escaped to the cytosol at the perinuclear region at 37 degrees C. When introduced at 4 degrees C, intracellular liposomes were observed within a specific region close to the plasma membrane, and internalization of the plasma membrane was completely inhibited. Therefore, at 4 degrees C, R8-liposomes appear to enter cells via unique pathway, which is separate and distinct from energy-dependent vesicular transport. The subsequent nuclear delivery of encapsulated pDNA, when introduced at 4 degrees C, was less prominent compared with those introduced at 37 degrees C. Collectively, these findings demonstrate that a vesicular transport-independent pathway is responsible for the cellular uptake of liposomes. In addition, the uptake route is closely related to the subsequent nuclear delivery process; the operation of an endogenous vesicular sorting system is advantageous for the nuclear delivery of pDNA.
  • Silencing of exogenous DNA in cultured cells
    Hiroshi Ochiai; Hideyoshi Harashima; Hiroyuki Kamiya
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 29, 6, 1294, 1296, 2006年06月
    英語, 研究論文(学術雑誌)
  • Cellular uptake and subsequent intracellular trafficking of R8-liposomes introduced at low temperature
    Akitada Iwasa; Hidetaka Akita; Ikramy Khalil; Kentaro Kogure; Shiroh Futaki; Hideyoshi Harashima
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1758, 6, 713, 720, 2006年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Significant Silencing Effect of a Multifunctional Envelope-Type Nano Device Encapsulating Antisense Oligodeoxynucleotide and Double-Stranded siRNA
    Kentaro Kogure; Yoshio Nakamura; Ikramy A. Khalil; Shiroh Futaki; Hideyoshi Harashima
    MOLECULAR THERAPY, 13, S202, S203, 2006年05月, [査読有り]
    英語
  • Cellular Uptake and Subsequent Intracellular of R8-Liposomes Introduced at Low Temperature
    Akitada Iwasa; Hidetaka Akita; Ikramy Khalil; Kentaro Kogure; Shiroh Futaki; Hideyoshi Harashima
    MOLECULAR THERAPY, 13, S129, S129, 2006年05月, [査読有り]
    英語
  • Interaction of hemoglobin vesicles, a cellular-type artificial oxygen carrier, with human plasma: Effects on coagulation, kallikrein-kinin, and complement systems
    Hideki Abe; Mitsuhiro Fujihara; Hiroshi Azuma; Hisami Ikeda; Kenji Ikebuchi; Shinji Takeoka; Eishun Tsuchida; Hideyoshi Harashima
    Artificial Cells, Blood Substitutes, and Biotechnology, 34, 1, 1, 10, 2006年04月01日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Quantitative comparison of intracellular trafficking and nuclear transcription between adenoviral and lipoplex systems
    S Hama; H Akita; R Ito; H Mizuguchi; T Hayakawa; H Harashima
    MOLECULAR THERAPY, 13, 4, 786, 794, 2006年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery
    IA Khalil; K Kogure; H Akita; H Harashima
    PHARMACOLOGICAL REVIEWS, 58, 1, 32, 45, 2006年03月, [査読有り]
    英語
  • Biocleavable polyrotaxane - Plasmid DNA polyplex for enhanced gene delivery
    T Ooya; HS Choi; A Yamashita; N Yui; Y Sugaya; A Kano; A Maruyama; H Akita; R Ito; K Kogure; H Harashima
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 128, 12, 3852, 3853, 2006年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression
    I.A. Khalil; K. Kogure; S. Futaki; H. Harashima
    Journal of Biological Chemistry, 281, 6, 3544, 3551, 2006年02月10日, [査読有り]
    英語
  • [Envelope-type nano device for gene delivery].
    Kogure K; Akita H; Harashima H
    Nihon rinsho. Japanese journal of clinical medicine, 64, 2, 258, 262, 2006年02月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), We introduced a new concept "Programmed Packaging" for the rational development of non viral gene delivery system. There are many non-viral gene delivery system, however, their utility is limited in the in vitro experiments. The major reason is considered that it is difficult to package many functional devices into a nanoparticle. The new concept which we introduce here is named as Programmed Packaging, which is composed of the strategy to targeting, molecular design of functional devices to overcome barriers, and assembly technique to package them into a nanoparticle. In this article, we explain this concept and provide newly developed gene delivery systems based on this concept.
  • Intranuclear disposition of exogenous DNA in vivo: Silencing, methylation and fragmentation
    H Ochiai; H Harashima; H Kamiya
    FEBS LETTERS, 580, 3, 918, 922, 2006年02月
    英語, 研究論文(学術雑誌)
  • Sugar-displaying quantum dots for cellular stress sensing
    Kenichi Niikura; Takashi Nishio; Yasutaka Matsuo; Hidetaka Akita; Kentaro Kogure; Hideyoshi Harashima; Kuniharu Ijiro
    Polymer Preprints, Japan, 55, 2, 5451, 5452, 2006年
    日本語, 研究論文(国際会議プロシーディングス)
  • Synthesis of sugar-displaying quantum dots and their intracellular dynamics
    Takashi Nishio; Kenichi Niikura; Yasutaka Matsuo; Hidetaka Akita; Kentaro Kogure; Hideyoshi Harashima; Kuniharu Ijiro
    Polymer Preprints, Japan, 55, 1, 2145, 2006年
    日本語, 研究論文(国際会議プロシーディングス)
  • Effects of supramolecular structure of cationic-polyrotaxanes on pDNA compaction
    Yamashita A; Ooya T; Kanda D; Choi H.S; Yui N; Maruyama A; Akita H; Kogure K; Harashima H
    Polymer Preprints, Japan, 55, 1, 2006年, [査読有り]
  • Quantitative comparison of intracellular trafficking between artificial and viral vector: Mechanism underlying the difference in dominant rate-limiting process
    Hidetaka Akita; Susumu Hama; Hiroyuki Mizuguchi; Hideyoshi Harashima
    Progress on Post-Genome Technologies, 521, 525, 2006年, [査読有り]
    英語, 研究論文(国際会議プロシーディングス)
  • Transient expression of Drosophila melanogaster deoxynucleoside kinase gene enhances cytotoxicity of nucleoside analogs
    Hiroyuki Kamiya; Hiroshi Ochiai; Hideyoshi Harashima; Mana Ito; Akira Matsuda
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 25, 4-6, 553, 560, 2006年
    英語, 研究論文(学術雑誌)
  • Evaluation of the nuclear delivery and intra-nuclear transcription of plasmid DNA condensed with μ (mu) and NLS-μ by cytoplasmic and nuclear microinjection: A comparative study with poly-L-lysine
    H. Akita; M. Tanimoto; T. Masuda; K. Kogure; S. Hama; K. Ninomiya; S. Futaki; H. Harashima
    Journal of Gene Medicine, 8, 2, 198, 206, 2006年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The efficient nuclear delivery of plasmid DNA (pDNA) is essential for the development of a promising non-viral gene vector. In an attempt to achieve nuclear delivery, NLS-mu, a novel pDNA condenser, was prepared. This consists of mu, a highly potent polypeptide for condensing the pDNA, and a SV40 T antigen-derived nuclear localization signal (NLS(SV40)). METHODS: The utility of NLS-mu was assessed in terms of green fluorescent protein (GFP) expression after cytoplasmic and nuclear microinjection of GFP-encoding pDNA along with the transfection, and compared with mu and poly-L-lysine (PLL). Trans-gene expression after cytoplasmic microinjection was affected by the efficiencies of nuclear transfer and following intra-nuclear transcription. To evaluate the nuclear transfer process separately, we introduced a parameter, a nuclear transfer score (NT score), which was calculated as the trans-gene expression after cytoplasmic microinjection divided by that after nuclear microinjection. RESULTS: As expected, the rank order of trans-gene expression after the transfection and cytoplasmic microinjection was NLS-mu > mu > PLL. However, the calculated NT scores were unexpectedly ranked as mu = NLS-mu > PLL, suggesting that mu, and not NLS(SV40), is responsible for the nuclear delivery of pDNA. In addition, confocal images of rhodamine-labeled pDNA indicated that pDNA condensed with mu and NLS-mu was delivered as a condensed form. In comparing the nuclear transcription, the rank order of trans-gene expression after nuclear microinjection was PLL = NLS-mu > mu, suggesting that intra-nuclear transcription is inhibited by efficient condensation by mu, and is avoided by the attachment of NLS(SV40). CONCLUSIONS: Collectively, NLS-mu, which consists of chimeric functions, is an excellent DNA condenser, and the process is based on mu-derived nuclear transfer and NLS(SV40)-derived efficient intra-nuclear transcription.
  • Pharmacokinetics and brain uptake of lactoferrin in rats
    B Ji; A Maeda; M Higuchi; K Inoue; H Akita; H Harashima; T Suhara
    LIFE SCIENCES, 78, 8, 851, 855, 2006年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • In vitro evaluation of cationic polyrotaxanes as gene carrier
    Kanda D; Yamashita A; Katoono R; Ooya T; Yui N; Maruyama A; Akita H; Kogure K; Harashima H
    Polymer Preprints, Japan, 55, 2, 5367, 5368, 2006年, [査読有り]
  • Synthesis of a biocleavable polyrotaxane-plasmid DNA (pDNA) polyplex and its use for the rapid nonviral delivery of pDNA to cell nuclei
    Atsushi Yamashita; Nobuhiko Yui; Tooru Ooya; Arihiro Kano; Atsushi Maruyama; Hidetaka Akita; Kentaro Kogure; Hideyoshi Harashima
    NATURE PROTOCOLS, 1, 6, 2861, 2869, 2006年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Conversion of nucleotide sequence with single-stranded DNA fragment prepared from phagemid DNA.
    Hiroyuki Tsuchiya; Tomoko Sawamura; Masayuki Uchiyama; Hideyoshi Harashima; Hiroyuki Kamiya
    Nucleic acids symposium series (2004), 93, 94, 2005年12月01日
  • Factors affecting SFHR gene correction efficiency with single-stranded DNA fragment
    H Tsuchiya; H Harashima; H Kamiya
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 336, 4, 1194, 1200, 2005年11月
    英語, 研究論文(学術雑誌)
  • Sunflower-shaped cyclodextrin-conjugated poly(-lysine) polyplex as a controlled intracellular trafficking device
    H. S. Choi; A. Yamashita; OOYA Tooru; N. Yui; H. Akita; K. Kogure; R. Ito; H. Harashima
    ChemPhysChem, Vol. 6, pp. 1986-1990, 11, 1986, 90, 2005年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Unique features of a pH-sensitive fusogenic peptide that improves the transfection efficiency of cationic liposomes
    S Futaki; Y Masui; Nakase, I; Y Sugiura; T Nakamura; K Kogure; H Harashima
    JOURNAL OF GENE MEDICINE, 7, 11, 1450, 1458, 2005年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Effect of methylated adenine in plasmid DNA on transgene expression in mice
    H Ochiai; H Harashima; H Kamiya
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 28, 10, 2019, 2022, 2005年10月
    英語, 研究論文(学術雑誌)
  • A multifunctional envelope-type nano device for novel gene delivery of siRNA plasmids
    R. Moriguchi; K. Kogure; H. Akita; S. Futaki; M. Miyagishi; K. Taira; H. Harashima
    International Journal of Pharmaceutics, 301, 1-2, 277, 285, 2005年09月14日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), A multifunctional envelope-type nano device (MEND) for use in the delivery of siRNA expression plasmids is described. The plasmid DNA encoding anti-luciferase short interfering RNA (siRNA) was condensed by poly-L-lysine (PLL) and packaged into the MEND. The silencing effect of the MEND(PLL) showed a 96% inhibition of luciferase activities in a co-transfection study. The silencing effect was maintained at more than 60%, even under the 100-fold diluted conditions. In the luciferase transformed cells, however, the MEND(PLL) showed no significant silencing effect (10%), indicating heterogeneity in transfection by the MEND(PLL). To solve this problem, the DNA condensing agents were optimized by comparing PLL, stearyl octaarginine (STR-R8) and protamine (Prot). No difference in silencing effect (95-97%) was found among these MENDs in a co-transfection study. However, the MEND(Prot) showed a 70% silencing effect in the transformed cells. These results suggest that the MEND(Prot) has less heterogeneity in transfection, while the MEND(PLL) and the MEND(STR-R8) have large heterogeneities. These results demonstrate that MEND(Prot) is a promising gene delivery system for siRNA expression plasmids with less heterogeneity associated with the transfection.
  • Mutagenesis induced by oxidized DNA precursors: Roles of Y family DNA polymerases in Escherichia coli
    K Satou; M Yamada; T Nohmi; H Harashima; H Kamiya
    CHEMICAL RESEARCH IN TOXICOLOGY, 18, 8, 1271, 1278, 2005年08月
    英語, 研究論文(学術雑誌)
  • Kinetic analysis of protein production after DNA transfection
    Y Yumada; H Kamiya; H Harashima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 299, 1-2, 34, 40, 2005年08月
    英語, 研究論文(学術雑誌)
  • Construction of a multifunctional envelope-type nano device by a SUV*-fusion method
    K Sasaki; K Kogure; S Chaki; Y Kihira; M Ueno; H Harashima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 296, 1-2, 142, 150, 2005年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Increased SFHR gene correction efficiency with sense single-stranded DNA
    H Tsuchiya; H Harashima; H Kamiya
    JOURNAL OF GENE MEDICINE, 7, 4, 486, 493, 2005年04月
    英語, 研究論文(学術雑誌)
  • Amino acid residues involved in substrate recognition of the Escherichia coli Orf 135 protein
    E Iida; K Satou; M Mishima; C Kojima; H Harashima; H Kamiya
    BIOCHEMISTRY, 44, 15, 5683, 5689, 2005年04月
    英語, 研究論文(学術雑誌)
  • Improved cell viability of linear polyethyleneimine through -cyclodextrin inclusion for effective gene delivery
    A. Yamashita; H. S. Choi; OOYA Tooru; N. Yui; H. Akita; K. Kogure; R. Ito; H. Harashima
    ChemPhysChem, Vol. 7, pp. 297-302, 297, 302, 2005年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Pharmacokinetics of gene delivery in cells
    Hidetaka Akita; Ikramy A. Khalil; Kentaro Kogure; Hideyoshi Harashima
    Non-viral Gene Therapy: Gene Design and Delivery, 135, 154, Springer-Verlag Tokyo, 2005年, [査読有り]
    英語, 論文集(書籍)内論文
  • Octaarginine-mediated stimulation of clathrin-independent endocytic uptake leading to enhanced gene expression through avoiding lysosomal degradation
    IA Khalil; K Kogure; S Futaki; H Harashima
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 125, 94, 95, 2005年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Newly designed DNA fragments for gene correction
    Hiroyuki Kamiya; Hiroyuki Tsuchiya; Hideyoshi Harashima
    Non-viral Gene Therapy: Gene Design and Delivery, 315, 322, Springer-Verlag Tokyo, 2005年
    英語, 論文集(書籍)内論文
  • Dual hydrolysis of diphosphate and triphosphate derivatives of oxidized deoxyadenosine by Orf17 (NtpA), a MutT-type enzyme
    M Hori; K Fujikawa; H Kasai; H Harashima; H Kamiya
    DNA REPAIR, 4, 1, 33, 39, 2005年01月
    英語, 研究論文(学術雑誌)
  • Cytokine induction by a bacterial DNA-specific modified base
    H Tsuchiya; T Matsuda; H Harashima; H Kamiya
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 326, 4, 777, 781, 2005年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Pharmacokinetic analysis of the tissue distribution of octaarginine modified liposomes in mice.
    D. Mudhakir; H. Akita; I.A. Khalil; S. Futaki; H. Harashima
    Drug metabolism and pharmacokinetics., 20, 4, 275, 281, 2005年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), We recently found that octaarginine modified liposomes (R8-Lip) can be efficiently internalized by cultured cells. The purpose of the present study was to quantitatively determine the effect of R8-density on the tissue distribution of R8-Lip in mice, using their clearance as an index. R8 was introduced in the form of stearylated R8 (STR-R8). The liposomes were composed of cholesterol and egg phosphatidylcholine and were labeled with [(3)H]cholesteryl hexadecyl ether. Various densities of R8 (3%, 10% and 30%) containing liposomes were prepared with a diameter of approximately 70-80 nm. The tissue distribution of R8-Lip was determined after their i.v. administration into mice and the effect of R8-density on tissue distribution was compared with uptake clearance, the calculated tissue distribution divided by the area under the blood concentration-time course. As results, R8-Lip were more rapidly eliminated from circulating blood and distributed to many tissues, especially liver depending on the R8-density. However, the tissue uptake clearance represented similar value to that of positively charge liposomes. Based on these results, we conclude that the R8-dependent increase in R8-Lip in various tissues tested indicates that positive charge, but not PTD function derived from R8 predominantly responsible for the enhancement of tissue distribution. Therefore, it is suggested that topology control of R8 is important to exhibit the PTD function.
  • Mutagenesis by damaged deoxyribonucleotides and its prevention by MutT-type hydrolyzing enzymes.
    Hiroyuki Kamiya; Kazuya Satou; Mika Hori; Emiko Iida; Chieko Ishiguro; Hideyoshi Harashima
    Nucleic acids symposium series (2004), 48, 271, 272, 2004年12月01日, [国際誌]
    英語, 研究論文(学術雑誌)
  • mutT株における8-ヒドロキシ-dGTP誘発変異の上昇 MutT蛋白質の酸化dGTPによる変異の防御の直接的証拠
    紙谷 浩之; 石黒 智恵子; 原島 秀吉
    日本放射線影響学会大会講演要旨集, 47回, 73, 73, (一社)日本放射線影響学会, 2004年11月
    日本語
  • Important amino acids in the phosphohydrolase module of Escherichia coli Orf135
    H Kamiya; E Iida; H Harashima
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 323, 3, 1063, 1068, 2004年10月
    英語, 研究論文(学術雑誌)
  • Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method
    KOGURE K
    J Control Release, 98, 2, 317, 323, 2004年08月11日, [査読有り]
    英語
  • Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo
    H Hatakeyama; H Akita; K Maruyama; T Suhara; H Harashima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 281, 1-2, 25, 33, 2004年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Characterization of a Nudix hydrolase from Deinococcus radiodurans with a marked specificity for (deoxy)ribonucleoside 5′-diphosphates
    David I. Fisher; Jared L. Cartwright; Jared L. Cartwright; Hideyoshi Harashima; Hiroyuki Kamiya; Alexander G. McLennan
    BMC Biochemistry, 5, 1, 24, BioMed Central Ltd., 2004年05月17日
    英語, 研究論文(学術雑誌)
  • Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: An artificial viral-like delivery system
    T Kakudo; S Chaki; S Futaki; Nakase, I; K Akaji; T Kawakami; K Maruyama; H Kamiya; H Harashima
    BIOCHEMISTRY, 43, 19, 5618, 5628, 2004年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Mechanism of improved gene transfer by the N-terminal stearylation of octaarginine: enhanced cellular association by hydrophobic core formation
    IA Khalil; S Futaki; M Niwa; Y Baba; N Kaji; H Kamiya; H Harashima
    GENE THERAPY, 11, 7, 636, 644, 2004年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Quantitative three-dimensional analysis of the intracellular trafficking of plasmid DNA transfected by a nonviral gene delivery system using confocal laser scanning microscopy
    H. Akita; R. Ito; I.A. Khalil; S. Futaki; H. Harashima
    Molecular Therapy, 9, 3, 443, 451, 2004年03月, [査読有り]
    英語
  • Probing the substrate recognition mechanism of the human MTH1 protein by nucleotide analogs.
    Hiroyuki Kamiya; Hiroyuki Yakushiji; Laurence Dugué; Mitsuhide Tanimoto; Sylvie Pochet; Yusaku Nakabeppu; Hideyoshi Harashima
    Journal of molecular biology, 336, 4, 843, 50, 2004年02月27日, [査読有り], [国際誌]
    英語
  • An assessment of relative transcriptional availability from nonviral vectors
    R Tachibana; N Ide; Y Shinohara; H Harashima; CA Hunt; H Kiwada
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 270, 1-2, 315, 321, 2004年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Factors affecting membrane transport of octaarginine-modified liposomes for gene delivery
    LA Khalil; K Kogure; S Futaki; H Harashima
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 124, 113, 116, 2004年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor.
    Hiroyuki Tsuchiya; Keizou Kuwata; Sekio Nagayama; Kazumasa Yamashita; Hiroyuki Kamiya; Hideyoshi Harashima
    Drug metabolism and pharmacokinetics, 19, 206, 215, 2004年01月01日
  • Pharmacokinetic and pharmacodynamic considerations in gene therapy
    H Kamiya; H Akita; H Harashima
    DRUG DISCOVERY TODAY, 8, 21, 990, 996, 2003年11月
    英語
  • No enhancement of nuclear entry by direct conjugation of a nuclear localization signal peptide to linearized DNA
    M Tanimoto; H Kamiya; N Minakawa; A Matsuda; H Harashima
    BIOCONJUGATE CHEMISTRY, 14, 6, 1197, 1202, 2003年11月
    英語, 研究論文(学術雑誌)
  • The complement- but not mannose receptor-mediated phagocytosis is involved in the hepatic uptake of cetylmannoside-modified liposomes in situ
    H Matsuo; K Funato; H Harashima; H Kiwada
    JOURNAL OF DRUG TARGETING, 11, 5, 273, 277, 2003年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Mutagenic effects of 2-hydroxy-dATP on replication in a HeLa extract: induction of substitution and deletion mutations
    K Satou; H Harashima; H Kamiya
    NUCLEIC ACIDS RESEARCH, 31, 10, 2570, 2575, 2003年05月
    英語, 研究論文(学術雑誌)
  • Erroneous incorporation of oxidized DNA precursors by Y-family DNA polymerases.
    Masatomi Shimizu; Petr Gruz; Hiroyuki Kamiya; Su-Ryang Kim; Francesca M Pisani; Chikahide Masutani; Yusuke Kanke; Hideyoshi Harashima; Fumio Hanaoka; Takehiko Nohmi
    EMBO reports, 4, 3, 269, 73, 2003年03月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Deranged oxidative metabolism is a property of many tumour cells. Oxidation of the deoxynucleotide triphosphate (dNTP) pool, as well as DNA, is a major cause of genome instability. Here, we report that two Y-family DNA polymerases of the archaeon Sulfolobus solfataricus strains P1 and P2 incorporate oxidized dNTPs into nascent DNA in an erroneous manner: the polymerases exclusively incorporate 8-OH-dGTP opposite adenine in the template, and incorporate 2-OH-dATP opposite guanine more efficiently than opposite thymine. The rate of extension of the nascent DNA chain following on from these incorporated analogues is only slightly reduced. These DNA polymerases have been shown to bypass a variety of DNA lesions. Thus, our results suggest that the Y-family DNA polymerases promote mutagenesis through the erroneous incorporation of oxidized dNTPs during DNA synthesis, in addition to facilitating translesion DNA synthesis. We also report that human DNA polymerase eta, a human Y-family DNA polymerase, incorporates the oxidized dNTPs in a similar erroneous manner.
  • Cationic liposome-mediated gene delivery: biophysical study and mechanism of internalization.
    Mohamad Radwan Almofti; Hideyoshi Harashima; Yasuo Shinohara; Ammar Almofti; Yoshinobu Baba; Hiroshi Kiwada
    Archives of biochemistry and biophysics, 410, 2, 246, 53, 2003年02月15日, [査読有り], [国際誌]
    英語, To identify factors affecting cationic liposome-mediated gene delivery efficiency, we studied the relationship between the biophysical characteristics of liposome/DNA complexes (lipoplexes) at different (+/-) charge ratios, their structures as monitored by atomic force microscopy (AFM), and their mechanism(s) of internalization into the cells. Significant changes were observed in the particle size and zeta potential of liposomes and their structures assessed by AFM upon addition of DNA, which depended on (+/-) charge ratios. AFM images showed that lipoplexes were formed from extensively fused and apparently homogeneous lipid particles encapsulating DNA. Lipoplexes were found to internalize the cells through the endocytosis pathway. Lipoplex-cell fusion was found to occur mainly at the plasma membrane level; however, this lipoplex-cell membrane fusion was found to be essential for the uptake of the large particles. A new perspective for the internalization of large lipoplex particles into cytoplasm is discussed.
  • Lipoplex size determines lipofection efficiency with or without serum
    MR Almofti; H Harashima; Y Shinohara; A Almofti; WH Li; H Kiwada
    MOLECULAR MEMBRANE BIOLOGY, 20, 1, 35, 43, 2003年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Immunoliposomes having high membrane fluidity delivery a large amount of liposomal doxorubicin into not only doxorubicin sensitive SBC-3 but also doxorubicin resistant SBC-3/ADM cell lines
    Kobayashi, T; Okada, Y; Ishida, T; Sone, S; Harashima, H; Maruyama, K; Kiwada, H
    J. Liposome Res., 13, 67, 2003年, [査読有り]
    英語
  • Utilization efficiency of the oxidized purine nucleotide analogs by DNA polymerase eta.
    Naomi Nishimoto; Hiroyuki Kamiya; Hideyoshi Harashima; Shunji Izuta
    Nucleic acids research. Supplement (2001), 3, 299, 300, 2003年01月01日, [国際誌]
    英語, 研究論文(学術雑誌)
  • Mutations induced by 2-hydroxy-dATP during in vitro replication with a HeLa extract.
    Kazuya Satou; Hideyoshi Harashima; Hiroyuki Kamiya
    Nucleic acids research. Supplement (2001), 325, 326, 2003年01月01日
  • pH-sensitive liposomes in nuclear targeting of macromolecules
    R Tachibana; S Futaki; H Harashima; H Kiwada
    LIPOSOMES, PT B, 372, 349, 361, 2003年, [査読有り]
    英語
  • Size and topology of exogenous DNA as determinant factors of transgene transcription in mammalian cells
    H. Kamiya; J. Yamazaki; H. Harashima
    Gene Therapy, 9, 1500, 1507, 2002年11月01日
  • Visualization of intracellular trafficking of exogenous DNA delivered by cationic liposomes
    H Kamiya; Y Fujimura; Matsuoka, I; H Harashima
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 298, 4, 591, 597, 2002年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Quantitative analysis of correlation between number of nuclear plasmids and gene expression activity after transfection with cationic liposomes
    R Tachibana; H Harashima; N Ide; S Ukitsu; Y Ohta; N Suzuki; H Kikuchi; Y Shinohara; H Kiwada
    PHARMACEUTICAL RESEARCH, 19, 4, 377, 381, 2002年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Troglitazone suppresses cell growth of KU812 cells independently of PPARγ
    Akihito Abe; Yoshimitsu Kiriyama; Masako Hirano; Toshiaki Miura; Hiroyuki Kamiya; Hideyoshi Harashima; Yukiko Tokumitsu; Yukiko Tokumitsu; Yukiko Tokumitsu
    European Journal of Pharmacology, 436, 1-2, 7, 13, 2002年02月
    英語, 研究論文(学術雑誌)
  • Liposome clearance.
    Ishida, T; Harashima, H; Kiwada, H
    Biosci. Rep., 22, 197, 224, 2002年
    英語
  • Pharmacokinetics of targeting with liposomes
    H Harashima; T Ishida; H Kamiya; H Kiwada
    CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 19, 3, 235, 275, 2002年
    英語
  • Substrate recognition by the human MTH1 protein.
    Hiroyuki Kamiya; Laurence Dugué; Hiroyuki Yakushiji; Sylvie Pochet; Yusaku Nakabeppu; Hideyoshi Harashima
    Nucleic acids research. Supplement (2001), 2, 85, 6, 2002年, [査読有り], [国際誌]
    英語
  • Intracellular trafficking and transgene expression of viral and non-viral gene vectors
    H Kamiya; H Tsuchiya; J Yamazaki; H Harashima
    ADVANCED DRUG DELIVERY REVIEWS, 52, 3, 153, 164, 2001年11月
    英語
  • Hydrolysis of oxidized nucleotides by the Escherichia coli Orf135 protein
    H Kamiya; N Murata-Kamiya; E Iida; H Harashima
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 288, 3, 499, 502, 2001年11月
    英語, 研究論文(学術雑誌)
  • Stearylated arginine-rich peptides: A new class of transfection systems
    S. Futaki; W. Ohashi; T. Suzuki; M. Niwa; S. Tanaka; K. Ueda; H. Harashima; Y. Sugiura
    Bioconjugate Chemistry, 12, 6, 1005, 1011, 2001年11月, [査読有り]
    英語
  • Effect of cholesterol content in activation of the classical versus the alternative pathway of rat complement system induced by hydrogenated egg phosphatidylcholine-based liposomes
    T Ishida; K Yasukawa; H Kojima; H Harashima; H Kiwada
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 224, 1-2, 69, 79, 2001年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • The complement system enhances the clearance of phosphatidylserine (PS)-liposomes in rat and guinea pig
    TM Huong; T Ishida; H Harashima; H Kiwada
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 215, 1-2, 197, 205, 2001年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Interactions of liposomes with in vitro and in vivo: opsonins and receptors.
    Ishida, T; Harashima, H; Kiwada, H
    Current Drug Metabolism, 2, 397, 409, 2001年
    英語
  • Molecular design and drug delivery of genetic drugs
    Yoshinobu Baba; Mitsuhiko Shionoya; Hideyoshi Harashima
    European Journal of Pharmaceutical Sciences, 13, 1, 1, 2001年, [査読有り]
    研究論文(学術雑誌)
  • Quantitative evaluation on relationship between liposome biodistribution in vivo and associated C3 fragments.
    Ishida, T; Kojima, H; Harashima, H; Kiwada, H
    Int. J. Pharm., 205, No.1-2, 183, 193, 2000年09月15日, [査読有り]
    英語, 研究論文(学術雑誌), The biodistribution of liposomes with two different kind phospholipids (hydrogenated egg phosphatidylcholine and egg phosphatidylcholine) plus cholesterol (CHOL) were investigated after intravenous administration to rats. Elimination of liposomes from blood circulation was affected by the lipid composition. It appeared that the inclusion of CHOL in liposomes accelerates the rate of liposome uptake by liver, resulting in rapid elimination of liposomes. The amount of C3 fragments bound to liposomes was quantitatively determined to assess the contribution of the complement system to liposome accumulation into organs and liposome destabilization in vivo and in vitro. The amount of bound C3 fragments was directly proportional to CHOL content, and the amount was also proportional to the CLh, CLs as well as CLrel. This relationship suggests that the complement system is responsible for the elimination of liposomes from blood circulation, presumably as a consequence of opsonization by C3 fragments and assembly of membrane attack complex (MAC) onto liposomes. In addition, substitution of cholesteryl methyl ether into the liposome formulation for CHOL significantly diminished not only the binding of C3 fragments but also the CLh, CLs and CLrel, resulting in increased mean resident time (MRT) of the liposomes. This result suggests that the hydroxyl-group on CHOL is a binding site for C3 fragments on the liposomes and that CHOL in a liposome formulation promotes the accumulation of liposomes into the liver and spleen, probably due to their uptake by phagocytic cells, and impairs the stability of the liposomes in blood circulation, via a mechanism involving the complement system.
  • Biodistribution of liposomes and C3 fragments associated with liposomes: evaluation of their relationship
    T Ishida; H Kojima; H Harashima; H Kiwada
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 205, 1-2, 183, 193, 2000年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Cardiomegaly in the juvenile visceral steatosis (JVS) mouse is reduced with acute elevation of heart short-chain acyl-carnitine level after L-carnitine injection
    Masamichi Kuwajima; Masahisa Horiuchi; Hideyoshi Harashima; Kang-Mo Lu; Miyuki Hayashi; Masako Sei; Kiyokazu Ozaki; Tomoko Kudo; Hiroshi Kamido; Akira Ono; Takeyori Saheki; Kenji Shima
    FEBS Letters, 443, 3, 261, 266, 1999年01月29日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Quantitative assay of transfected plasmid DNA in nucleus using PCR
    N. Ide; R. Tachibana; Y. Oota; H. Harashima; Y. Shinohara; H. Kiwada
    Proceedings of the Controlled Release Society, 26, 777, 778, 1999年
    英語, 研究論文(国際会議プロシーディングス)
  • Kinetic analysis of lipophilic drug encapsulated in liposomes
    Y. Ikemoto; K. Masuda; H. Harashima; H. Kiwada
    Proceedings of the Controlled Release Society, 26, 757, 758, 1999年
    英語, 研究論文(国際会議プロシーディングス)
  • Pharmacokinetics/pharmacodynamic modeling of liposomally encapsulated doxorubicin: Scaling up from rats to humans
    H. Doi; H. Harashima; S. Iida; M. Tsuchihashi; H. Kiwada
    Proceedings of the Controlled Release Society, 26, 779, 780, 1999年
    英語, 研究論文(国際会議プロシーディングス)
  • Incorporation of the nuclear localization signal (NLS) peptide-albumin conjugate to macrophages using pH-sensitive liposomes
    S Futaki; R Tachibana; M Shono; M Azumano; M Niwa; H Kiwada; H Harashima
    PEPTIDE SCIENCE - PRESENT AND FUTURE, 699, 700, 1999年, [査読有り]
    英語, 研究論文(国際会議プロシーディングス)
  • Intracellular regulation of macromolecules using pH-sensitive liposomes and nuclear localization signal: Qualitative and quantitative evaluation of intracellular trafficking
    R Tachibana; H Harashima; M Shono; M Azumano; M Niwa; S Futaki; H Kiwada
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 251, 2, 538, 544, 1998年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Complement dependent and independent liposome uptake by peritoneal macrophages: Cholesterol content dependency
    TM Huong; H Harashima; H Kiwada
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 21, 9, 969, 973, 1998年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Kinetic analysis of the interaction between liposomes and the complement system in rat serum: Re-evaluation of size-dependency
    M Yamada; H Harashima; H Kiwada
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 21, 9, 964, 968, 1998年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Mechanism of initial distribution of blood-borne colon carcinoma cells in the liver
    N Mizuno; Y Kato; K Shirota; Y Izumi; T Irimura; H Harashima; H Kiwada; N Motoji; A Shigematsu; Y Sugiyama
    JOURNAL OF HEPATOLOGY, 28, 5, 878, 885, 1998年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Effects of repeated clarithromycin administration on the pharmacokinetic properties of pindolol in rats
    Takafumi Komori; Kazuki Shimoishi; Hideyoshi Harashima; Masaki Otagiri
    Biological and Pharmaceutical Bulletin, 21, 12, 1376, 1378, Pharmaceutical Society of Japan, 1998年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans
    D. Russell Wada; Sven Björkman; William F. Ebling; Hideyoshi Harashima; Sandra R. Harapat; Donald R. Stanski
    Anesthesiology, 87, 4, 884, 899, 1997年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • No effect of age on the dose requirement of thiopental in the rat
    Hideyoshi Harashima; William F. Ebling; D. Russell Wada; Donald R. Stanski
    Experimental Gerontology, 32, 3, 315, 324, 1997年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Kinetic analysis of the interaction between liposomes and complement system in rat serum
    M. Yamada; H. Harashima; J. Kikuishi; Y. Nemoto; M. Shibuya; H. Kiwada
    Proceedings of the Controlled Release Society, 24, 793, 794, 1997年
    英語, 研究論文(国際会議プロシーディングス)
  • Verification of satiated model in the saturable hepatic uptake clearance of liposomes
    T. Shimada; H. Harashima; H. Kiwada
    Proceedings of the Controlled Release Society, 24, 569, 570, 1997年
    英語, 研究論文(国際会議プロシーディングス)
  • Synergistic effect between size and cholesterol content in the enhanced hepatic uptake clearance of liposomes through complement activation in rats
    H Harashima; TM Huong; T Ishida; Y Manabe; H Matsuo; H Kiwada
    PHARMACEUTICAL RESEARCH, 13, 11, 1704, 1709, 1996年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Species difference in the disposition of liposomes among mice, rats, and rabbits: Allometric relationship and species dependent hepatic uptake mechanism
    H Harashima; S Komatsu; S Kojima; C Yanagi; Y Morioka; M Naito; H Kiwada
    PHARMACEUTICAL RESEARCH, 13, 7, 1049, 1054, 1996年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Carnitine transport defect in fibroblasts of juvenile visceral steatosis (JVS) mouse
    Masamichi Kuwajima; Kang-Mo Lu; Hideyoshi Harashima; Akira Ono; Izumi Sato; Akira Mizuno; Takashi Murakami; Hiromu Nakajima; Jun-Ichiro Miyagawa; Mitsuyoshi Namba; Toshiaki Hanafusa; Jun-Ichiro Hayakawa; Yuji Matsuzawa; Kenji Shima
    Biochemical and Biophysical Research Communications, 223, 2, 283, 287, Academic Press Inc., 1996年06月14日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Effects of thiopental on regional blood flows in the rat
    D. Russell Wada; Hideyoshi Harashima; William F. Ebling; Eileen W. Osaki; Donald R. Stanski
    Anesthesiology, 84, 3, 596, 604, 1996年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Size-dependent release of carboxyfluorescein from cetylmannoside-modified liposomes in human plasma
    AJ Ferdous; T Ishida; M Shinohara; H Harashima; H Kiwada
    BIOPHARMACEUTICS & DRUG DISPOSITION, 17, 2, 145, 154, 1996年03月
    英語, 研究論文(学術雑誌)
  • Studies on the mechanism of uptake of liposomes using an isolated perfused liver system
    Hideyoshi Harashima; Hiroshi Kiwada
    Journal of Liposome Research, 6, 1, 61, 75, Informa Healthcare, 1996年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Simulation study on the optimization of antitumor effect of liposomally encapsulated doxorubicin based on the physiological model with cell kill kinetic model
    S Iida; Y Urakami; H Harashima; H Kiwada
    23RD INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE OF BIOACTIVE MATERIALS, 1996 PROCEEDINGS, 653, 654, 1996年, [査読有り]
    英語, 研究論文(国際会議プロシーディングス)
  • The effect of dose on the intracellular fate of liposomes
    K Yoshimura; Y Morioka; H Harashima; H Kiwada
    23RD INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE OF BIOACTIVE MATERIALS, 1996 PROCEEDINGS, 683, 684, 1996年, [査読有り]
    英語, 研究論文(国際会議プロシーディングス)
  • Effect between size and cholesterol content in the enhanced hepatic uptake clearance of liposomes through complement activation in rats
    Harashima, H; Huong, T.M; Ishida, T; Manabe, Y; Matsuo, H; Kiwada, H
    Progress in Drug Delivery System, V, 93, 96, 1996年
    英語
  • EFFECTS OF THE SIZE AND FLUIDITY OF LIPOSOMES ON THEIR ACCUMULATION IN TUMORS - A PRESUMPTION OF THEIR INTERACTION WITH TUMORS
    K UCHIYAMA; A NAGAYASU; Y YAMAGIWA; T NISHIDA; H HARASHIMA; H KIWADA
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 121, 2, 195, 203, 1995年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • KINETIC MODELING OF LIPOSOME DEGRADATION IN PERITONEAL-MACROPHAGES
    H HARASHIMA; N HIRAI; H KIWADA
    BIOPHARMACEUTICS & DRUG DISPOSITION, 16, 2, 113, 123, 1995年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Size dependent liposome degradation in blood: In vivo/in vitro correlation by kinetic modeling
    H Harashima; T Hiraiwa; Y Ochi; H Kiwada
    JOURNAL OF DRUG TARGETING, 3, 4, 253, 261, 1995年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Size dependent characterization of cetylmannoside-modified liposomes (Man-MLVs) in human plasma
    Ishida, T; Ferdous, A.J; Shinohara, M; Harashima, H; Kiwada, H
    J.Liposome Res., 6, 252, 1995年
    英語
  • KINETIC MODELING OF LIPOSOME DEGRADATION IN SERUM - EFFECT OF SIZE AND CONCENTRATION OF LIPOSOMES IN-VITRO
    H HARASHIMA; Y OCHI; H KIWADA
    BIOPHARMACEUTICS & DRUG DISPOSITION, 15, 3, 217, 225, 1994年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • ENHANCED HEPATIC-UPTAKE OF LIPOSOMES THROUGH COMPLEMENT ACTIVATION DEPENDING ON THE SIZE OF LIPOSOMES
    H HARASHIMA; K SAKATA; K FUNATO; H KIWADA
    PHARMACEUTICAL RESEARCH, 11, 3, 402, 406, 1994年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • COMPLEMENT-MEDIATED HEPATIC UPTAKE OF MANNOSIDE-MODIFIED LIPOSOMES
    松尾 浩民; 船戸 耕一; 山下 親正; 原島 秀吉; 際田 弘志
    薬物動態, 9, 118, 121, The Japanese Society for the Study of Xenobiotics, 1994年
    英語, In the elimination of injected liposomes in vivo, it is considered that several serum components play an important role on hepatic uptake of them. This study was conducted to clarify the hepatic uptake mechanism of cetylmannoside (Man) -modified multilamellar vesicles (Man-MLV) using perfused rat liver. In the presence of serum, Man-MLV was taken up by the liver depending on the serum concentration, and it showed an approximately 2-fold higher accumulation than non-modified MLV (PC-MLV). These hepatic uptake of liposomes were obviously inhibited by preheating the serum at 56 °C for 30 min or by the treatment with anti-rat C3 antiserum. Further, SDS-PAGE followed by immunoblot analysis showed the deposition of iC3b on the opsonized Man-MLV. These results obtained in the present study suggested that hepatic uptake of Man-MLV was mainly mediated by complement receptor rather than mannose receptor on Kupffer cells in vivo.
  • THE COMPLEMENT-MEDIATED BUT NOT MANNOSE RECEPTOR-MEDIATED PHAGOCYTOSIS IS INVOLVED IN THE HEPATIC-UPTAKE OF CETYLMANNOSIDE-MODIFIED LIPOSOMES IN-SITU
    H MATSUO; K FUNATO; H HARASHIMA; H KIWADA
    JOURNAL OF DRUG TARGETING, 2, 2, 141, 146, 1994年, [査読有り]
    英語, 研究論文(学術雑誌)
  • KINETIC-ANALYSIS OF TISSUE DISTRIBUTION OF DOXORUBICIN INCORPORATED IN LIPOSOMES IN RATS .2.
    H HARASHIMA; Y MIDORI; S OHSHIMA; K YACHI; H KIKUCHI; H KIWADA
    BIOPHARMACEUTICS & DRUG DISPOSITION, 14, 7, 595, 608, 1993年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Tissue distribution of fentanyl and alfentanil in the rat cannot be described by a blood flow limited model
    Sven Björkman; Donald R. Stanski; Hideyoshi Harashima; Robert Dowrie; Sandra R. Harapat; D.Russell Wada; William F. Ebling
    Journal of Pharmacokinetics and Biopharmaceutics, 21, 3, 255, 279, Kluwer Academic Publishers-Plenum Publishers, 1993年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • KINETIC-ANALYSIS OF AUC-DEPENDENT SATURABLE CLEARANCE OF LIPOSOMES - MATHEMATICAL-DESCRIPTION OF AUC DEPENDENCY
    H HARASHIMA; C YAMANE; Y KUME; H KIWADA
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 21, 3, 299, 308, 1993年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • KINETIC MODELING OF LIPOSOME DEGRADATION IN BLOOD-CIRCULATION
    H HARASHIMA; Y KUME; C YAMANE; H KIWADA
    BIOPHARMACEUTICS & DRUG DISPOSITION, 14, 3, 265, 270, 1993年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • DISTINCTION BETWEEN THE DEPLETION OF OPSONINS AND THE SATURATION OF UPTAKE IN THE DOSE-DEPENDENT HEPATIC-UPTAKE OF LIPOSOMES
    H HARASHIMA; K SAKATA; H KIWADA
    PHARMACEUTICAL RESEARCH, 10, 4, 606, 610, 1993年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • KINETIC ANALYSIS OF LIPOSOME UPTAKE BY RES IN COMPARISON TO THEIR DEGRADATION IN BLOOD AND RES
    原島 秀吉; 越智 良仁; 平岩 智子; 杉野 香織; 際田 弘志
    薬物動態, 8, 751, 754, The Japanese Society for the Study of Xenobiotics, 1993年
    英語, Kinetic analysis of the hepatic uptake of liposomes was performed in comparison to the degradation of liposomes in blood and liver. The degradation clearance of liposomes in blood was shown to depend on the size of liposomes. In vitro kinetic study on the degradation of liposomes suggested the mechanism of this size dependency due to the Increased affinity of liposomes for complement. There was two kinds of hepatic uptake components of liposomes, one is a size dependent opsonized pathway, and the other is a size Independent unopsonized pathway. The size dependent opsonization of liposomes was shown to result from the size dependent complement activation and this component explained the size dependended hepatic uptake clearance of liposomes in vivo. The kinetic analysis of the hepatic degradation of liposomes was also performed by labeling liposomes with both 125I-albumin and 3H-cholesterylhexadecylether. Although the mechanism of hepatic uptake are considered to be different depending on the size of liposomes, the kinetics of hepatic degradation of liposomes was same for each size of liposomes and lay in the order of hour.
  • KINETIC-ANALYSIS OF TISSUE DISTRIBUTION OF DOXORUBICIN INCORPORATED IN LIPOSOMES IN RATS .1.
    H HARASHIMA; S OHSHIMA; Y MIDORI; K YACHI; H KIKUCHI; H KIWADA
    BIOPHARMACEUTICS & DRUG DISPOSITION, 13, 3, 155, 170, 1992年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Kinetic Modeling of Ouabain Tissue Distribution Based on Slow and Saturable Binding to Na,K-ATPase
    Hideyoshi Harashima; Michio Mamiya; Masayo Yamazaki; Yasufumi Sawada; Tatsuji Iga; Manabu Hanano; Yuichi Sugiyama
    Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists, 9, 12, 1607, 1611, 1992年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Significance of Binding to Na,K-ATPase in the Tissue Distribution of Ouabain in Guinea Pigs
    Hideyoshi Harashima; Michio Mamiya; Masayo Yamazaki; Yuichi Sugiyama; Yasufumi Sawada; Tatsuji Iga; Manabu Hanano
    Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists, 9, 4, 474, 479, 1992年, [査読有り]
    英語, 研究論文(学術雑誌)
  • SATURABLE, NON-MICHAELIS-MENTEN UPTAKE OF LIPOSOMES BY THE RETICULOENDOTHELIAL SYSTEM
    Y KUME; F MAEDA; H HARASHIMA; H KIWADA
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 43, 3, 162, 166, 1991年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Kinetic analysis of the dose-dependent hepatic handling of 1-anilino-8-naphthalene sulfonate in rats
    Youn Bok Chung; Seiji Miyauchi; Yuichi Sugiyama; Hideyoshi Harashima; Tatsuji Iga; Manabu Hanano
    Journal of Pharmacokinetics and Biopharmaceutics, 18, 4, 313, 333, Kluwer Academic Publishers-Plenum Publishers, 1990年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Effect of various organic anions on the plasma disappearance of 1-anilino-8-naphthalene sulfonate
    Youn Bok Chung; Seiji Miyauchi; Yuichi Sugiyama; Hideyoshi Harashima; Tatsuji Iga; Manabu Hanano
    Journal of Hepatology, 11, 2, 240, 251, 1990年, [査読有り]
    英語, 研究論文(学術雑誌)
  • NONLINEAR TISSUE DISTRIBUTION OF OUABAIN IN RABBITS
    H HARASHIMA; Y SUGIYAMA; T IGA; M HANANO
    DRUG METABOLISM AND DISPOSITION, 16, 4, 645, 649, 1988年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • INFUSION RATE-DEPENDENT POSITIVE INOTROPIC ACTION OUABAIN IN RABBITS
    H HARASHIMA; Y SUGIYAMA; Y SAWADA; K SHIGENOBU; Y KASUYA; T IGA; M HANANO
    CHEMICAL & PHARMACEUTICAL BULLETIN, 35, 7, 2923, 2927, 1987年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • ANALYSIS OF NONLINEAR TISSUE DISTRIBUTION OF QUINIDINE IN RATS BY PHYSIOLOGICALLY BASED PHARMACOKINETICS
    H HARASHIMA; Y SAWADA; Y SUGIYAMA; T IGA; M HANANO
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 13, 4, 425, 440, 1985年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • PREDICTION OF THE VOLUMES OF DISTRIBUTION OF BASIC DRUGS IN HUMANS BASED ON DATA FROM ANIMALS
    Y SAWADA; M HANANO; Y SUGIYAMA; H HARASHIMA; T IGA
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 12, 6, 587, 596, 1984年, [査読有り]
    英語, 研究論文(学術雑誌)
■ その他活動・業績
■ 書籍等出版物
  • THE創薬 小資源国家にっぽんの生きる道
    薬物送達システムから革新的医薬品の創出へ
    日本薬学会編、薬事日報社, 2021年03月, [分担執筆]
  • DDSキャリア設計入門
    原島秀吉, 編集と総論の執筆
    丸善出版株式会社, 2019年01月, [編者(編著者)]
  • Mitochondrial Biology and Experimental Therapeutics
    山田勇磨; 原島秀吉, Targeting the Mitochondrial Genome Through a Nanocarrier and the Regulation of Mitochondrial Gene Expression
    Springer International Publishing Switzerland, 2018年, [分担執筆]
  • 製剤学(改訂第7版)
    原島秀吉, 薬物速度論
    南江堂, 2017年, [共著]
  • パートナー薬剤学(改訂第3版)
    原島秀吉; 伊藤智夫; 寺田勝英, 編集、序章薬剤学総論と「分布」の執筆
    南江堂, 2017年, [共編者(共編著者)]
  • 医療・診断・創薬の化学 医療分野に挑む革新的な化学技術
    原島秀吉, 新しい遺伝子キャリア:多機能性エンベロープ型ナノ構造体の創製
    日本化学会編, 2017年, [共著]
  • スタンダード薬学シリーズII
    原島秀吉, VI.薬の生体内運命 第6章 薬物速度論
    東京化学同人, 2016年, [共著]
  • Pharmacology of Mitochondria. Handbook of Experimental Pharmacology 240
    原島秀吉, MITO-Porter for Mitochondrial Delivery and Mitochondrial Functional Analysis
    Springer International Publishing Switzerland, 2016年, [分担執筆]
  • 生物薬剤学(改訂第3版)
    原島秀吉, 生理学的モデル
    南江堂, 2015年, [共著]
  • 公益社団法人日本薬剤学会薬剤学概史 私はこう見る120人による俯瞰図
    原島秀吉, 薬剤学発展に影響をお呼びした会議、セミナーと国立大学 北海道大学
    公益社団法人日本薬剤学会, 2015年, [共訳]
  • Mitochondrial Medicine, Volume II, Manipulating Mitochondrial Function. (Methods in Molecular Biology 1265 Springer Protocols)
    山田勇磨; 原島秀吉, Targeting the mitochondrial genome via a dual function MITO-oter: Evaluation of mtDNA levels and mitochondrial function
    Humana Press, 2015年, [分担執筆]
  • 遺伝子治療・診断の最先端技術と新しい医薬品・診断薬の開発
    秋田英万; 原島秀吉, 非ウイルスベクターでの適切なプロトコール、トラブル対策
    技術情報協会, 2014年, [分担執筆]
  • 薬剤学実験法必携マニュアル~Pharmaceutical Scientistのために~ II 生物薬剤学
    秋田英万; 原島秀吉, 7.1 核酸製剤
    南江堂, 2014年, [分担執筆]
  • 非経口投与製剤の開発と応用~次世代型医薬品の新規投与携帯の開拓を目指して~
    中村孝司; 梶本和昭; 原島秀吉, 遺伝子の体内動態・細胞内動態制御システムの構築とその最適化
    株式会社シーエムシー出版, 2013年, [分担執筆]
  • 応用が拡がるDDS
    秋田英万; 山田勇磨; 畠山浩人; 林泰弘; 原島秀吉, 第6章 遺伝子治療におけるDDS. 1. 非ウイルスベクター
    株式会社エヌ・ティー・エス, 2013年, [分担執筆]
  • 毛髪再生の最前線
    小暮健太朗; 原島秀吉, 人工遺伝子デリバリーシステムMENDによる毛孔内へのBMPR1A遺伝子の送達
    株式会社シーエムシー出版, 2013年, [分担執筆]
  • ファインケミカルシリーズ、ペプチド医薬の最前線
    梶本和昭; 原島秀吉, 第3章 ペプチド創薬に向けてー製剤化・安定化・投与法ー、8 脂肪血管指向性ペプチドを搭載したナノデバイスによる肥満治療の新戦略
    シーエムシー出版, 2012年
  • 先端バイオマテリアルハンドブック
    小暮健太朗; 林泰弘; 原島秀吉, 第3章 DDS用バイオマテリアル 第5節多機能性エンベロープ型ナノ構造体による遺伝子デリバリー
    株式会社エヌ・ティー・エス, 2012年, [分担執筆]
  • ドラッグデリバリーシステム(高分子学会 編集)
    中村孝司; 原島秀吉, 遺伝子治療DDS」最先端材料システムone pointシリーズ(9巻)
    共立出版, 2012年, [分担執筆]
  • 新薬剤学
    原島 秀吉
    南江堂, 2011年12月07日, 4524402861, 458, [編者(編著者)]
  • 新薬剤学
    原島 秀吉
    南江堂, 2011年, 9784524402861, 日本語
  • バイオとナノの融合〈2〉新生命科学の応用
    居城 邦治; 有賀 寛万; 五十嵐 靖之; 伊藤 悦朗; 上出 利光; 長田 義仁; 小野江 和則; 小林 淳一; 志田 壽利; 高田 賢三; 田村 守; 西村 伸一郎; 野口 昌幸; 畠山 昌則; 原島 秀吉; 松田 彰; 研究成果編集委員会
    北海道大学図書刊行会, 2007年03月30日, 4832981781, 355, [共著]
  • バイオとナノの融合〈1〉新生命科学の基礎
    高畑 雅一; 原島 秀吉; 田中 勲; 辻井 薫; 出村 誠; 永井 健治; 中村 貴義; 山口 淳二; 守内 哲也; 金城 政孝; 芳賀 永; 長田 義仁; 稲垣 冬彦; 山下 正兼; 田中 一馬; 笹木 敬司; 下村 政嗣; 鈴木 範男; 土田 義和; 研究成果編集委員会
    北海道大学図書刊行会, 2007年03月30日, 4832981773, 363, [共著]
  • ウイルスを用いない遺伝子導入法の材料,技術,方法論の新たな展開-先端生物医学研究・医療のための遺伝子導入テクノロジー
    原島 秀吉; 田畑 泰彦; 原島 秀吉; 田畑 泰彦
    メディカルドゥ, 2006年04月15日, 4944157355, 268, 日本語, [共編者(共編著者)]
■ 講演・口頭発表等
  • Multifunctional Envelope-type Nano Device for Gene Delivery: Application for Nanomedicine
    原島秀吉
    大塚創薬化学シンポジウム2018、徳島, 2018年11月21日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • 多機能性エンベロープ型ナノ構造体の創製と核酸ナノ医療への展開
    原島秀吉
    日本薬剤学会経口吸収FG第8回合宿討論会、小樽, 2018年10月29日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • Multifunctional Envelope-type Nano Device for Gene Delivery: Concept and Application for Nanomedicine
    原島秀吉
    13th France-Japan Drug Delivery System Symposium、Mie, Japan, 2018年10月22日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • 最新のナノDDS戦略
    原島秀吉
    第16回社内勉強会(ナノキャリア), 2018年09月26日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • Multifunctional Envelope-type Nano Device for Gene Delivery: Concept and Clinical Application for Nanomedicine
    原島秀吉
    The 19th International Pharmaceutical Technology Symposium, Antalya, Turkey, 2018年09月17日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • Multifunctional Envelope-type Nano Device for Nanomedicine
    原島秀吉
    The 5th International Biomaterials Symposium, Chanchun, China, 2018年08月25日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • Controlled Intracellular Trafficking and Selective Tissue Targeting by Multifunctional Envelope-type Nano Device for Nucleic Acid Nanomedicine
    原島秀吉
    The 45th CRS Annual Meeting & Exposition, New York, USA, 2018年07月23日, 英語, シンポジウム・ワークショップパネル(指名)
    [招待講演], [国際会議]
  • リポソームからの薬物放出と殺細胞効果の関係について
    原島秀吉
    第6回事例報告会、製剤種差検討会、京都, 2018年07月04日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • 多機能性エンベロープ型ナノ構造体の開発とナノ医療への展開:ナノ医療の現状と今後の展開
    原島秀吉
    日本薬剤学会第33回年会、学術シンポジウム:微粒子製剤設計と医薬品開発~現状と将来展望~、静岡, 2018年05月30日, 日本語, シンポジウム・ワークショップパネル(指名)
    [招待講演], [国内会議]
  • 多機能性エンベロープ型ナノ構造体の開発と核酸ナノ医薬の展望
    原島秀吉
    核酸分析化学特論、広島大学大学院医歯薬保健学研究科, 2018年05月17日, 日本語, 公開講演,セミナー,チュートリアル,講習,講義等
    [招待講演], [国内会議]
  • DDSの現状と核酸医薬への展望
    原島秀吉
    徳島大学特別講演会、徳島, 2018年02月05日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • リポソーム研究の現状と産学官の連携で目指すDDS
    原島秀吉
    講演会(小野薬品工業株式会社、水無瀬研究所), 2017年12月18日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • Multifunctional Envelope-type Nano Device for Gene Delivery: Concept and Application for Nanomedicine
    原島秀吉
    3rd International Conference on Biomaterials Science in Tokyo, 2017年11月28日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • 多機能性エンベロープ型ナノ構造体の創製とナノ医療への展開
    原島秀吉
    講演会(秋吉ERATO)、京都, 2017年11月24日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • EPR効果はヒトでも有効か?:DoxilとDoxorubicinのメタ解析から
    原島秀吉
    製剤種差検討会、第3回事例報告会、東京, 2017年06月30日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • 多機能性エンベロープ型ナノ構造体の創製とナノ医療への展開
    原島秀吉
    日本薬剤学会第32年会、ラウンドテーブル2、核酸・遺伝子医薬の臨床応用に立ちはだかる障壁について考える、大宮, 2017年05月12日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • 多機能性エンベロープ型ナノ構造体の創製とナノ医療への応用
    原島秀吉
    社内講演会(アンジェス)、大阪, 2017年04月05日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • Multifunctional Envelope-type Nano Device for Nanomedicine
    原島秀吉
    AsiaTIDES: Oligonucleotide & Peptide Therapeutics, Kyoto, 2017年02月21日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • 多機能性エンベロープ型ナノ構造体の開発とナノ医療への展開
    原島秀吉
    薬物動態懇話会 第39年会、薬物動態研究と繋がるサイエンス~DDSと毒性バイオマーカーを薬物動態から俯瞰する~、浜松, 2016年11月11日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • Multifunctional Envelope-type Nano Device for Gene Delivery: Concept and Application for Nanomedicine
    原島秀吉
    12th France-JapanDrug Delivery System Symposium, Paris, 2016年10月10日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • Multifunctional Envelope-type Nano Device for Gene Delivery: Concept and Application for Nanomedicine
    原島秀吉
    18th International Pharmaceutical Technology Symposium, Antalya, Turkey, 2016年09月21日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • 多機能性エンベロープ型ナノ構造体の創製とナノ医療への展開
    原島秀吉
    ポスト片岡CRESTミニシンポジウム、川崎, 2016年07月08日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • Multifunctional Envelope-type Nano Device for Gene Delivery: Concept and Application for Nanomedicine
    原島秀吉
    30th Anniversary Symposium of The Nagai Foundation Tokyo、“Link to the Past and Bridge to the Future”, 2016年07月07日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • 多機能性エンベローブ型ナノ構造体の創製とナノ医療への展開
    原島秀吉
    第31回日本薬剤学会、薬剤学会賞受賞講演、岐阜, 2016年05月20日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • Multifunctional Envelope-type Nano Device for Gene Delivery: Concept and Application for Nanomedicine
    原島秀吉
    14th European Symposium on Controlled Drug Delivery, Egmond, Netherland, 2016年04月13日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • 多機能性エンベロープ型ナノ構造体の開発とナノ医療への展開
    原島秀吉
    講演会(理研杉山雄一研究室)、横浜, 2016年01月08日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • 多機能性エンベロープ型ナノ構造体の開発とナノ医療への展開
    原島秀吉
    第1回日本核酸医薬学会年会 シンポジウム, 2015年12月02日, 日本語, シンポジウム・ワークショップパネル(指名)
    [招待講演], [国内会議]
  • 大学発ナノ医薬品の創出拠点の形成と早期実用化
    原島秀吉
    日本薬物動態学会第30年会 シンポジウム-8、船堀, 2015年11月12日, 日本語, シンポジウム・ワークショップパネル(指名)
    [招待講演], [国内会議]
  • 多機能性エンベロープ型ナノ構造体の創製とナノ医療への展開
    原島秀吉
    講演会、徳島大学、徳島, 2015年10月16日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • Multifunctional lipid-based systems for drug and gene delivery
    原島秀吉
    20th International Symposium on Microencapsulation, Boston, USA, 2015年10月01日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • Activities of Education and Researches at Faculty of Pharmaceutical Sciences in Hokkaido University
    原島秀吉
    The UP-HU Joint Workshop for Academic Exchange, university of Pretoria, South Africa, 2015年09月17日, 英語, 公開講演,セミナー,チュートリアル,講習,講義等
    [招待講演], [国際会議]
  • Multifunctional envelope-type nano device for gene delivery: Concept and application for Nanomedicine
    原島秀吉
    International Seminar on Pharmaceutics 2015, Bandung, Indonesia, 2015年08月04日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • Multifunctional envelope-type nano device for gene delivery: Concept and application for Nanomedicine
    原島秀吉
    Biomaterials International 2015, Kenting, Taiwan, 2015年06月02日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • アカデミア発DDSによる医療イノベーション
    原島秀吉
    日本薬剤学会第30年会、学術シンポジウム-3:アカデミア発DDS製剤シーズによる医療イノベーションを考える、長崎, 2015年05月22日, 日本語, シンポジウム・ワークショップパネル(指名)
    [招待講演], [国内会議]
  • Multifunctional envelope-type nano device for gene delivery: Concept and application for Nanomedicine
    原島秀吉
    The 5th Asian Biomaterials Congress, Taipei, Taiwan, 2015年05月07日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • 日本発革新的ナノ医薬品の創出を目指して
    原島秀吉; 秋田英万; 加藤くみ子; 松村保広; 片岡一則
    日本薬学会第135年会 シンポジウム:健康・医療戦略推進法の与えるインパクト~先端的研究開発の実現に向けて~、神戸学院大学, 2015年03月28日, 日本語, シンポジウム・ワークショップパネル(指名)
    [招待講演], [国内会議]
  • 多機能性エンベロープ型ナノ構造体の創製とナノ医療への展開
    原島秀吉
    第114回 医工学フォーラム、京都大学再生医科学研究所, 2014年12月08日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • 多機能性エンベロープ型ナノ構造体による遺伝子デリバリーとナノ医療への展開
    原島秀吉
    日本認知症学会、シンポジウム6:核酸創薬とドラッグデリバリーシステムの革新による認知症の遺伝子治療への道、横浜, 2014年11月29日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • 11) Hideyoshi Harashima, Multifunctional Envelope-type Nano Device for Nanomedicine
    原島秀吉
    Workshop on Global Future Healthcare, on Materials Science and Engineering, Jointly Organized by Nanyang Technological University (NTU) and Hokkaido University, 2014年10月21日, 英語, 公開講演,セミナー,チュートリアル,講習,講義等
    [招待講演], [国際会議]
  • Multifunctional Envelope-type Nano Device for gene delivery: Concept and application for Nanomedicine
    原島秀吉
    The 11th France - Japan DDS Symposium, Awaji, Tokushima, 2014年10月07日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • 多機能性エンベロープ型ナノ構造体の創製とナノメディシンへの応用
    原島秀吉
    化学とマイクロ・ナノシステム学会、第30回研究会、北海道大学, 2014年10月02日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • 多機能性エンベロープ型ナノ構造体の開発とナノメディシンへの展開
    原島秀吉
    第3回創薬イノベーション懇話会in札幌, 2014年09月26日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • 遺伝子・核酸デリバリーシステムの開発とナノメディシンへの展開
    原島秀吉
    平成26年度 未踏科学サマー道場、次世代バイオマテリアルとその応用、湘南, 2014年08月31日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • Multifunctional envelope-type nano device for gene delivery: Concept and application for Nanomedicine
    原島秀吉
    Current and Future Aspect of Drug Delivery, National Yang-Ming University, Taiwan, 2014年08月08日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • 「血管を標的とする革新的医薬品分子送達方の基盤技術の確立」のまとめと「血管を標的とするナノ医療の実用化に向けた拠点形成」へ向けて
    原島秀吉
    公開シンポジウム「血管を標的とするナノ医療の実用化に向けた拠点形成、北海道大学, 2014年06月27日, 日本語, シンポジウム・ワークショップパネル(指名)
    [招待講演], [国内会議]
  • MITO-Porter: Membrane-type nano device for mitochondrial drug delivery via membrane fusions
    原島秀吉
    Euromit 2014, Tampere, Finland, 2014年06月19日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • 多機能性エンベロープ型ナノ構造体の創製とナノ医療への展開
    原島秀吉
    Biotech2014、BIO-3:ナノテクノロジーがもたらす革新的医薬品開, 2014年05月15日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • Breakthrough technology based on controlled intracellular trafficking of functional nucleic acids with MEND
    原島秀吉
    5th FIP Pharmaceutical Sciences World Congress (PSWC), APSA Symposium, Intracellular drug trafficking and targeting, Melbourne, Australia, 2014年04月15日, 英語, 口頭発表(招待・特別)
    [招待講演], [国際会議]
  • 多機能性エンベロープ型ナノ構造体の創製とナノ医療への展開
    原島秀吉
    講演会、日本化薬, 2014年01月29日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
  • 多機能性エンベロープ型ナノ構造体の創製とナノ医療への展開
    原島秀吉
    第10回レギュラトリーサイエンス学会シンポジウム、~ナノメディシンの実現に向けて~、東京, 2014年01月16日, 日本語, 口頭発表(招待・特別)
    [招待講演], [国内会議]
■ 所属学協会
  • 日本核酸医薬学会
  • AAPS: American Association of Pharmaceutical Sciences
  • 日本癌学会
  • Controlled Release Society
  • 日本薬物動態学会
  • 日本DDS学会
  • 公益社団法人日本薬学会
  • 公益社団法人日本薬剤学会
■ 共同研究・競争的資金等の研究課題
  • LNPとスマートポリマーが創るコアシェル構造を有する活性型mRNA送達システム
    科学研究費助成事業
    2026年02月27日 - 2028年03月31日
    原島 秀吉
    日本学術振興会, 基盤研究(S), 北海道大学, 25K24570
  • LNPとスマートポリマーが創るコアシェル構造を有する活性型mRNA送達システム
    科学研究費助成事業
    2023年04月12日 - 2028年03月31日
    原島 秀吉; 佐藤 悠介; 中村 孝司; 山田 勇磨; 西山 伸宏; 内田 智士
    日本学術振興会, 基盤研究(S), 北海道大学, 23H05451
  • 組織選択的に核酸送達可能な高分子ー脂質ハイブリッドナノ粒子の戦略的創出
    科学研究費助成事業 挑戦的研究(萌芽)
    2022年06月30日 - 2024年03月31日
    磯野 拓也; 原島 秀吉; 佐藤 悠介; 佐藤 敏文
    日本学術振興会, 挑戦的研究(萌芽), 北海道大学, 22K19907
  • 肝疾患治療のための遺伝子送達システムの開発 とがん治療
    科学研究費助成事業 特別研究員奨励費
    2021年04月28日 - 2023年03月31日
    原島 秀吉; YOUNIS MAHMOUD
    日本学術振興会, 特別研究員奨励費, 北海道大学, 21F21105
  • 律速段階の解明に基づいたウイルスを凌駕する革新的医薬分子送達システムの創製
    科学研究費助成事業 基盤研究(A)
    2019年04月01日 - 2023年03月31日
    原島 秀吉; 佐藤 悠介; 中村 孝司; 山田 勇磨
    日本学術振興会, 基盤研究(A), 北海道大学, 19H01170
  • 糖脂質に対するサルT細胞応答の実証に基づく、新たな抗結核ワクチンの開発
    科学研究費助成事業 基盤研究(B)
    2012年04月01日 - 2015年03月31日
    杉田 昌彦; 五十嵐 樹彦; 中村 孝司; 原島 秀吉
    世界人口の約3分の1が結核菌に感染しており、現行唯一の抗結核ワクチンであるBCGに代わる新たなワクチン開発が社会的急務である。研究代表者は結核菌脂質に対する免疫応答について、第一線の研究を進めてきた。本研究ではこの知見を活用し、脂質をベースにした新しいコンセプトの抗結核ワクチン開発に向けて、その研究基盤の確立を目指した研究を進めた。その結果、モルモットにおいて結核を制御する新しい脂質ワクチンの原型を確立できた。またサルを用いた実験から脂質に対する免疫応答を効率的に誘導できるプロトコールを見いだした。以上から抗結核脂質ワクチン開発の基盤を確立できた。
    日本学術振興会, 基盤研究(B), 京都大学, 24390255
  • 肝臓中microRNAの発現変動が薬物代謝酵素活性に及ぼす影響
    科学研究費助成事業 挑戦的萌芽研究
    2012年04月01日 - 2015年03月31日
    中島 美紀; 木村 健人; 小田 祐輝; 佐藤 悠介; 原島 秀吉
    ヒト初代培養肝細胞にリファンピシンを処置することにより40種類のmiRNAの発現が2倍以上に変化し、それらが標的遺伝子の発現変化をもたらしている可能性が示された。マウスにmiRNAに対するアンチセンスオリゴを尾静注し、肝臓中の発現をノックダウンすると、薬物代謝酵素活性が変化したことから、miRNAが薬物代謝能の制御に重要な役割を担っていることをin vivoで明らかにした。
    日本学術振興会, 挑戦的萌芽研究, 金沢大学, 24659074
  • BCG搭載ナノ粒子の細胞内動態制御に基づいた革新的膀胱癌治療システムの創製
    科学研究費助成事業 挑戦的萌芽研究
    2013年04月01日 - 2014年03月31日
    原島 秀吉
    日本学術振興会, 挑戦的萌芽研究, 北海道大学, 25670007
  • MENDで拓く遺伝子治療への道:遺伝子の運び屋からナノマシンへ
    科学研究費助成事業 基盤研究(S)
    2010年05月31日 - 2014年03月31日
    原島 秀吉; 山田 勇磨; 中村 孝司; 兵藤 守; 馬場 嘉信; 篠原 康雄; 紙谷 浩之; 渡慶次 学; 松尾 保孝; 秋田 英万
    パッチワーク法による新しいMEND構築方法を確立し一枚膜でコア粒子をパッケージする新しい方法を開発し、平均粒子径が25nm程度でゼータ電位が-40mV程度の構造体を得ることに成功し、P-MENDと命名した。D-MEND法と組み合わせることでPD- MEND(3枚膜構造)を構築したところ、市販の試薬より高い活性を示した。マイクロ流体デバイスを開発し、最小粒径30nmのMENDを作製することに成功した。一方でマイクロ流路作製についての検討し、ナノインプリント手法によりガラスマイクロ流路の量産が可能であることをしめした。また、シースフローと電場を利用したマイクロフリーフロー電気泳動デバイスの構造・分離条件の最適化を行い、MEND精製に適用することでMENDの定性的かつ定量的評価法を確立した。KALAペプチドを導入した脂質膜封入型ナノ粒子にがん抗原等をコードした遺伝子を封入することで、抗腫瘍活性を得ることに成功した。また、本粒子は細胞に対し免疫活性化効果を有することを示し、その機構に細胞質内DNAセンサーが関与することを示唆する結果を得た。酵素耐性RNAアプタマーの単離に世界で始めて成功した。Mt移行性ペプチドを搭載したMTS-MITO-Porterを構築し、生細胞内での選択的Mt送達システムを開発し、MTS-MITO-Porterは従来型MITO-Porterと比較してミトコンドリア移行能が飛躍的に上昇した。GAL4とVP16の融合蛋白質を用いる自己活性化システムを構築し、reporterプラスミドDNAの単独投与に比べて数十倍にルシフェラーゼ活性が上昇した。アンチセンスRNA (ASO)をMITO-Porterを用いて細胞Mtに送達し、ミトコンドリアmRNAを40%抑制し、さらに標的mRNAがコードする内因性Mtタンパク質の発現量が低下した。
    日本学術振興会, 基盤研究(S), 北海道大学, 22229001
  • インテリジェント人工核酸を搭載したナノDDSによる革新的分子標的治療薬の研究
    科学研究費助成事業 基盤研究(S)
    2009年05月11日 - 2014年03月31日
    佐々木 茂貴; 原島 秀吉; 兵藤 守; 永次 史; 新藤 充; 野村 政壽
    本研究では次世代核酸医薬の基盤構築を目的に疾患遺伝子を標的化するナノ分子標的薬の創製を目指し、 核酸医薬の設計、標的遺伝子の決定、目的臓器への輸送、疾患モデル動物による検証について融合研究を実施した。
    miRNA-375標的とする新規人工核酸をβ-MENDに内包し、膵β細胞株MIN6に輸送しグルコース刺激によるインスリン分泌を増加させた。ボンクレキン酸誘導体をMITO-Porterで輸送することでアポトーシス抑制効果を著しく増強した。Drp1に対するsiRNAを搭載した肝指向性ナノエンベロープ (YSK-MEND)をマウス動物実験を行い、核酸医薬による新しい糖尿病治療の可能性を示した。
    日本学術振興会, 基盤研究(S), 九州大学, 21229002
  • in vivoで機能するがん治療用MENDの創製
    科学研究費助成事業 特別研究員奨励費
    2010年 - 2012年
    原島 秀吉; MOHAMMAD A.E.; AYMANELSAYED Mohammad; AYMAN EL-SAYED Mohammad
    昨年度までの研究により、元来エンドソーム脱出を促進するための素子として開発されてきたGALAペプチドがリボソームの肺移行性を促進する有力な素子であることを見いだしている。さらに、その機構を明らかとした結果、本粒子は血液中を凝集せずに循環し、さらにその細胞への取り込みには、細胞膜上のシアル酸末端糖鎖が関与することを明らかとしている。一方、これまで、我々は、脳毛細血管内皮細胞を用いた検討によりApical側(血管側)からBasal側(脳実質側)までのリボソームの輸送を可能とするペプチド(Clone95)の同定に成功している。本素子は、血管内皮細胞のカベオラ経路を標的化する素子として期待される。そこで、GALAペプチドとClone95の併用により、肺毛細血管内皮細胞を透過し、上皮細胞まで送達可能なシステムの構築を試みた。共焦点レーザー顕微鏡により血管透過を可視化するため、蛍光標識されたリボソームの肺内分布を解析した。GALA修飾リボソームの殆どが血管内皮のシグナルと共局在する様子が観察された。一方、さらにCL95を修飾した粒子においては、赤色単独で観察される点が観察された。CL95の修飾により肺組織内における分布が変化し、血管から一部上皮細胞まで移行することが示唆された。本上皮細胞への移行を機能の点から解析するために、本粒子内に上皮細胞の特異的マーカーであるEpCAMに対するsiRNAを導入したリボソーム粒子を構築した。本粒子を2mg/kgとなるように尾静脈内投与し、その後の遺伝子ノックダウン効果を解析した。従来のGALA-MENDに関しては、遺伝子ノックダウン効果が認められなかったのに対し、CL95/GALA-MENDに関しては、まだ弱いながらも有為な遺伝子ノックダウン効果が認められた。これらの結果から、CL95/GALA-MENDは、血中投与により肺の実質細胞(上皮細胞)を標的化可能なシステムであることが示唆された。
    日本学術振興会, 特別研究員奨励費, 北海道大学, 10F00421
  • スイッチ機能を有する人工遺伝子デリバリーシステムの創製
    科学研究費助成事業 挑戦的萌芽研究
    2010年 - 2012年
    原島 秀吉; 梶本 和昭; 林 泰弘; 秋田 英万
    遺伝子デリバリーシステムが標的細胞とinteractiveに情報交換を行い、細胞の協力を得ながら遺伝子発現効率を飛躍的に促進できるシステムを開発することを目的とした。本研究ではこれをスイッチ機能と呼び、KALA修飾リポソームをモデルとして、スイッチ機能を担う遺伝子群の探索と同定を行った。さらに、スイッチ機能を搭載した人工遺伝子デリバリーシステムを開発し、invivoで機能するシステムへと展開した。
    日本学術振興会, 挑戦的萌芽研究, 北海道大学, 22659006
  • 糖脂質特異的免疫応答に着目した、新たな抗結核ワクチンノ開発
    科学研究費助成事業 基盤研究(B)
    2009年 - 2011年
    杉田 昌彦; 原島 秀吉; 松永 勇
    生体内増殖菌が宿主由来のグルコースを基質として産生するグルコースモノミコール酸によって誘起されるT細胞応答を、モルモットを用いて検証した。その結果、グルコースモノミコール酸が感作個体において遅延型アレルギー応答を誘起することを初めて実証した。さらに、グルコースモノミコール酸によって誘起されるメモリー応答は、TH1サイトカイン産生に極度にシフトしたものであった。以上より、グルコースモノミコール酸が新しいタイプの結核ワクチンとして機能することが考えられた。
    日本学術振興会, 基盤研究(B), 京都大学, 21390304
  • Programmed Activationに基づく人工DNAワクチンの創製
    科学研究費助成事業 基盤研究(A)
    2010年 - 2010年
    原島 秀吉
    日本学術振興会, 基盤研究(A), 北海道大学, 22240057
  • ヌクレアーゼ抵抗性修飾核酸を搭載した多機能性ナノ構造体による新規核酸医薬の創製
    科学研究費助成事業 基盤研究(S)
    2006年 - 2010年
    松田 彰; 原島 秀吉; 南川 典昭
    (1)MENDに搭載したヌクレアーゼ抵抗性2'-O-methyl-4'-thioribonucleosidesを含むsiRNA(標的:ルシフェラーゼ遺伝子,apoB遺伝子)はin vitroで作用の持続が,in vivoで血中コレステロール濃度の低下が観察された。この時,副作用となる自然免疫系を賦活化しなかった。(2)ヌクレアーゼ抵抗性ベクター作製のためにPCRによりdSNTPsを取り込ませた。2種類までのdNTPsをdSNTPsに置換できたが,それ以上の置換では増幅しなかった。そこで,化学合成した4'-thioDNA(42mer)を酵素的に組み込んだルシフェラーゼ発現ベクターを構築し,NIH3T3細胞での発現を調べたところ,天然型ベクターと比較して20-40%ではあるが活性発現が見られた。(3)MEND をマトリックスメタロプロテアーゼで切断されるPEG修飾しPPD-MENDを作製した。また,pH応答性膜融合ペプチドGALAを短鎖化したshGALA-MENDを作製した。これらは,細胞内取り込みの増加,エンドソーム脱出効率の向上によりin vitroのみならずin vivoでの抗腫瘍性を増強した。
    日本学術振興会, 基盤研究(S), 北海道大学, 18109001
  • がん選択的多機能性エンベロープ型ナノ構造体の開発とがん治療への応用
    科学研究費助成事業 特定領域研究
    2008年 - 2009年
    原島 秀吉; 紙谷 浩之; 山田 勇磨; 畠山 浩人; 馬場 嘉信; 秋田 英万
    我々が独自に開発したin vivoがん送達型多機能性エンベロープ型ナノ構造体(PPD-MEND)に、がん細胞で選択的に発現している遺伝子に対するsiRNAを搭載し、抗腫瘍効果を誘起することができ、かつ、安全性の高い人工遺伝子デリバリーシステムを開発し、がん治療へと応用することを最終目標とした。その結果、shGALA修飾PEG-MENDは、静脈内投与により腫瘍組織でmRNAをノックダウンし抗腫瘍効果を誘起できることがわかった。
    日本学術振興会, 特定領域研究, 北海道大学, 20015003
  • 抗原提示バランスとアジュバントの制御に基づいたオーダーメイド癌ワクチン
    科学研究費助成事業 挑戦的萌芽研究
    2008年 - 2009年
    原島 秀吉; 小暮 健太朗; 秋田 英万; 山田 勇磨
    本年度は、アジュバントのトポロジー制御の観点からアジュバント搭載型ナノ構造体の構築とその機能評価を行った。まず認識受容体の局在が異なる2種類のアジュバントを搭載したMENDの構築を行い、細胞性免疫誘導効率への影響を調べた。polyI:Cはエンドソーム内のTLR3及び細胞質中のMda5により認識され、CpG-ODNはエンドソーム内のTLR9によって認識される。それ故、細胞への取り込み後に認識されるように、MENDの内部に抗原と共に内封した。polyI:CもしくはCpG-ODNを内封したMENDをマウスに皮下免疫し、CTL活性を測定した結果、polyI:C内封MENDを免疫したマウス群では、CpG-ODN搭載MENDを免疫した群と比較して著しく高いCTL活性の誘導が認められた。
    次にpolyI:C搭載MENDとpolyI:C/R8複合体のCTL活性誘導能を比較した。その結果、polyI:C搭載MENDを免疫したマウス群の方が高いCTL活性及び抗腫瘍活性を示した。MEND内にpolyI:Cを内封することで、効率良くTLR3及びMda5に認識され、強力な細胞性免疫が誘導されたと考えられる。このことからアジュバントの機能を十分に発揮させるためには、そのトポロジーを考慮することが重要であることが示唆された。
    またpolyI:CをMEND内に内封することでアジュバント投与時の炎症等の副作用が軽減されるかを調べた。polyI:C搭載MEND及びpolyI:C単独をマウス尾静脈から投与し、2時間後の炎症性サイトカインIL-6の産生を調べた。その結果、polyI:C搭載MEND投与群では、polyI:C単独投与群と比較してIL-6産生の著しい抑制が認められた。
    以上の結果より、効率的な細胞性免疫誘導及び副作用の軽減には、アジュバントのトポロジーを考慮したワクチン設計が重要であることが明らかになった。
    日本学術振興会, 挑戦的萌芽研究, 北海道大学, 20659020
  • SIRNA搭載多重型ナノ構造体の開発と2型糖尿病関連遺伝子群の機能解析
    科学研究費助成事業 基盤研究(A)
    2006年 - 2009年
    原島 秀吉; 紙谷 浩之; 山田 勇磨; 馬場 嘉信; 秋田 英万; 小暮 健太朗; 中谷 明弘
    本研究は、肝臓、筋肉、脂肪組織などの主要標的組織において2型糖尿病発症の前後で遺伝子発現が変動している遺伝子群の中で、サンプリングが容易な白血球においてもその変動を反映する遺伝子群を診断用候補遺伝子として網羅的に探索した。同時に、静脈内投与により、肝臓で高い遺伝子発現を誘導できる革新的送達システムの開発に成功した。さらに、ナノ粒子が血管内皮細胞を透過する過程を定量的に評価する系世界に先駆けて確立し、トランスサイトーシス可能なリガンドの探索にも成功した。
    日本学術振興会, 基盤研究(A), 北海道大学, 18200032
  • 腫瘍選択的なin vivo用人工遺伝子デリバリーシステムの開発
    科学研究費助成事業 特別研究員奨励費
    2007年 - 2008年
    原島 秀吉; KHALIL A. Ikramy
    オクタアルギニン(R8)は、細胞膜透過性ペプチドとして優れた細胞送達性を示すことが明らかになっている。R8で表面修飾した多機能性エンベロープ型ナノ構造体(MEND)は強力な遺伝子導入力を示し、優れたエンドソーム脱出能があることを報告している。平成20年度は、R8のエンドソーム脱出機構をオクタリジン(K8)と比較することにより解析した。その結果、R8とK8は共にマクロピノサイトーシスを誘起して同程度の効率で細胞内へ侵入することが明らかになった。エンドソーム脱出機構を両者で比較したところ、R8の方がK8よりも効率的に脱出することが明らかとなった。両者の脱出機構を解明するため、エンドソームの酸性化を阻止するバフィロマイシン存在下で比較したところ、R8は感受性を示し、K8は非感受性であった。In vitroの実験系で、FRETの原理を用いて膜融合能を両者で比較したところ、K8-リポソームは中性条件下でのみ膜融合を示し、R8-リボソームは中性でも酸性でも膜融合を示した。この結果は、細胞系の実験結果と良く対応し、R8-リポソームはマクロピノサイトーシスで取込まれた後、エンドソーム内が酸性になっても効率的に脱出できるのに対して、K8-リポソームは酸性になると脱出できないことが明らかとなった。本研究成果は、細胞膜透過性ペプチドの細胞内動態特性における新たなメカニズムの発見であり、この領域で高く評価されている。
    さらに、韓国のChung教授と共同で、ソルビトールを基盤とした新しい細胞膜透過性素子(G8)に基づいたデリバリーシステムの開発を行ない、G8でMENDの表面を修飾することにより、高い遺伝子発現が可能となった。また、本新規デバイスは、pDNAやsiRNAをコア形成にも有用であることを初めて明らかにした。
    日本学術振興会, 特別研究員奨励費, 北海道大学, 07F07195
  • 非分裂細胞で高効率に遺伝子発現可能な人工遺伝子デリバリーシステムの創製
    科学研究費助成事業 特別研究員奨励費
    2007年 - 2008年
    原島 秀吉; SHAHEEN Sharif
    人工遺伝子ベクターのボトルネックとして、遺伝子発現効率の悪さが挙げられる。ウイルスベクターは発現効率が高いことが知られているが、その要因は主に、遺伝子の核移行後の発現効率にあることを明らかとした。遺伝子の核内動態を支配する要因としては、遺伝子のベクターからの脱凝縮化か大きく関与すると考えられる。そこで、細胞内、核内における脱凝縮化効率の定量化を試みるため、DNAを量子ドットでラベル化し、FRETの原理を用いて、脱凝縮化過程を解析した。蛍光プローブのローダミンラベル化ポリカチオンと量子ドットラベル化したDNAを凝縮する際の条件を最適化することで、効率的なFRETを検出できる条件を見出すことに成功した。また、本凝集コア粒子を搭載した多機能性エンベロープ型ナノ構造体(MEND)によって細胞内へ導入することにより、FRETの原理を用いて、核内の脱凝縮化過程を可視化し、脱凝縮化効率を定量的に評価することに成功した。さらに、核内の領域を核内DNAの染色像の強弱よりユークロマチン領域とヘテロクロマチン領域に分離し、各コンパートメントにおける脱凝縮効率を定量化することに成功した。現在本研究に関する論文の投稿準備を行っている。
    日本学術振興会, 特別研究員奨励費, 北海道大学, 07F07452
  • がん選択的多機能性エンベロープ型ナノ構造体の開発とがん遺伝子治療への応用
    科学研究費助成事業 特定領域研究
    2006年 - 2007年
    原島 秀吉; 紙谷 浩之; 秋田 英万; 山田 勇磨; 小暮 健太朗
    我々は、多機能性エンベロープ型ナノ構造体(MEND)の開発に成功し、細胞膜透過機能を有するオクタアル,ギニン(R8)修飾したR8-MENDは、培養細胞系においてアデノウイルスと同等の遺伝子発現を示すことを明らかにした(Khalil,et al.Gene Ther.2007)。さらに、in vivoでがん組織選択的な遺伝子デリバリーシステムを開発するために、がん組織内で特異的に発現するペプチダーゼ(MMP)により切断されてPEGを脱離し、がん細胞内へ侵入するという新しい戦略(PEG-peptide-DOPE(PPD)-MEND)を設計し,本コンセプトが機能するかをin vitro系で検証した。その結果、PPD-MENDはMMP依存的にPEGが解離し、高い遺伝子導入を誘起できることが明らかとなった。さらに、本PPD-MENDをマウスに静脈内投与すると、血中滞留性を示すと同時に、腫瘍組織へ有為な送達が可能であり、in vivoにおける遺伝子発現にも成功した(Hatakeyama,et al.Gene Ther.2007)。さらに、PPD-MENDにsiRNAを搭載し、in vivoで腫瘍組織へ標的化可能、かつ、がん細胞で発現している遺伝子(ルシフェラーゼ遺伝子)を選択的にノックダウンすることにも成功した。本、PPD-MENDに抗腫瘍効果を誘起するsiRNAを搭載することにより、がん治療への道が拓かれることが期待できる。
    日本学術振興会, 特定領域研究, 北海道大学, 18015004
  • DNAワクチン用多機能性エンベロープ型ナノ構造体の構築
    科学研究費助成事業 特別研究員奨励費
    2005年 - 2006年
    原島 秀吉; HOMHUAN Atthachai; HOMHUAN ATTHACHAI
    本研究では、アジュバントであり膀胱ガン治療薬として期待されているBCG菌体成分のリポソーム化を検討した。BCG菌体成分は、疎水性部分と親水性部分が複雑に組み合わされた構造をしているため、水溶性溶媒にも有機溶媒にも不溶である。従来、界面活性剤によってミセル化した製剤が用いられているが、小さい粒子としての製剤化が困難であり、治療標的部位(例えば膀胱ガン細胞)への取り込み効率は低いことが問題となっていた。この問題を解決するために、水相と脂質膜相から成るリポソーム化を試みた。さらに、細胞への取り込み効率向上のため、BCG含有リポソーム表面のオクタアルギニンR8ペプチド修飾を行った。構築されたR8/BCGリポソーム(R8/BCG-L)の免疫担当細胞(マウス骨髄由来樹状細胞)への取り込みを調べたところ、R8未修飾リポソームに比較して著しく高い取り込みを示した。BCGをFTSCで、脂質をローダミンでラベル化したR8/BCG-Lを調製し、細胞内動態を共焦点レーザー顕微鏡観察したところ、共に細胞内の取り込まれライソゾームに局在していることが明らかになった。さらに、R8/BCG-Lを取り込んだ細胞におけるアジュバントの効果(成熟化)を、樹状細胞表面のマーカータンパク質CD80,CD86,MHCIIの発現を指標に解析したところ、BCGリポソームでは弱い成熟化が認められ、またR8リポソームでは全く成熟化は誘導されなかったのに対して、R8/BCG-LはLPSに匹敵する高い成熟化誘導能を有することが明らかになった。また、Th1応答性の細胞性免疫誘導の指標であるIL12-p40の分泌をELISAにより評価したところ、R8/BCG-Lにおいて非常に高い分泌が確認された。このように本研究において、従来のミセル化BCG製剤に取って代わる新しい治療製剤としてR8/BCG-Lの開発に成功した(特許出願中)。
    論文投稿中
    Atthachai Homhuan, Kentaro Kogure, Hideyuki Akaza, Shiroh Futaki, Takashi Naka, Yukiko Fujita, Ikuya Yano, Hideyoshi Harashima. New packaging method of mycobacterial cell wall using octaarginine-modified liposomes : enhanced uptake by and immunostimulatory activity of dendritic cells. (submitted)
    日本学術振興会, 特別研究員奨励費, 北海道大学, 05F05169
  • ミトコンドリアを標的とする多重型・多機能性エンベロープ型ナノ構造体の開発
    科学研究費助成事業 萌芽研究
    2005年 - 2006年
    原島 秀吉; 紙谷 浩之; 秋田 英万
    本研究は、蛋白質をミトコンドリア(MT)へ送達するための新規送達システムの開発を目的とした。研究戦略は、蛋白質をコアとするナノ粒子(直径100nm以下)を形成し、細胞膜とMT膜を突破するためにエンベロープを多重構造にする(多重型MEND)。最外層にはオクタアルギニンを、中間層にはMT targeting signal(MTS)を付加し、ナノ粒子のままMT内へ送達するシステムを開発する。
    1)蛋白質を封入したMENDの構築:これまで、多機能性エンベロープ型ナノ構造体(MEND)に遺伝子を封入する方向を確立してきたが、本研究では、蛋白質を封入する方法を確立することに成功した。本MENDは、マクロピノサイトーシスで細胞内へ導入後、封入したGFPを細胞質中に放出可能であることが明らかと成った。
    2)R8-MENDによるミトコンドリアへの送達システムの開発:オクタアルギニン(R8)修飾したMENDはマクロピノサイトーシスにより細胞内へ取込まれ、細胞質中へ脱出し、ミトコンドリアへGFPを送達可能であることが明らかとなった。
    3)MTS結合エンベロープ体の構築:まず、脂質誘導体-MTSの合成を行った。合成は困難を極めたが、純度の高い合成品を得ることに成功した。エンベロープ化したナノ粒子に脂質誘導体一MTSを導入し、MTS結合エンベロープ体を構築した。MTS結合型多重型MENDにより、選択的なミトコンドリア送達が可能となった。
    日本学術振興会, 萌芽研究, 北海道大学, 17659039
  • がん選択的多機能性エンベロープ型ナノ構造体の開発とがん遺伝子治療への応用
    科学研究費助成事業 特定領域研究
    2005年 - 2005年
    原島 秀吉
    本申請研究は、ウイルスベクターを越える安全かつ有効な人工遺伝子デリバリーシステムを開発し、がんの遺伝子治療のための基盤技術を開発することを目的としている。本研究の基本戦略は、Tf/PEG/GALA-MENDとR8-MENDの長所を相乗的に発揮させるため,外側はTf-PEG/GALAで修飾し,コア粒子はR8修飾した多重構造を有するMEND(以下,多重型MEND)を作成し、がん組織選択的に,高い遺伝子発現能力を有する多重型MENDを構築し,in vivo遺伝子ベクターを開発し,がん遺伝子治療へ応用することを最終目的としている。平成17年度は、多重型MENDの構築方法を確立した。構築原理は、基本的にこれまでのMEND同様に、コアとなる凝縮化核酸粒子を脂質膜でコートするのであるが、リポソームの膜融合を利用した。すなわち、1)静電的相互作用によって凝縮化させ正に帯電させた凝縮化核酸ナノ粒子を調製し、2)負電荷脂質を含む小さい一枚膜リポソーム(SUV)を、凝縮化核酸ナノ粒子に静電的に結合させることでナノ粒子表面を覆い、3)酸性化や多価カチオン添加によってSUV同士の膜融合を誘起することで二枚膜を形成させ、ナノ粒子をコートする。得られたものは、二枚膜構造を有するMENDであるので、double-lamellar MEND(DMEND)と命名した。4)DMEND表面に正電荷を付与するため、ステアリル化オクタアルギニン(STR-R8)を添加し表面をR8ペプチドで修飾する。5)正に帯電したDMENDに、負電荷SUVを添加し、2と同様に表面をSUVで覆う。このときのSUVとして、2のSUVと異なる脂質組成を有するものを用いることが可能である。6)3と同様にSUV同士の膜融合を誘起し、DMENDをさらに二枚膜でコートする。得られたものは、四枚膜から構成されたMENDであるので、tetra-lamellar MEND(TMEND)と命名した。(特願2005-10998)
    日本学術振興会, 特定領域研究, 北海道大学, 17016005
  • 2型糖尿病の遺伝子診断用候補遺伝子の網羅的解析及びその機能解析
    科学研究費助成事業 特定領域研究
    2004年 - 2004年
    原島 秀吉; 馬場 嘉信; 鈴木 要介; 紙谷 浩之
    我々は血液サンプルに基づいて2型糖尿病の遺伝子診断法を開発することを提案し,2002年10月に特許の出願を行った.しかしながら、この特許においては候補遺伝子の探索が不十分で実用性に欠けていた.そこで,本研究においては,DNAマイクロアレイ法により,2型糖尿病の候補遺伝子を網羅的に探索し,より精度の高い診断方法の開発を行うことを目的とした.基本戦略として,2型糖尿病モデル動物として大塚製薬が開発したOthuka Long-Evans Tokushima Fatty(OLETF)ラットを用い,発病前後の遺伝子発現を網羅的に測定し,候補遺伝子を探索する.今年度は,OLETFとLETO(コントロール)ラットの遺伝子発現を比較する条件として,1)絶食時,2)インスリン投与時を選択し探索を行った.得られた結果をさらに検討して,より信頼性の高い候補遺伝子を選抜し血液サンプルに基づいた2型糖尿病の遺伝子診断法の基盤を構築することを目的とする。
    2型糖尿病関連遺伝子は病態変動が起こる前にその遺伝子発現が変動するとの予測のもとに、発症前(6週齢)OLETFを用いて、絶食時およびインシュリン投与時における白血球と、糖尿病関連臓器である肝臓における遺伝子発現変動をDNAマイクロアレイを用いて調べた。有意な遺伝子発現変動を2倍以上と考えて遺伝子を探索した結果、合計1、495遺伝子が発現変動している事が確認された。
    絶食下では3遺伝子が白血球と肝臓の両臓器間で発現変動に相関を示した。このうち1遺伝子は脂質代謝に関連する既知の2型糖尿病関連遺伝子であった。またインシュリン投与時では54遺伝子が両臓器間で遺伝子発現相関を示した。この中には、インシュリン抵抗性やコレステロール合成に関与する、少なくとも5つの2型糖尿病関連遺伝子が含まれる。このことは、今回の発現解析により得られた白血球と肝臓間で発現相関を持つ遺伝子中に、新規診断用候補遺伝子が含まれる可能性を強く示唆している。
    日本学術振興会, 特定領域研究, 北海道大学, 16012201
  • 臨床試験導入を目指した肝がん用in vivo高発現型人工遺伝子ベクターの開発
    科学研究費助成事業 特定領域研究
    2004年 - 2004年
    原島 秀吉; 松村 保広
    本研究は,肝がんの遺伝子治療のための人工遺伝子デリバリーシステムの開発を行い、将来の臨床試験導入を目的とした.平成16年度は,オクタアルギニン(R8)修飾エンベロープ型ナノ構造体の構築と機能評価及びトランスフェリン(Tf)修飾エンベロープ型ナノ構造体の構築と機能評価を行った。さらに、ウサギ肝がんモデルの構築を行った。
    1)R8修飾リポソームのマウスにおける体内動態:R8修飾リポソームの体内動態をマウスにおいて検討した。その結果、R8修飾リポソームは組織移行クリアランスはコントロールリポソームと比較して、脳(20倍)、腎臓(3倍)、肺(11倍)、肝臓(8倍)著しく促進した。
    2)Tf修飾エンベロープ型ナノ構造体の構築と機能評価:トランスフェリン-PEG修飾したMENDは,pH-感受性膜融合ペプチドGALAをコレステロール誘導体及びPEG誘導体の形で導入することにより,相乗的にエンドソーム脱出に成功し,遺伝子発現を促進することに成功した(原島,他:特願2004-205217).
    3)Tf修飾エンベロープ型ナノ構造体のマウスにおける機能評価:Tf修飾エンベロープ型ナノ構造体がマウスで遺伝子発現可能か、現在、in vivo image analyzerを用いて検討中である。
    4)ウサギ肝がんモデルの構築:ニュージーランド白ウサギの肝左葉にVX2腫瘍を移植後、腹部CTにてリピオドールがVX2腫瘍にのみ集積していることを確認した。さらに、ヒト肝がん細胞株5種類すべてにおいてDNAヘリカーゼの一亜系RecQが強く発現していることを確認し、かつそのsiRNAでRecQの発現が抑制された。以上より、本肝がん遺伝子動注のターゲットになりうることが証明できた。
    日本学術振興会, 特定領域研究, 北海道大学, 16023201
  • 細胞内動態制御・核内転写制御の最適化に基づいた人工遺伝子ベクターの開発
    科学研究費助成事業 基盤研究(B)
    2003年 - 2004年
    原島 秀吉; 紙谷 浩之; 秋田 英万
    本申請研究は,遺伝子デリバリーシステムの細胞内動態と核内転写過程を独自の戦略に基づいて最適化し,ウイルスベクターを越える高い発現効率を有する人工遺伝子ベクターを開発しがん治療へ貢献することを目的とした.本申請研究は、(1)遺伝子及びそのベクターの細胞内動態の素過程を定量的に評価するシステムの構築:量子ドットを用いて蛍光強度の減衰を防止するとともに,3次元解析により細胞内局在を定量的に評価する。(2)上記定量系をスクリーニングシステムに活用し,各ステップを促進する素子の分子スクリーニングを行う.(3)アデノウイルスベクターと我々が構築した人工遺伝子ベクターとをin vivo及びin vitroで比較評価し,ウイルスベクターと比較して弱点となる過程を選択的に促進する素子を探索する.(4)以上のスクリーニングと最適化に基づいて構築された人工遺伝子デリバリーシステムのin vivoにおける標的組織到達性と遺伝子発現効率を定量的に評価する、という四つのステップからなり,ウイルスベクターを越える人工遺伝子ベクターを開発した.これまでに人工遺伝子ベクターとウイルスベクターはそれぞれ別個の研究グループにより開発が行われ,互いに一長一短を主張している.本研究は,それぞれのベクターの細胞内動態の律速段階を明らかとすると同時に,本スクリーニングシステムによりウイルスを越える機能を有する新たな細胞内ソーティング素子を開発することに成功した.遺伝子及びベクターの細胞内動態の素過程を定量的に評価した研究は非常に少なく,ブラックボックスとして扱われいる.我々はすでに遺伝子に核移行量の定量に成功しているが,各ステップ(kint, kesc, klys, kdeg, lys, kdeg, cyt, knuc, ktra)のを定量化することが可能となり,どこが律速段階になっているのか,ウイルスベクターと比較してどこに弱点があるのかが解明できるようになった.
    日本学術振興会, 基盤研究(B), 北海道大学, 15300151
  • ゲノム機能情報に基づいた糖尿病薬の処方設計支援システムの構築
    科学研究費助成事業 萌芽研究
    2002年 - 2004年
    原島 秀吉; 桑島 正道; 紙谷 浩之
    本申請研究は,糖尿病病態モデル動物において疾患に深く関連する遺伝子の発現と薬物の感受性の関係を解明し,病態時における遺伝子発現パターンに基づいて適切な薬物を選択し,投与量を予測しうる処方設計システムを構築することを目的とした。本研究においては,DNAマイクロアレイ法により,2型糖尿病の候補遺伝子を網羅的に探索し,より精度の高い診断方法の開発を行った.基本戦略として,2型糖尿病モデル動物として大塚製薬が開発したOthuka Long-Evans Tokushima Fatty(OLETF)ラットを用い,発病前後の遺伝子発現を網羅的に測定し,候補遺伝子を探索する.OLETFとLETO(コントロール)ラットの遺伝子発現を比較する条件として,1)絶食時,2)インスリン投与時を選択し探索を行った.得られた結果をさらに検討して,より信頼性の高い候補遺伝子を選抜し血液サンプルに基づいた2型糖尿病の遺伝子診断法の基盤を構築することを目的とした。
    2型糖尿病関連遺伝子は病態変動が起こる前にその遺伝子発現が変動するとの予測のもとに、発症前(6週齢)OLETFを用いて、絶食時およびインシュリン投与時における白血球と、糖尿病関連臓器である肝臓における遺伝子発現変動をDNAマイクロアレイを用いて調べた。有意な遺伝子発現変動を2倍以上と考えて遺伝子を探索した結果、合計1、495遺伝子が発現変動している事が確認された。
    絶食下では3遺伝子が白血球と肝臓の両臓器間で発現変動に相関を示した。このうち1遺伝子は脂質代謝に関連する既知の2型糖尿病関連遺伝子であった。またインシュリン投与時では54遺伝子が両臓器間で遺伝子発現相関を示した。この中には、インシュリン抵抗性やコレステロール合成に関与する、少なくとも5つの2型糖尿病関連遺伝子が含まれる。このことは、今回の発現解析により得られた白血球と肝臓間で発現相関を持つ遺伝子中に、新規診断用候補遺伝子が含まれる可能性を強く示唆している。
    日本学術振興会, 萌芽研究, 北海道大学, 14657612
  • ウイルスVS非ウイルスベクターの体内・細胞内動態の定量的比較評価に基づく最適化
    科学研究費助成事業 基盤研究(B)
    2001年 - 2003年
    原島 秀吉; 水口 裕之; 紙谷 浩之; 松田 彰; 鈴木 要介
    本申請研究は,遺伝子ベクターの体内動態及び細胞内動態を定量的に解析し,各素過程をウイルスベクターと非ウイルスベクター間で定量的に比較評価し,遺伝子ベクターの開発に新しい突破口を開くことを目的とした.ウイルスベクター及び非ウイルスベクターに関して,細胞内動態に関する定量的比較評価を中心に,細胞内動態の各素過程を両ベクター間で定量的に評価し,発現効率に見られる大きな差の原因を追求した.第一段階は,細胞内動態の定量的評価系の確立のために,リポフェクタミンプラス(LFM),オクタアルギニン(R8),ステアリルオクタアルギニン(STR-R8)の比較を行った.その結果,いずれのベクターもエンドサイトーシスにより細胞内へ取り込まれ,エンドソームを脱出の後に,核へ移行し,遺伝子発現を行うことが明らかとなった.しかしながら,エンドソーム脱出速度には,大きな差がみられ,LFM>STR-R8>R8の順番であった.また,核移行速度にも同様の順位が見られ,LFMの細胞内動態は,アデノウイルスベクターに匹敵する効率を有することが明らかとなった(H.Akita, R.Ito, I.A.Khalil, S.Futaki and H.Harashima. Quantitative three-dimensional analysis of the intracellular trafficking of plasmid DNA transfected by non-viral gene delivery system using confocal laser scanning microscopy. Mol. Ther. 9:443-51 (2004)).ウイルスベクターと非ウイルスベクターの細胞内動態に関する定量的比較評価についても検討を行っており,現在予備的な結果では,細胞内取込過程,核内転写効率の過程に大きな違いが見られている.
    日本学術振興会, 基盤研究(B), 北海道大学, 13557217
  • 選択的抗癌システムを目指した細胞内動態の分子シンクロナイゼーション
    科学研究費助成事業 特定領域研究
    2001年 - 2002年
    原島 秀吉; 曽根 三郎; 紙谷 浩之; 丸山 一雄
    平成14年度は,オクタアルギニンとステアリルオクタアルギニンの細胞内導入機構および,遺伝子との複合体の細胞内導入機構について解析した.オクタアルギニンはエンドサイトーシスを介さずに細胞内へ移行することが明らかとなった.ステアリルオクタアルギニンはエンドサイトーシスで細胞内に移行した.これらを遺伝子との複合体にすると,いずれもエンドサイトーシスにより細胞内へ移行した.遺伝子とオクタアルギニンとステアリルオクタアルギニンの複合体の粒子径とゼータ電位を測定すると,粒子径はそれぞれ100nm,120nmでゼータ電位はそれぞれ,10mV,20mVであり,大きな違いは見られなかったが,オクタアルギニンの方が強固なパッケージングであると予想した.ところが,原子間顕微鏡により粒子の形状を観察したところ,ステアリルオクタアルギニンの方がより精密なパッケージを形成していることが明らかとなった.このことは,ステアリルオクタアルギニンの高い遺伝子発現効率の主要因と考えられた.
    日本学術振興会, 特定領域研究, 北海道大学, 13022201
  • 細胞内動態制御に基づく選択的耐性癌細胞増殖抑制システムの構築
    科学研究費助成事業 基盤研究(B)
    2000年 - 2002年
    原島 秀吉; 曽根 三郎; 丸山 一雄; 五十嵐 靖之
    平成14年度は,In vitroで耐性癌細胞における抗腫瘍効果増強を目指したキャリアーの細胞内動態の最適化を行った.その結果,トランスフェリン修飾リポソームは,トランスフェリンレセプターを介してK562細胞に取り込まれ,リポソーム封入物質及びリポソーム膜とトランスフェリンは細胞内コンパートメントに局在することが明らかとなった.通常,トランスフェリンは細胞膜へとリサイクルするが,リポソーム修飾することで細胞内コンパートメント(おそらくライソゾームと思われる)に局在した.pH-依存性膜融合ペプチドGALAを脂質誘導体とすることにより,トランスフェリン修飾リポソームに内封した蛍光マーカーを細胞質中へ遊離させることが可能となった.この機構を解明するために,FRETによる膜融合をin vitroで検討したところ,pHを7から5へ低下させることにより,著しい膜融合が観察され,同時に,リポソームの粒子径が大きく増大した.これらの結果は,GALA-脂質誘導体により,エンドソーム膜とリポソーム膜の融合が起こることにより細胞質中への放出が起きていることが示唆された.この膜融合仮説は,GALA脂質誘導体を用いた場合に見られる,トランスフェリンの細胞膜集積性をも良く説明することができ,GALA-脂質誘導体の作用機構として有力と思われる.
    日本学術振興会, 基盤研究(B), 北海道大学, 12470521
  • 遺伝子ベクター開発のための細胞内ソーティング素子のスクリーニング系の構築
    科学研究費助成事業 特定領域研究(C)
    2001年 - 2001年
    原島 秀吉
    ヒトゲノムプロジェクトの完成を間近にして,遺伝子治療の可能性に対する期待も益々大きくなることが予想される.しかしながら,これまで多数の遺伝子導入方法の開発が行われてきたにもかかわらず,ほとんど全ての研究は最終的な遺伝子発現を指標として行われ,遺伝子自体の細胞内動態はブラックボックスとなっている.我々は「細胞内動態制御シグナルの分子スクリーニングシステムを確立し,人工遺伝子キャリアーの細胞内動態を最適化する」ことが焦眉の急であると考え,そのために細胞内各オルガネラ中の遺伝子量を定量的に測定し,各素過程を速度定数で定量的に評価できるスクリーニング系を確立することを第一目標とした.申請者は,平成12年度に,本特定領域研究にて,PCR法とサザンブロッティング法を用いて核内遺伝子量を定量する新たな手法の開発に成功した(Tachibana, et al., accepted by Pharm. Res.).平成13年度は,以下のような検討を行った.
    1)細胞内動態の素過程の分子スクリーニングシステムの構築:細胞内の遺伝子の分布は,細胞膜,細胞質、エンドソーム、ライソゾームそして核が主要な分画である.各分画中の遺伝子量は,我々が確立したPCR法とサザンブロッティング法により定量した.この定量法に基づいて,遺伝子の細胞内動態の各素過程を速度定数として定量的に評価し,分子スクリーニングシステムを構築した.
    2)非ウイルスベクターの細胞内動態の最適化:細胞内動態のそれぞれの素過程について最適化した.例えば,kescに関しては最大になるように,kdeg, lys(ライソゾームでの分解)に関しては最小になるように分子設計を行った.各ステップの促進あるいは抑制は核局在化シグナルのようなシグナルペプチドや特異的脂質のオルガネラ局在化機構を導入することにより検討した.
    日本学術振興会, 特定領域研究(C), 北海道大学, 13218001
  • 核ターゲティングの新戦略:核膜の特殊性に基づいた標的化
    科学研究費助成事業 萌芽的研究
    2000年 - 2001年
    原島 秀吉; 宮内 正二
    我々は核膜の特殊性に着目し,核膜孔を介さない新しい遺伝子の核内導入ルートを開発し,遺伝子のサイズに依存せず高い発現効率を有する遺伝子導入キャリアーを開発することを研究目的とした.そのために(1)ゴルジ体-小胞俸-核膜という新しい遺伝子送達ルートの開発と(2)核膜の特殊性に基づいた膜融合能の制御に基づく核内遺伝子導入技術の開発を行い,ウイルスベクターと比較して安全で十分な遺伝子導入効率を有する人工遺伝子キャリアーの開発を試みた.前年度の膜融合機構に基づいて,核膜融合機構に基づく遺伝子の核内挿入法に焦点を絞って基礎的検討を行った.
    遺伝子は外膜と内膜を単純拡散で透過することはできないので,ここでPEIによる膜perturbationを利用した.前年度の結果から,核膜とリポソーム封入PEI・プラスミド複合体が融合する最適な条件を用い,核膜を透過させた.プラスミドはrhodamine(赤)で蛍光ラベルし,核内はSUTO24(緑)で染色し,共焦点レーザー顕微鏡にて核内移行を測定した.その結果,リポソーム封入PEI-プラスミド複合体は,直接核膜と融合している瞬間を3次元的にとらえることに成功した.この映像は,遺伝子・キャリアー複合体が核膜孔を通らずに,核内に直接導入可能なことを世界で初めて示した結果である.この結果は,現在Gene Therapyへ投稿中である.
    日本学術振興会, 萌芽的研究, 北海道大学, 12877351
  • トリプルターゲティングによるがん細胞に特異的な核内転写抑制システムの構築
    科学研究費助成事業 特定領域研究(A)
    2000年 - 2000年
    原島 秀吉; 五十嵐 靖之; 大熊 芳明; 篠原 康雄
    本研究は,生物工学的手法と薬剤学的概念を併用して,特定の遺伝子の転写阻害剤を,特定の細胞の核に特異的に移行させる系を構築することを目的とする.具体的な戦略としては,
    1)がん細胞に特徴的に発現しており,その増殖に必須の遺伝子の転写阻害剤をデザインし,
    2)pH-sensitive mechanismを用いて,細胞内での分解過程を回避してサイトソルに放出させ,
    3)細胞内での動態を制御して,これを核に選択的に濃縮する.
    という複数のターゲッティング方法を併用して,がん細胞の特異的増殖抑制系を構築することを目標とする.本年度は,トランスフェリンレセプターを標的とし,細胞内へ選択的に導入させることに成功した.最適な表面密度に関しても検討を行い,5〜10%が最適であることが明らかとなった.エンドソーム脱出過程の促進に関しては,pH-依存性に膜融合能を持つペプチドGALAを用いて,エンドソームから細胞質中への放出過程を促進することを検討した.共焦点レーザー顕微鏡による解析の結果,GALAをリポソームの水相に封入しても促進効果は見られなかったが,GALA-脂質誘導体をリポソーム膜に封入したところ,エンドソームから細胞質中への放出過程を促進させることに成功した.
    日本学術振興会, 特定領域研究(A), 北海道大学, 12019201
  • 遺伝子ベクター開発のための細胞内ソーティング素子のスクリーニング素の構築
    科学研究費助成事業 特定領域研究(C)
    2000年 - 2000年
    原島 秀吉
    本研究は,「細胞内動態制御シグナルの分子スクリーニングシステムを確立し,人工遺伝子キャリアーの細胞内動態を最適化する」という新しい戦略を提唱し,細胞内各オルガネラ中の遺伝子量を定量的に測定し,各素過程を定量的に評価できるスクリーニング系を確立するとともに,遺伝子の細胞内動態における素過程の最適化を行い,ウイルスを凌駕する人工遺伝子ベクターを開発することを目的とする.
    1.細胞内動態の素過程の分子スクリーニングシステムの構築:細胞内の遺伝子の分布は,細胞膜,細胞質、エンドソーム・ライソゾーム系そして核が主要な分画である.遺伝子を蛍光ラベルして,リポフェクタミンプラスとの複合体を形成させ,NIH3T3細胞へ導入した.経時的に共焦点レーザー顕微鏡により蛍光マーカーを追跡した.蛍光強度の画像解析は浜松ホトニクスのAQUACOSMOSで定量化を行った.検量線を作成することにより蛍光強度をプラスミドの個数に換算し,個々の細胞において各オルガネラ中の量を定量的に評価する方法を確立した.
    2.人工遺伝子キャリアーの細胞内動態の素過程に関する最適化:遺伝子の細胞内動態の中でも主要なバリアーの一つであるエンドソームから細胞質中への遊離過程に着目し,エンドソーム遊離過程を促進させるソーティング素子として,ウイルス由来の膜融合ペプチドGALAを合成した.GALAをリポソームの水層に封入したところ,顕著な促進効果は見られなかった.そこで,GALAを脂質誘導体とし,リポソーム膜に封入した.その結果,リポソームに封入した水層マーカーの細胞質中への遊離を顕著に促進させることが明らかとなった.
    日本学術振興会, 特定領域研究(C), 北海道大学, 12217004
  • 選択的抗腫瘍システムの開発を目指した細胞内動態の分子シンクロナイゼーション
    科学研究費助成事業 特定領域研究(A)
    1999年 - 2000年
    原島 秀吉; 宮内 正二; 篠原 康雄; 丸山 一雄
    本研究は,リポソームに臓器レベル,細胞レベル,オルガネラレベルで正常細胞と耐性癌細胞とを識別する能力を有する分子を設計し,各プロセスが分子レベルでシンクロナイズすることにより相乗的に抗腫瘍効果を発揮する殺細胞キャリアーシステムの開発する.その基本戦略は,
    1)臓器レベルでの識別:LCLを用いることにより癌組織への選択的送達(原島)
    2)細胞レベルでの識別:LCLをリガンドで修飾→細胞内で内在化→汲み出しポンプからの回避(丸山)
    3)オルガネラレベルでの識別(原島,紙谷)
    という,3段階の各ステップで正常細胞と耐性癌細胞を識別し,強力な選択毒性を発揮せしめる.本年は,癌細胞標的化リガンドの分子シンクロナイゼーションの最適化を中心に検討した.
    (1)リガンド修飾リポソームによる癌細胞標的化の最適化(原島・丸山):耐性癌細胞に選択的に発現している細胞表面レセプターを標的とし,トランスフェリンレセプターにより標的化と最適化を行った.
    (2)細胞内動態における分子シンクロナイゼーションの最適化(原島):エンドソーム膜融合能を有するGALA誘導体をリポソームに付与し,細胞質への放出効率の促進に成功した.
    日本学術振興会, 特定領域研究(A), 北海道大学, 11167258
  • パーキンソン病治療を目的とした脳細胞へのチロシンヒドロキシラーゼ遺伝子の導入
    科学研究費助成事業 基盤研究(C)
    1999年 - 2000年
    小薮 紀子; 松尾 浩民; 際田 弘志; 大谷 壽一; 澤田 康文; 菊池 寛; 原島 秀吉; 小藪 紀子; 菊地 寛
    1.膜融合リポソームを用い、FITCラベル化したデキストランおよびオリゴヌクレオチド等の高分子を、培養マウス脳毛細血管内皮細胞に導入できることが示された。
    2.膜融合リポソームを用いβガラクトシダーゼ遺伝子を培養マウス脳毛細血管内皮細胞に導入し、βガラクトシダーゼを発現させることができた。
    3.βガラクトシダーゼ遺伝子発現ベクターを封入した膜融合リポソームをラットに外頸動脈から投与することにより、脳毛細血管にβガラクトシダーゼ遺伝子を導入することができた。βガラクトシダーゼを発現した脳毛細血管は脳全体に渡り確認された。
    4.2.3.より、膜融合リポソームは、in vitroのみならずin vivoにおいても、脳毛細血管内皮細胞への遺伝子の導入に有用であることが示された。
    5.パーキンソン病の治療に有用とされているGlial-Derived Neurotrophic Factor(GDNF)遺伝子を脳毛細血管内皮細胞に導入し、GDNFを脳側へ分泌発現させることを計画した。Mouse GDNF遺伝子を導入した培養マウス脳毛細血管内皮細胞は、GDNFを主に分泌発現することが確認された。また、分泌の方向は、脳側への分泌がその逆方向への分泌よりも優位であることが確認された。
    日本学術振興会, 基盤研究(C), 九州大学, 11672264
  • トリプルターゲティングによるがん細胞に特異的な核内転写抑制システムの構築
    科学研究費助成事業 特定領域研究(A)
    1999年 - 1999年
    原島 秀吉; 宮内 正二; 大熊 芳明; 篠原 康雄
    平成11年度は,標的化リポソームに関する検討,核内の特異的転写阻害に関する検討,核内送達量の定量化に関する検討を行った.
    (1)トランスフェリン(Tf)をリガンドとした癌細胞標的化リポソームによる抗腫瘍効果:血中滞留性リポソームのPEGの先端にTfを結合させて,がん細胞を選択的に認識する標的化リポソームを調製した.このリポソームにドキソルビシンを封入し,Tf-receptorを介して細胞内へ抗癌剤の導入させた.その結果,ドキソルビシンに耐性である癌細胞に対しても有効となり,Tf-receptorを標的とした細胞内送達の有用性を示すことができた.
    (2)転写阻害リガンドの合成とin vitro系におけるTFIIHの転写因子阻害実験:RNAポリメラーゼIIの最大サブユニットRPB1(分子量約200kDa)のC末端にあるCTD(C-Terminal Domain)とよばれる繰り返し配列に対するペプチドを合成した.精製した五つの基本転写因子とRNAポリメラーゼIIからなる再構築系にて転写阻害活性について検討したところ,IC50は約1mMであり,さらに特異性の高いリガンドについて現在検討中である.
    (3)核内送達遺伝子の定量法の確立:本年度はサザンブロッティング法に基づいた核内プラスミドの定量法を新たに確立した.その結果,PCR法よりも正確に核内プラスミド量の定量が可能となった.
    日本学術振興会, 特定領域研究(A), 北海道大学, 11132256
  • 核内転写制御による抗腫瘍効果を最適化するための細胞内動態制御システムの開発
    科学研究費助成事業 萌芽的研究
    1998年 - 1999年
    原島 秀吉; 大熊 芳明; 篠原 康雄
    本研究は,がん細胞に対する選択毒性が極めて高い抗がん剤開発のための戦略を確立することを最終目標として,1)キャリアーによるがん細胞への選択的送達,2)細胞内動態を制御による核への濃縮,3)がん細胞での特異的転写阻害,という3つの方法を併用し、がん細胞への「選択毒性の相乗効果」により増殖抑制を試みた.その結果,(1)トランスフェリン(Tf)をリガンドとした癌細胞標的化リポソームによる抗腫瘍効果 : 血中滞留性リポソームのPEGの先端にTfを結合させて,がん細胞を選択的に認識する標的化リポソームを調製した.このリポソームにドキソルビシンを封入し,Tf-receptorを介して細胞内へ抗癌剤の導入させた.その結果,ドキソルビシンに耐性である癌細胞に対しても有効となり,Tf-receptorを標的とした細胞内送達の有用性を示すことができた.(2)転写阻書リガンドの合成とin vitro系におけるTFIIHの転写因子阻害実験 : RNAポリメラーゼIIの最大サブユニットRPB1(分子量約200kDa)のC末端にあるCTD(C-Terminal Domain)とよばれる繰り返し配列に対するペプチドを合成した.精製した五つの基本転写因子とRNAポリメラーゼIIからなる再構築系にて転写阻害活性について検討したところ,IC50は約1uMであり,さらに特異性の高いリガンドについて今後更なる検討を行う.
    日本学術振興会, 萌芽的研究, 10877390
  • トリプルターゲティングによるがん細胞に特異的な核内転写抑制システムの構築
    科学研究費助成事業 特定領域研究(A)
    1998年 - 1998年
    原島 秀吉; 大熊 芳明; 篠原 康雄
    本年度は,研究代表者は研究分担者と協力して,
    (1) キャリアーとしてのリポソームの特性の最適化に成功し(Third International Symposium on Measurement and Kinetics of In vivo Drug Effects(招待講演),オランダ,1998年),(2) pH-sensitive liposomesと核移行シグナルの付与により,高分子を細胞外から核内へ選択的に送達することに成功した(Biochem.Biophys.Res.Comm.251:538-544,1998).さらに,核への選択的なDNAの送達に着手した.
    しかしながら,核内へ送達されたDNA量を評価する系が確立されていないため,その方法の開発に着手した.
    (3) 我々はPCRを応用することにより,核一個あたりに導入されたプラスミドの数を定量可能な方法を確立することに成功した(橘ら,第13回日本薬物動態学会,11月).本法の確立により,遺伝子の核内送達量と発現量との関係が明らかとなり,著しい飽和性の存在が明らかとなった.本定量法は細胞内動態の最適化を行うための有用な手段となる.更に,(4) TFIIHに対するリガンドを設計し,CTD-配列に対応したペプチドを3回繰り返した構造をもつ阻害リガンドを合成した.その転写阻害活性をin vitro再構築系において検討したところ,阻害効果を確認することに成功した.
    これらの研究成果に基づいて,次年度は細胞系での転写抑制を可能とするキャリアーの設計に入る予定である.
    日本学術振興会, 特定領域研究(A), 徳島大学, 10145242
  • 腫瘍選択的なエネルギー代謝遮断機構に基づいた抗がん剤の抗腫瘍効果の最適化
    科学研究費助成事業 基盤研究(B)
    1997年 - 1998年
    原島 秀吉; 寺崎 哲也; 篠原 康雄
    本研究は,抗癌剤を選択的に腫瘍組織へ送達し,癌細胞のエネルギー代謝を特異的に遮断することにより抗腫瘍効果を発現させる最適な薬物送達システムを開発し,その実用化への基礎研究を目的とした.
    まず,抗癌剤のキャリアーとしてリポソームを選択し,細胞内動態制御のストラテジーを構築した.pH-感受性リポソームを用いることにより,エンドサイトーシスにより細胞内に取り込ませたのち,ライソゾームでの分解を回避して細胞質中へ脱出させることが可能となった.さらに,核局在化シグナルを付与することにより,細胞質中へ放出させた高分子を能動的に核内へ輸送させることに成功した.この細胞内動態制御法は,種々の高分子化合物のための細胞内動態制御キャリアーとして有用である.
    一方,癌細胞においてII型へキソキナーゼの転写活性が亢進していることが明らかとなり,核内転写レベルでの遺伝子発現抑制を行うことを目指した.そのためにまず,核内へ送達した遺伝子の定量法の開発が重要となるので,定量法の開発に着手した.その結果,PCRを利用して核一個あたりの遺伝子送達量を定量する方法の確立に成功した.その結果,核内に送達した遺伝子量と発現量との関係を世界で初めて明らかにすることができた.今後は,II型ヘキソキナーゼの転写活性を抑制する遺伝子の最適化を図るとともに,キャリアーの最適化を行い,in vivoに適用可能な人工遺伝子キャリアーを開発したい.
    日本学術振興会, 基盤研究(B), 徳島大学, 09557197
  • RESによるリポソームの取込機構と細胞内運命に関する速度論的研究
    科学研究費助成事業 一般研究(C)
    1993年 - 1995年
    原島 秀吉; 際田 弘志
    本研究は細網内皮系(RES)によるリポソームの取込様式とその機構の解明、さらにリポソームの細胞内運命が取込過程によりどのように支配されているかを明らかにすることを目的とした。肝臓によるリポソームの取込過程の特徴として投与量による飽和が知られている。我々はこの飽和過程に着目して速度論的解析を行ない、肝臓による取込クリアランスはミカエリスーメンテン型の飽和様式に従うのではなく、取込量に依存して減少するということを示し、「満腹モデル」を提唱した。次に、肝潅流システムでリポソームの取込機構について検討したところ、リポソームが補体レセプターを介してマクロファージにファゴサイトーシスで取込まれていることを示した。さらに、リポソームの細胞内への取込過程と細胞内動態がどのような関係にあるかを検討した。in vivoでの実験では、^3H-cholesterylhexadecylether (^3H-CHE)に対するインタクトな^<125>I-albuminの比をとることにより細胞内分解過程の指標とした。その結果、細胞内での分解過程は速い分解に約8割、遅い分解に約2割が振分けられることが明らかとなった。単離した腹腔マクロファージを用いて酸性コンパートメントへの移行過程に投与量がどのように影響するかを検討した。その結果、高投与量になるとリポソームは細胞内に取込まれても、すみやかな酸性化を受けていないことがわかった。このことは、2種類の分解コンパートメントを仮定する「振分モデル」で説明することは難かしく輸送過程のヘテロジェネイティを仮定する「渋滞モデル」を示唆した。以上、マクロファージへの取込過程と細胞内運命との関係について定量的評価と機構的解明を行ない、リポソームを用いて薬物送達システムを構築するうえで有用な知見を得ることができた。今後はこれらの成果をふまえて、細胞内動態制御に基づいた新しい薬物送達システムの構築を目指し、さらなる努力を続けてゆきたい。
    日本学術振興会, 一般研究(C), 徳島大学, 05671783
  • リポソームによる細胞内薬物送達システムの開発
    科学研究費助成事業 一般研究(C)
    1990年 - 1992年
    際田 弘志; 杉山 雄一; 原島 秀吉
    リポソームの薬物担体としての可能性はこれまでに種々の角度から検討され、特に肝臓での取込過程に関する研究は数多い。しかしながら、細胞内での挙動に関してはライソゾームに移行し、崩壊されるという"常識"のもとに、研究はほとんど行なわれていない。さらに、ライソゾームへの移行を回避するなど、細胞内移行性をコントロールする試みは皆無に等しい。リポソームに高分子化合物を内封して標的部位に送達してその薬理効果を期待する時、第一に、リポソームを細胞に選択的にターゲッティングするにはどのようなリポソームを用いるべきか、第二に、細胞内に取込まれた後、ライソゾームへの取込を回避する必要のある化合物とその必要のない化合物でのリポソームをどのように選択すべきか、という課題に答える必要がある。本研究はこれらの課題に答えるための細胞内分布過程までを考慮したリポソームによる肝臓への薬物送達システムの開発を目的とした。
    細胞内の過程を解析する前に、まず、取込過程に関して、リポソームの粒子径、投与量、表面修飾の効果等について検討した。肝還流系で、リポソームの粒子径に依存してオプソナイズされることが明らかとなった。投与量に関しては、リポソームの肝臓の取込過程にみられる飽和性は従来のミカエリスメンテンの速度過程には従わず、取込量に依存して取込クリアランスが減少することを見いだした。表面修飾の効果については、マンノース修飾リポソームはマンノースレセプターを介してではなく、補体レセプターを介して取込まれることが明らかとなった。次に、ライソゾームでのリポソームの分解過程を定量的に評価する方法を開発した。リポソームの細胞内分解のマーカーは ^<125>I-アルブミンを用いた。この方法により、細胞系では腹腔マクロファージ、全身系では肝臓と脾臓におけるリポソームの分解過程を測定することができた。これらのタイムコースをさらに速度論解析することにより、分解過程の定量化にも成功した。今後、リポソームの取込過程と細胞内運命の間にどのような関係があるかを解明し、有効な細胞内ターゲッティングシステムの開発を行なっていく予定である。
    日本学術振興会, 一般研究(C), 徳島大学, 02670981
  • 受容体結合動態に基づく薬物作用速度論の構築研究
    科学研究費助成事業
    1987年 - 1988年
    花野 学; 沢田 康文; 杉山 雄一; 伊賀 立二; 福田 英臣; 原島 秀吉
    1)強心配糖体ウアバインの動態と心、収縮力増加作用を検討した。ウアバインをウサギにinfusion速度を変えて投与し、心臓収縮圧の時間変化をみたところ顕著なinfusion速度依存性があらわれた。これは作用出現にかなりの遅れ時間がかかることを示している。ウアバインの心筋収縮力増強の分子的機構はまだ明確ではないが、ウアバインの細胞膜結合蛋白であるNa^+,K^+ATPaseへの結合と、この結集によるNa^+ポンプ作用の阻害が問題となる。in vitro心筋ホモジネートを使用したNa^+,K^+ATPaseへの結合には2種の結合部が示された。さらに摘出ウサギ心臓灌流実験、すなわちランゲンドルフの心臓を使用して灌流液中のウアバイン濃度と薬物濃度の関係より、薬効とATPase占有率の関係は良く一致していた。以上よりウアバインの強心作用にはNa^+,K^+ATPaseの高親和性結合部位への結合占有が密接に関与していることが強く示唆された。さらに結合にはかなりの時間がかかることが知られており、強心作用の発現遅れはこの結合解離の時間遅れだけでは説明がつかなかった。我々は速用速度論モデルに時間遅れに対応する過程を導入し、各infusion速度における薬物作用発現の時間推移をもとめ実測値と比較したところよい対応がみられた。しかしこの時間遅れの過程の分子的機構は不明である。
    2)客観的な脳機能の指標としての局所グルコース消費速度(G)の変化をマウスを用いて捉えることが可能となった。ベンゾジアゼピンであるクロナゼパムはGを有意に低下させた。更にクロナゼパムのレセプター結合占有率とGの変化の関係より、少ない占有率(20〜30%)で最大の効果が得られることが明らかになった。以上の知見より、ベンゾジアゼピンとベンゾジアゼピンレセプターとの相互作用に余剰レセプターの概念が適用できることが明らかとなった。
    日本学術振興会, 一般研究(B), 東京大学, 62460215
  • 強心配糖体の薬効発現過程の薬物速度論的解析
    科学研究費助成事業 奨励研究(A)
    1987年 - 1987年
    原島 秀吉
    日本学術振興会, 奨励研究(A), 東京大学, 62771894
■ 産業財産権
■ 学術・社会貢献活動/その他
学術貢献活動
  • リポソーム国際会議 2019
    2019年09月15日 - 2019年09月18日
    企画立案・運営等
    大会・シンポジウム等
    原島 秀吉
メディア報道
  • 創薬におけるパラダイムシフト ナノ医療の幕開け
    2021年09月
    本人
    (株)フロムページ
    夢ナビ講義
    [インターネットメディア]